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ABSTRACT 
  
Heme is indispensable for mammalian life. It is an essential component of numerous 
heme proteins, with functions including oxygen transport and storage, energy metabolism, drug 
and steroid metabolism and signal transduction. Under normal physiological conditions 
intracellular free heme levels are extremely low because increased levels of free heme are 
cytotoxic and accordingly, heme biosynthesis is tightly regulated. Although, 5-aminolevulinic 
acid synthase (ALAS) mediated regulation of heme synthesis is considered the key step in 
heme biosynthesis, recent reports have identified a second regulatory step in heme 
biosynthesis mediated by the mitochondrial ATP binding cassette transporter b6 (Abcb6). Abcb6 
expression is directly related to enhanced de novo porphyrin biosynthesis, and Abcb6 
overexpression activates the expression of genes important for heme biosynthesis. Thus, Abcb6 
represents a previously unrecognized rate-limiting step in heme biosynthesis.  
The dissertation outlines the progress made since its initiation in understanding the 
mechanism(s) that regulate Abcb6 expression and the significance of Abcb6 expression to 
cellular heme homeostasis.  
Exposure to therapeutic drugs and environmental contaminants leads to an increase in 
heme demand to compensate for the increased expression of the heme-dependent cytochrome 
P450s (P450s) detoxifying enzymes. Cells respond to this increasing heme demand by 
increasing heme synthesis. Thus, exposure to environmental contaminants serves as an 
optimal in vivo and in vitro model system to study mechanisms that regulate heme synthesis. In 
this model, Abcb6 expression was induced in response to exposure to xenobiotics [polyaromatic 
hydrocarbons (PAHs), 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) and 
pregnenolone 16α-carbonitrile (PCN)] suggesting a co-ordinate induction of Abcb6 to support 
the increased heme synthesis. Increased Abcb6 expression in response to cellular heme 
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demands was mediated by the xenobiotic sensing nuclear receptors aryl-hydrocarbon receptor 
(AhR), the constitutive androstane receptor (CAR), and the pregnane-X receptor (PXR).  
Exposure to environmental contaminants also leads to the generation of oxidative stress, 
a primary mechanism by which these compounds cause cellular damage. Cells respond to this 
increased oxidative stress by activating anti-oxidant defense mechanisms, whose principal 
components include hemo-proteins (such as catalase, superoxide dismutase, etc). Arsenic, an 
environmental contaminant and a major hazard following occupational exposure exerts its 
chronic toxicity through the generation of reactive oxygen species. Of importance, exposure to 
arsenic also activates the antioxidant defense mechanism. Thus, exposure to arsenic serves as 
a good model system to evaluate in vivo and in vitro oxidative stress response. In this model 
system, sodium arsenite induced Abcb6 expression in a dose-dependent manner both in mice 
fed sodium arsenite in drinking water and in cells exposed to sodium arsenite in vitro. Arsenite-
induced Abcb6 expression was transcriptionally regulated but was not mediated by the redox 
sensitive transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2).  
The significance of Abcb6 expression to cellular heme homeostasis under conditions of 
heme demand was evaluated in vitro by both gain of function (cells engineered to overexpress 
Abcb6) and loss of function (cells where endogenous Abcb6 expression was knocked down 
using Abcb6 specific ShRNA) analysis. Loss of Abcb6 expression in these in vitro model 
systems significantly compromises the ability of cells to respond to increased heme demand 
and the ability to protect against oxidative stress following exposure to environmental 
contaminants. 
To understand the significance of Abcb6 function to heme homeostasis in vivo, we 
generated mice carrying homozygous deletion of the Abcb6 allele (Abcb6 null mice). Abcb6 null 
animals appear phenotypically normal with a trend towards decreased hepatic heme levels, 
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although, the decreased heme levels did not appear to be statistically significant. Interestingly 
however, Abcb6 null mice demonstrate genotypic changes that suggest a role for Abcb6 in lipid 
and cholesterol homeostasis. Abcb6 null mice have increased fasting serum cholesterol and 
increased accumulation of androstone metabolites. Abcb6 null mice also show decreased 
expression and activity of a specific set of P450s suggesting a role for Abcb6 in drug 
metabolism and disposition.   
Mitochondrial ABC transporters are difficult to study because of the two-membrane 
architecture of mitochondria, problems associated with analyzing transport process, and the 
high abundance of other ATPases and carriers/transporters. Thus, the development of an in 
vitro system with pure and active protein is a prerequisite toward understanding the mechanistic 
relationships between ATP binding and hydrolysis and coupling of these events to translocation 
of substrates across the lipid membranes. Towards this end, we developed an in vitro liposomal 
transport system with pure and active Abcb6 protein. Reconstitution of Abcb6 into liposomes 
allowed biochemical characterization of the ATPase including (i) substrate stimulated ATPase 
activity (ii) transport kinetics of its proposed endogenous substrate coproporphyrinogen III and 
(iii) transport kinetics of substrates identified using a HTS assay. 
In summary, this dissertation provides insight into the mechanisms that regulate Abcb6 
expression in response to increasing heme demand and the in vitro significance of Abcb6 to 
cellular heme homeostasis. Development of the Abcb6-null mice suggests that loss of Abcb6 
does not severely affect heme-dependent functions in the liver probably because of the 
activation of compensatory mechanisms that balance the loss of Abcb6. More interestingly, 
Abcb6-null mice show a phenotype that is characteristic of the deficiency of a protein that is 
involved in cholesterol and lipid homeostasis. Development of the Abcb6-null mice and the 
development of an in vitro system with purified Abcb6 should serve as useful tools to 
understand the transport function of Abcb6 and its role in normal and patho-physiology.  
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Chapter 1. BACKGROUND AND INTRODUCTION
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1.1. Heme as a magnificent molecule with multiple functions   
Heme and porphyrins are vital for cell survival. Heme, the iron and protoporphyrin IX 
complex senses and utilizes oxygen in nearly all living cells. It is an essential component of 
various hemoproteins, including those involved in oxygen transport and storage (hemoglobin, 
myoglobin), mitochondrial electron transport (complexes II-IV), drug and steroid metabolism 
(cytochromes), signal transduction (nitric oxide synthases), and regulation of antioxidant-
defense enzymes (1).  
Heme is also a regulatory molecule; its intracellular localization (cytosolic vs nuclear) 
and concentration affects gene transcription and translation (1). Binding of heme to selected 
transcription factors such as HAP1 and Bach1 markedly alters gene expression patterns, 
orchestrating cell-wide multi-component responses to different stimuli. In erythroid cells, heme 
deficiency results in inhibition of protein synthesis, because of the activation of the heme-
regulated inhibitor kinase (HRI) (2). Iron concentration in the cell is sensed and regulated by the 
heme-mediated oxidization and subsequent degradation of iron regulatory protein 2 (IRP2) (3). 
Heme also binds to certain types of potassium channels, thereby inhibiting transmembrane K+ 
currents (4).   
While heme and porphyrins are considered as the “pigments of life” and are essential for 
life, excess intracellular heme, porphyrins or both is highly toxic to cells. The damaging effect of 
excess heme is, at least in part, due to its iron-induced pro-oxidant effect on DNA, proteins, 
membrane lipids, and the cytoskeleton (5-9). This effect is caused by iron catalyzing the Fenton 
reaction. An elevated level of non-iron protoporphyrin has been linked to numerous diseases 
and pathologic conditions (e.g. anemia, lead poisoning and thalassemias) (10-17). The 
damaging effect of excess protoporphyrins is caused by their ability to absorb energy leading to 
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photosensitization. Photosensitizers, such as protoporphyrin, accumulate in membranes and 
upon exposure to light (430–635 nm) cause the release of singlet oxygen, which causes cellular 
damage. Therefore, the amount of cellular heme and porphyrins need to be tightly regulated. 
Cellular heme homeostasis is achieved by a fine balance between biosynthesis, utilization (for 
hemoproteins), transport (into and out of cells and organelles to prevent porphyrin over 
accumulation) and catabolism (by hemeoxygenase).  
 
1.2. Pathologies associated with disruption of heme homeostasis   
Heme synthesis is orchestrated by eight enzymes and few transporters in a regulated 
manner. Any defect in the heme biosynthesis pathway enzymes (except ALAS1) can alter  
porphyrin homeostasis and lead to accumulation of porphyrins, clinically known as the 
porphyrias. Table 1.1 provides a list of pathologies associated with defects in enzymes of heme 
biosynthesis.  
Effect on heme biosynthesis can alter the hemoprotein function; one such example is 
P450, a major drug metabolism enzyme family. In 1972 Kappas et al. showed that lead and 
methyl mercury affected heme biosynthesis in rats and as a consequence their P450 enzymes 
were decreased which affected hexabarbital metabolism and increased animals sleeping time 
after hexabarbital administration (18). In another case of acquired heme deficiency by lead 
acetate Meyer et al. showed that heme deficiency decreases content and heme saturation of 
Cyp1a (19). PBGD-/- mice also showed resistance to phenobarbital induced change in P450 
activity (20). HL-60 cells with succinylacetone were demonstrated to decrease the activity of 
another hemoprotein, catalase, but the mechanism of this decrease has not been defined. 
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Table 1.1. Pathologies associated with disruption of heme homeostasis 
DISEASE/DISORDERS/PHENOTYPE GENE 
PORPHYRIAS  
5-Aminolevulinic acid dehydratase porphyria 5-Aminolevulinic acid dehydratase 
Acute intermittent porphyria Porphobilinogen deaminase 
Congenital erythropoietic porphyria Uroporphyrinogen III cosynthase 
Porphyria cutanea tarda Uroporphyrinogen decarboxylase 
Hepatoerythropoietic porphyria Uroporphyrinogen decarboxylase 
Hereditary coproporphyria Coproporphyrinogen oxidase 
Variegate porphyria Protoporphyrinogen oxidase 
Erythropoietic protoporphyria Ferrochelatase 
ANEMIA  
X-Linked Sideroblastic Anemia 5-aminolevulinic acid synthase (ALAS2) 
X-Linked Sideroblastic Anemia with Ataxia ABCB7 
OTHERS  
Cyp2a5 Porphobilinogen deaminase 
Lead Poisoning 5-Aminolevulinic acid dehydratase 
Hepatorenal tyrosinemia 5-Aminolevulinic acid dehydratase 
Ocular Coloboma Abcb6 
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1.3. Cellular heme homeostasis 
Cellular heme homeostasis is achieved by a fine balance between biosynthesis, 
catabolism (by hemeoxygenase), utilization (for hemoproteins) and transport (into and out of 
cells and organelles to prevent porphyrin over accumulation).  
 
1.3a. Heme biosynthesis 
The biosynthesis of heme, identical in all mammalian cells, is initiated from simple 
molecules and comprises eight enzymatic steps (Figure 1.1). David Shemin and Albert 
Neuberger first elucidated that heme biosynthesis begins with condensation of glycine and 
Succinyl CoA to form 5-aminolevulinic acid (ALA) (21,22). This reaction is catalyzed by ALA 
synthase (ALAS) which is located in the mitochondria and is the rate limiting enzyme of the 
pathway. ALA synthesized in the mitochondria is thought to be transported by the mitochondrial 
ABC transporter Abcb10 that localizes to the inner mitochondrial membrane (23).   
Once in the cytosol, condensation of two ALA molecules forms the monopyrrole 
porphobilinogen (PBG). This reaction is catalyzed by aminolevulinate dehydratase (ALAD) 
(24,25). Four molecules of PBG form tetrapyrrole with the help of cytosolic porphobilinogen 
deaminase (PBGD) (26,27). The tetrapyrrole polymer formed is unstable and designated as 
hydroxymethylbilane (HMB). HMB serves as the substrate for the next enzyme in the heme 
synthesis pathway, uroporphyrinogen III synthase (UROIIIS). UROIIIS catalyzes the conversion 
of HMB to uroporphyrinogen III (UROIII) which is converted to coproporphyrinogen III (COPIII) 
by uroporphyrinogen decarboxylase (UROD) (27).  
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Cytosolic COPIII is an anionic molecule and requires active transport into the 
mitochondria which is mediated by the outer mitochondrial ABC transporter Abcb6 (28,29). 
Once inside the mitochondria oxidative decarboxylation of COPIII by coproporphyrinogen 
oxidase, a mitochondrial intermembrane space enzyme, converts COPIII to protoporphyrinogen 
IX. Protoporphyrinogen IX is then oxidized to protoporphyrin IX (PPIX) by the enzyme 
protoporphyrinogen oxidase (PPO) (27). The final step in the heme biosynthesis pathway 
occurs on the inner surface of the inner mitochondrial membrane where iron is inserted into 
PPIX by ferrochelatase (FECH) (27).  
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Figure 1. 1. 
 
 
Model of heme biosynthesis pathway.  
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Figure 1. 1. (continued). 
Heme biosynthesis occurs in 8 steps through coordination between cytosolic and mitochondrial 
enzymes. These steps begin in the mitochondria when one of the rate limiting enzymes, delta-
amino-levulinate synthase (ALAS), condenses glycine and succinyl-CoA to form amino-levulinic 
acid (ALA). ALA is then transported into the cytosol by the ABC transporter Abcb10, where 
successive enzymes catalyze the formation of coproporphyrinogen III (COPIII). COPIII is 
transported back into the mitochondria for further oxidation by coproporphyrinogen oxidase 
(CPO) tethered to the inner membrane. Transport of COPIII into the mitochondria is an energy 
dependent mechanism. Abcb6 is ideally located in the outer membrane where it can move 
COPIII from the cytoplasm into the mitochondria using ATP hydrolysis as the source of energy. 
COPIII is further decarboxylated by CPO to form PPIX which combines with iron to form heme. 
The final step of iron incorporation is catalyzed by enzyme ferrochelatase (FECH). OMM: Outer 
mitochondrial membrane; IMM: inner mitochondrial membrane; IMS: Inter membrane space. 
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1.3b. Heme catabolism  
Heme catabolism is mediated by the enzyme heme oxygenase (HO).  Heme 
degradation by HO involves three sequential oxidation reactions. (Figure 1.2). Overall heme is 
converted to biliverdin, carbon monoxide (CO), and iron. The released iron is largely recycled 
for heme production; carbon monoxide functions as a cell-signaling molecule, and biliverdin is 
immediately converted to bilirubin, a powerful antioxidant (30,31).  
Heme oxygenase is represented in 2 isoforms, Heme oxygenase-1 (HO-1) and Heme 
oxygenase-2 (HO-2), encoded by genes on ch22q12 and ch16p13.3 respectively.  HO-1 is an 
inducible isoform upregulated by heme and oxidative stress signals such as hypoxia, 
inflammatory cytokines, metals and hydrogen peroxide (31-33). Studies with HO-1 null mice 
provided insight into the role of HO-1 as an important enzymatic antioxidant system. HO-1 
deficient mice demonstrate growth retardation, tissue iron overload, and vulnerability to 
oxidative stress, phenotypes that are similar to those found in patients with HO-1 deficiency (33-
35). The protective effects of HO-1 are related to this enzyme’s capacity to provide biliverdin 
and bilirubin, both of which are powerful antioxidants.  
HO-2 was initially thought to be a constitutively-induced enzyme but recent reports 
suggest that HO-2 expression might also be regulated depending on the cellular 
microenvironment (36,37). Like HO-1, HO-2 also plays an important role in protecting against 
oxidative injury. Mice lacking HO-2 had substantially increased mortality following chronic 
hyperoxia (32). Interestingly, loss of HO-2 in HO-2 knockout mice results in a compensatory 
increase in HO-1 expression. However this was not sufficient to protect the HO-2 knockout mice 
from hyperoxia-induced oxidative injury (38,39).  
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Figure 1.2.  
 
 
 
Heme catabolism 
Three steps in the degradation of heme catalyzed by hemeoxygenase (HO). First, heme binds 
to HO as a substrate and activates the first O2 mediated oxidation. Second, HO regiospecifically 
hydroxylates α-meso carbon atom of the porphyrin ring which immediately reacts with a second 
O2 molecule to yield verdoheme and carbon monoxide (CO). Finally a third oxidation reaction 
cleaves the heme macrocycle to form biliverdin and Fe(II). 
  
11 
 
1.3c. Regulation of heme biosynthesis and heme catabolism 
Heme biosynthesis is regulated by the rate-limiting enzyme ALAS which catalyzes the 
first step in heme biosynthesis (40). In animals, two separate genes have been identified for 
ALAS; one encodes the erythroid specific form (ALAS2 or ALAS-E) and the other, the 
housekeeping gene (ALAS1 or ALAS-H) which is ubiquitously expressed (32). The evolution of 
two isoforms for the same enzyme is probably associated with the differential requirements of 
heme in different cells/tissues. ALAS1 controls the production of heme for basic cellular 
functions while ALAS2 is mainly involved in the synthesis of heme for the production of 
hemoglobin in differentiating erythrocytes. Likely to accommodate the different functional 
requirements, the two genes for ALAS are under separate control mechanisms, and in man, are 
localized to different chromosomes (32).  
Heme synthesis in non-erythroid cells: role of  ALAS1. ALAS1 is mainly involved in the 
production of heme for basic cellular functions and as such, ALAS1 synthesis is negatively 
regulated by heme, the end product of the heme biosynthetic pathway (Figure 1.3) (41). 
Conversely, ALAS in the liver can be induced by treatment with chemicals, particularly those 
that induce the expression P450s and those that decrease free heme concentration, which can 
be accomplished by decreasing its synthesis or by increasing its catabolism (42,43). The most 
important effect of heme on hepatic heme synthesis appears to occur at the level of repression 
of ALAS synthesis. ALAS repression occurs at four different levels which are all influenced by 
heme; 1) direct inhibition of ALAS activity, 2) repression of the synthesis of mRNA for ALAS, 3) 
repression of ALAS at the translational level, and 4) inhibition of the translocation of the 
cytoplasmic form of the enzyme into the mitochondrial matrix (32,44). Importantly, heme 
mediated repression of ALAS1 is responsible for rendering this enzyme the rate limiting step in 
non-erythroid heme biosynthesis.  
12 
 
Heme synthesis in erythroid cells, role of iron: ALAS2 is solely involved in synthesizing 
heme for the production of hemoglobin in differentiating erythrocytes (1). Thus, erythroid 
differentiation requires a coordinate regulation of expression of globin genes and the genes for 
the enzymes of the heme biosynthetic pathway (1,32). Regulation of ALAS2 is therefore very 
complex and occurs at many different levels. In erythroid cells, heme does not inhibit the 
synthesis of ALAS2; rather heme treatment of erythroid cells significantly increases the 
incorporation of radiolabeled Glycine into heme, indicating that all enzymes in the pathway 
including ALAS2 are increased. ALAS2 expression is regulated at the posttranslational level, by 
iron. ALAS2 mRNA contains an Iron Response Element (IRE) at its 5’ UTR, this localization of 
the IRE dictates that the translation of erythroid ALAS mRNA depends on the availability of iron 
(Figure 1.3) (45). Another important feature of ALAS2, with possible implications for heme 
synthesis regulation in erythroid cells, is that this enzyme associates with succinyl CoA 
synthase. It seems that succinyl CoA serves as an anchor protein for erythroid specific ALAS2 
and may provide succinyl CoA more efficiently to ALAS (41).  In erythroid cells, heme does not 
inhibit ALAS2 activity; rather it blocks the uptake of iron from transferrin. Hence, although 
hemoglobin-synthesizing cells remain faithful to the basic principles whereby heme feedback 
inhibits heme synthesis, this feedback regulation is executed differently in erythroid cells than 
non-erythroid cells (32,41). 
The mechanisms controlling heme catabolism involves transcriptional regulation of HO-1 
gene through the transcriptional repressor Bach 1. Bach 1 is a heme regulated repressor, and is 
able to bind to Maf (musculoaponeurotic fibrosarcoma oncogene homolog) recognition element 
(MARE) as a hetero-dimer with a small Maf family member (46). When a small Maf transcription 
factor binds to MARE site with NF-E2 (p45) or Nrf2, they can stimulate transcription of genes, 
while heterodimers consisting of small Maf and Bach 1, on MARE site suppresses transcription 
of the target genes (46,47). Heme modulates the Heme Regulatory Motif (HRM) on Bach 1 
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which then reverses the repressor function of Bach 1 at the MARE of HO-1 to induce its 
expression (41,48,49). 
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Figure 1.3. 
 
 
Modified with permission from: Ponka, P: Blood (1997) 89:1-25. 
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Figure 1.3. (continued) 
Regulation of heme synthesis in A) non-erythroid cells B) erythroid cells.  
Heme synthesis involves eight distinct enzymes (see Figure 1.1). Differences in Fe metabolism 
and in genes for delta-amino levulinate synthase (ALAS) probably account for the differences in 
the rate of heme synthesis and its regulation in erythroid cells (B) compared with that in 
nonerythroid cells (A). In nonerythroid cells, the rate-limiting step of heme production is that 
catalyzed by the ALAS1. The synthesis and possibly the activity of ALAS1 is subject to 
feedback inhibition by heme, and this is probably one of the factors making ALAS1 the rate-
limiting enzyme of the heme pathway. On the other hand, in erythroid cells, heme does not 
inhibit either the activity or the synthesis of ALAS2, but does inhibit cellular iron acquisition from 
transferrin without affecting its utilization for heme synthesis. This negative feedback is likely to 
explain the mechanism by which the availability of transferrin iron limits heme synthesis rate. 
Since the 5′ untranslated region of ALAS2 mRNA contains iron response element (IRE), the 
availability of iron controls ALAS2 translation, the rate of ALA formation, and consequently the 
overall rate of heme synthesis. In addition, iron may play a role in the synthesis and/or stability 
of ALAS2 mRNA. Heme is also essential for globin translation and may also be involved in 
globin gene transcription. In contrast, in nonerythroid cells the removal of iron from transferrin is 
not regulated by intracellular heme and the ubiquitous ALAS1 mRNA does not contain the IRE 
so that Fe availability does not control the overall heme synthesis rate. (Tf, transferrin; Gly, 
glycine; PPIX, protoporphyrin IX; HO, heme oxygenase; FC, ferrochelatase.) 
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1.3d. Heme and porphyrin transport 
Heme is readily associated with membranes because of its lipophilic nature but, contrary 
to earlier beliefs, these compounds (heme and porphyrins) are incapable of readily traversing 
the biological membranes. Heme and porphyrins carry anionic carboxylate side chains which 
introduce negative charges to the molecule, limiting their ability to diffuse across membranes. 
So an energy-dependent mechanism is required to move the carboxylate side chains through 
the lipid bilayer. Furthermore, kinetic studies in model membrane lipid bilayers and isolated 
membranes have indicated that transmembrane diffusion of heme is inadequate to support the 
synthesis of hemoproteins. In addition, the reduction in cellular energy redistributes intracellular 
heme, suggesting that intracellular heme gradients are maintained actively. In fact, the lipophilic 
nature of heme and porphyrins causes these molecules to accumulate in the lipid bilayer of 
membranes rather than be transported across the membrane.  
1.3d.i. Heme transport across the plasma membrane  
Heme carrier protein 1 (HCP-1) a heme uptake carrier 
HCP1 was originally isolated from mouse duodenum using subtractive hybridization (50). 
HCP1 gene codes for a 50-kDa protein with 9 predicted transmembrane domains (TM) that is 
highly conserved across species and has a striking homology to bacterial metal-tetracycline 
transporters, which belong to a large family of transporters known as the major facilitator 
superfamily (MFS) (50,51). MFS proteins transport small molecules (e.g., sugars, amino acids) 
across membranes by using either ion or proton gradients as an energy source.  
HCP1 protein localizes to the apical membrane of the duodenum, and plays a role in the 
uptake of dietary heme (51). Xenopus oocytes and HeLa cells expressing HCP1 demonstrate a 
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2- to 3-fold increase in heme uptake that is both saturable and temperature dependent (52-54). 
Furthermore, HCP1-specific siRNA reduces HCP1-induced increase in 55Fe-heme uptake (51). 
The strongest in vivo evidence supporting the role of HCP1 in intestinal heme transport comes 
from blocking studies using HCP1-specific antisera. The uptake of 55Fe into everted duodenal 
sacs was blocked by HCP1 antisera but not by preimmune sera (51). The source of energy for 
HCP1-mediated heme transport is yet to be defined, though it most likely involves co-transport 
of a proton or ion along a favorable concentration gradient similar to the mechanism used by 
other MFS transporters. Moreover, effective competition of HCP1-mediated transport revealed 
that while the porphyrin ring is important, the presence of a metal ion (Zn+2 or Fe+2) is not. 
Feline leukemia virus receptor C (FLVCR1a) a heme efflux protein 
FLVCR was originally cloned as a cell surface protein that served as a receptor for feline 
leukemia virus, subgroup C. FLVCR is highly expressed in tissues that either transport heme 
(i.e., intestinal or hepatic cells) or synthesize high levels of heme (erythroid cells). Like HCP1, 
FLVCR is a MFS protein that transports small solutes across membranes by using the energy of 
ion-proton gradients. However, unlike cells that express HCP1, cells engineered to 
express FLVCR show significant reduction in cellular heme content, which was assessed by 
measuring the retention of radioactive hemin (52,53). The level of 55Fe-hemin was substantially 
reduced only in FLVCR-expressing cells and not in cells engineered to express a nonfunctional 
FLVCR (53,55). Moreover, FLVCR-mediated heme export was time and temperature 
dependent. Finally, FLVCR mediates unidirectional heme transport and does not appear to 
import heme (53,55). Even under conditions of low intracellular heme concentration, FLVCR 
does not reverse function to increase heme uptake. 
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Abcg2/Bcrp in the efflux of heme and porphyrins 
  Abcg2 (Bcrp) is a “half” transporter and a member of the ATP-binding cassette (ABC) 
family that is capable of moving substrates against a concentration gradient. Abcg2 localizes to 
the plasma membrane and was initially identified in a cell line that had a specific resistance 
phenotype characteristic of an ABC transporter (i.e., an ATP-dependent reduction in the 
intracellular accumulation of anticancer drugs) (56-58). Subsequent studies showed that Abcg2 
is expressed in normal tissues, with the highest expression in placental syncytiotrophoblasts. 
These cells are in contact with the maternal blood; and therefore Abcg2 is thought to protect the 
human fetus by transporting drugs and toxins from the placenta back into maternal circulation 
(59-61). 
Role of ABCG2 in porphyrin transport was noted when Bcrp-null mice were inadvertently 
exposed to a dietary modification that caused phototoxicity. The underlying cause of skin 
phototoxicity was the increased accumulation of pheophorbide, a phototoxic chlorophyll-
degradation product (62). Subsequent studies confirmed that pheophorbide was indeed an 
Abcg2 substrate (62,63). It is notable that the structure of pheophorbide is very closely related 
to that of porphyrins, which are strong photosensitizing agents. The possibility that Abcg2 
interacts with heme and protoporphyrin molecules was assessed by affinity-precipitation studies 
using hemin-agarose. Abcg2 was precipitated by hemin-agarose, and its binding was specific as 
hemin decreased the amount of precipitated heme in a dose-dependent manner (64). The 
tetrapyrrole structure is an important molecular feature in the interaction with Abcg2, because 
porphobilinogen, a monopyrrole precursor of tetrapyrroles, was unable to compete with the 
Abcg2–hemin-agarose complex (64). 
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1.3d.ii. Intracellular heme/porphyrin transport 
In mammalian cells, transport of heme and porphyrins takes place not only across the 
plasma membrane but also across the membranes of intracellular organelles. For example, 
intracellular transport of heme takes place across mitochondrial membranes during heme 
synthesis, across the lysosomal membrane during hemoglobin catabolism, across the nucleus 
where it can activate or repress transcription, and across the endoplasmic reticulum for 
synthesis of P450s and for heme oxygenase. Further, the biological effects of heme are highly 
compartment-specific.     
A) Mitochondrial heme transporters  
One of the most intriguing aspects of heme metabolism is the subcellular 
compartmentalization of the enzymes of heme synthesis and catabolism. Heme synthesis is 
initiated in the mitochondrial by ALAS, and continues via intermediates synthesized in the 
cytosol, which is followed by the return of corporporphyrinogen III to the mitochondrion for final 
steps in heme formation (Figure 1.1). Thus, transfer of tetrapyrole intermediates across 
mitochondrial membranes must occur in the later stages of heme synthesis and presents an 
interesting problem in terms of the intracellular movement of pyrrolic compounds. 
Peripheral benzodiazepine receptor 
The peripheral-type benzodiazepine receptor (PBR) was initially identified as a 
benzodiazepine (diazepam)-binding receptor located in the outer mitochondrial membrane (65-
67). To determine if an endogenous ligand existed, tissue extracts were prepared and assayed 
for their ability to displace radiolabeled benzodiazepines. Analysis of the activity that displaced 
radiolabeled benzodiazepines revealed that porphyrins were potent disrupters of the interaction 
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between radiolabeled benzodiazepine and PBR (66). Further analysis indicated that among the 
porphyrins, PPIX was most potent, whereas hemin was less effective (66). These studies 
supported the idea that porphyrins are endogenous ligands. While these studies were 
interpreted as demonstrating PBR transports PPIX, a closer inspection reveals that these 
studies do not effectively discriminate between PPIX transport and binding. Furthermore, given 
the relatively low affinity of the PBR for a porphyrin precursor such as COPIII and the lack of 
energy requirement, it seems unlikely that PBR is a porphyrin transporter. 
Mitochondrial ATP-binding cassette transporter Abcb6  
Abcb6 is highly expressed in fetal liver, erythroid cells and in adult tissues that have 
substantial heme requirements because of their high metabolic activity (e.g., heart and skeletal 
muscle). Abcb6 is a specific heme-binding protein by virtue of its ability to be “pulled down” 
by the affinity resin hemin-agarose and the requirement of a specific domain (28). The 
interaction between Abcb6 and hemin-agarose is specifically disrupted only by tetrapyrole-
containing molecules (hemin and other protoporphyrins such as COPIII) and not by monopyrole-
containing molecules such as porphobilinogen. Moreover, COPIII, an oxidized form of the 
ultimate cytosolic protoporphyrin heme biosynthetic precursor, was highly effective in disrupting 
Abcb6 interaction with hemin-agarose (28,68,69). Furthermore, in transport assays, COPIII (the 
oxidized form of coproporphyrin) functioned as a better competitor for 55Fe-Heme uptake than 
other porphyrins (28). This is interesting, since the reduced form COPIII is the final byproduct of 
heme biosynthesis in the cytoplasm and has to be transported into the mitochondria for further 
catalysis, a process which has been shown to require an energy dependent mechanism. In this 
context, the ideal localization of Abcb6 to the outer mitochondrial membrane and its ability to 
interact and transport coproporphyrinogen suggests that COPIII is the endogenous substrate for 
Abcb6 in vivo. 
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Feline leukemia virus 1b 
FLVCR1b is an isoform which contains a shortened N terminus of the previously 
described FLVCR1a mRNA (described above). The protein encoded by the FLVCR1b transcript 
has a mitochondrial targeting signal at the N terminus (70,71). Flvcr1b is ubiquitously expressed 
in mouse tissues with highest transcript levels in the brain, followed by tissues with high heme 
synthesis rates, such as the heart, skeletal muscle, bone marrow, and spleen (70,71). 
Knockdown of the FLVCR1b isoform impaired erythroid differentiation in vitro (70,72). 
Overexpression of the protein increases cytosolic heme and that knockdown of FLVCR1b 
results in mitochondrial heme retention, suggest that the FLVCR1b could serve as a heme 
exporter at mitochondria (70,71). However, FLVCR1b mediated direct transport of heme out of 
mitochondria or not needs to be demonstrated.  
 
B) Endoplasmic reticulum heme transporters (Ligandin) 
Transport of newly synthesized heme from mitochondria to the apocytochrome in 
vesicles has been reported to be mediated by ligandin (73). However, ligandin mediated 
transport process in intact cells is not demonstrated yet.   
C) Peroxisomal heme transporters 
Peroxisomes which, like mitochondria, are a major site of oxygen utilization, contain 
most of the cell’s catalase the antioxidant hemoprotein that neutralizes the potentially lethal 
oxidant hydrogen peroxide. Catalase is not synthesized as a precursor, but is released into the 
cytosol as apocatalase. Concomitant with transport across the peroxisomal membranes, the 
chains are assembled into tetramers, and heme transported from the mitochondria is added. 
However, the details of this process are not defined (74).   
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Figure 1.4. 
 
 
 
Model for heme/porphyrin transporters  
Heme/porphyrin transporters are located at the plasma membrane and mitochondria. FLVCR1a 
and Abcg2 localize to the plasma membrane and efflux intracellular porphyrin/heme whereas 
HCP1 is located on the plasma membrane and imports extracellular heme. The mitochondrial 
transporter Abcb6 localizes to the outer mitochondrial membrane and transports 
heme/porphyrins from the cytoplasm into the mitochondria. FLVCR1b is the mitochondrial heme 
exporter. 
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1.4. The human ATP binding cassette transporter subfamily 
 
1.4a. Evolution of ABC transporter superfamily 
All cells are separated from the external milieu by lipid membranes, which are crucial to 
the life of the cell. This lipid bilayer functions as a barrier that defines the cellular boundary and 
maintains the essential difference between the cytosol and the extracellular environment. In 
addition, inside a eukaryotic cell, the membranes of the endoplasmic reticulum, golgi apparatus, 
mitochondria, and other membrane-enclosed organelles maintain the characteristic differences 
between the content of each organelle and the cytosol. However, in order to benefit from this 
barrier, cells have had to evolve ways of transferring specific water-soluble molecules and ions 
across their membranes. This necessitates the development of specialized transmembrane 
proteins that regulate the selective passage of specific molecules across these membranes to 
not only acquire nutrients and excrete waste products, but also perform a multitude of regulatory 
and other functions. The importance of membrane transport to the cell is reflected in the large 
number of genes in all organisms that code for transport proteins, which make up almost 20% of 
membrane proteins in all cells, with some specialized mammalian cells devoting up to two-thirds 
of their total metabolic energy consumption to membrane transport processes.  
The evolution of transport proteins in cells can be grouped under two broad classes, 
transporters and channels, both of which form continuous protein pathways across the lipid 
bilayer. Whereas transmembrane movement of solutes mediated by channel proteins is always 
passive, solute movement mediated by transporters can be either active or passive. 
Transporters belong to a small number of protein families that bind specific solutes and transfer 
them across the lipid bilayer by undergoing conformational changes that expose the solute-
binding site sequentially on one side of the membrane and then on the other. Each transporter 
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family contains proteins of similar amino acid sequences that are thought to have evolved from 
a common ancestral protein and to operate by a similar mechanism. The superfamily of ABC 
transporters is the largest family of membrane proteins and is especially important clinically. 
1.4b. General features of ABC transporters 
 Transport proteins are designated as ABC transporters based on the highly conserved 
ATP-binding cassette, which is the most characteristic feature of this superfamily. The ATP-
binding cassette (ABC) consists of two conserved sequence motifs known as the Walker A and 
Walker B motifs that bind and hydrolyze ATP. In addition all ABC transporters also share a third 
sequence motif known as the Walker C or the signature  motif, located just upstream of the 
Walker B site (Figure 1.5) (4). The Walker C motif distinguishes ABC transporters from other 
ATP-binding proteins and is thought to be essential for ATP hydrolysis. The ABC transporters 
use the energy of ATP hydrolysis to drive the transport of various molecules across the cell 
membranes (1–3) (Figure 1.5).  
ABC transporters require the function of multiple polypeptides/protein domains, 
organized in a characteristic fashion (Figure 1.5). The typical transporter consists of four 
membrane-associated domains. Two of these domains are highly hydrophobic and each 
consists (normally) of six membrane-spanning segments. These domains form the pathway 
through which substrate crosses the membrane and, in large part, are believed to determine the 
substrate specificity of the transporter. The other two domains are the nucleotide binding 
domains, described above, that are peripherally located at the cytoplasmic face of the 
membrane, bind ATP and couple ATP hydrolysis to the transport process. In addition, certain 
ABC transporters have additional domains that serve regulatory or other peripheral functions. 
For example, the cystic fibrosis gene product, CFTR, has a fifth domain, the R-domain, which 
has no equivalent in any other ABC transporter and serves a regulatory function (75,76). The 
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ATP-binding domain of the maltose transporter (MaIK) has a C-terminal extension that has an 
enzymatic function apparently independent of the transport process (77).  
The eukaryotic ABC genes are organized either as full transporters containing two TMDs 
and two NBDs within a single polypeptide chain, or as half transporters with one TMD and one 
NBD. The latter must form either homodimers or heterodimers to form a functional 
transporter. In eukaryotes, most functional ABC proteins move substrates from the cytoplasm to 
the outside of the cell or into an intracellular compartment such as endoplasmic reticulum (ER), 
mitochondria, peroxisome and lysosome.  
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Figure 1.5. 
 
Diagram of a typical ABC transporter protein 
A) A diagram of the structure of a representative ABC protein is shown with the lipid bilayer 
in yellow, the transmembrane (TM) domains in crimson, and the nucleotide binding domains 
(NBD) in magenta. Although the most common arrangement is a full transporter with motifs 
arranged N-TM-NBD-TM-NBD-C, as shown, NBD-TM-NBD-TM, TM-NBD, and NBD-TM 
arrangements are also found. B) The NBD of an ABC gene contains the walker A and B motifs 
found in all ATP-binding proteins. In addition, a signature or C motif is also present.  
 
  
27 
 
1.4c. Classification and nomenclature of ABC gene subfamilies 
ABC genes are broadly dispersed in eukaryotic genomes and are highly preserved 
between species, demonstrating evolutionary conservation of these genes. The genes can be 
divided into subfamilies based on similarity in gene structure (half versus full transporters), and 
on sequence homology in the NBD and TMDs.  Human and mouse ABC genes have standard 
nomenclature, developed by the Human Genome Organization (HUGO) Gene Nomenclature 
Committee (HGNC). Details of the nomenclature scheme can be found at: 
http://www.genenames.org/genefamilies/ABC.  
 Several sequences in the genome with homology to ABC genes are positioned in 
incompletely sequenced regions and may represent pseudogenes. The existing eukaryotic 
genes are grouped into seven major subfamilies, A to G, based on sequence alignment of the 
NBDs and phylogenetic analysis. A list of all known human ABC genes and pseudogenes is 
presented in Table 1.2 with their chromosomal location and known function, when defined. 
28 
 
 
 
Table 1.2. List of human ABC genes, chromosomal location, and function. 
Approved Symbol Alias Chromosome Function 
ABCA1 ABC1, HDLDT1 9q31 
Cholesterol efflux onto 
HDL 
ABCA2 ABC2 9q34 Drug resistance 
ABCA3 ABC3 16p13.3 Surfactant secretion? 
ABCA4 
STGD1, ABCR, RP19, 
STGD 
1p22 N-Retinylidiene-PE efflux 
ABCA5 17q24.3 
ABCA6 17q21 
ABCA7 19p13.3 
ABCA8 17q24 
ABCA9 17q24 
ABCA10 17q24 
ABCA11P# ABCA11 4p16.3 
ABCA12 ICR2B 2q34 
ABCA13 7p12.3 
ABCA17P# 16p13.3 
ABCB1 PGY1, MDR1, CLCS 7q21.12 Multidrug resistance 
TAP1 ABCB2 6p21.3 Peptide transport 
TAP2 ABCB3 6p21.3 Peptide transport 
ABCB4 PGY3, MDR3 7q21 PC transport 
ABCB5 7p14 
Abcb6 2q36 Iron transport 
ABCB7 ABC7 Xq13.3 Fe/S cluster transport 
ABCB8 7q36.1 
ABCB9 12q24 
ABCB10 1q32 
ABCB11 BSEP, PFIC2 2q24 Bile salt transport 
ABCC1 MRP, MRP1 16p13.1 Drug resistance 
ABCC2 CMOAT 10q24 Organic anion efflux 
ABCC3 17q21 Drug resistance 
ABCC4 13q31 Nucleoside transport 
ABCC5 3q27 Nucleoside transport 
ABCC6 ARA, PXE 16p13.11 
CFTR CF, ABCC7 7q31-q32 Chloride ion channel 
ABCC8 SUR, HRINS 11p15.1 Sulfonylurea receptor 
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Table 1.2. (continued) 
Approved Symbol Alias Chromosome Function 
ABCC9  12p12.1 K(ATP) channel regulation
ABCC10 6p12.3 
ABCC11 16q12 
ABCC12 16q12.1 
ABCC13# 21q11.2 
ABCD1 ALD Xq28 VLCFA transport  
ABCD2 ALDL1 12q12 
ABCD3 PXMP1 1p21.3 
ABCD4 PXMP1L 14q24 
ABCE1 
RNASEL1, RNASELI, 
RNS4I 
4q31 
Oligoadenylate binding 
protein 
ABCF1 ABC50 6p21.33 
ABCF2 7q36.1 
ABCF3 3q27.1 
ABCG1 21q22.3 Cholesterol transport? 
ABCG2 4q22.1 Toxin and drug efflux 
ABCG4 11q23 
ABCG5 2p21 Sterol transport 
ABCG8 2p21 Sterol transport 
30 
 
ABCA 
The human ABCA subfamily comprises 12 full transporters (Table 1.2). Two members of 
this subfamily, the ABCA1 and ABCA4 proteins, have been studied extensively. The 
mammalian ABCA1 is required for cholesterol transport from peripheral cells such as 
macrophages into high-density lipoprotein (HDL) particles (78). Thus, mutation in huABCA1 is 
associated with disorders of cholesterol transport and HDL biosynthesis like Tangiers disease 
and familial HDL deficiency (79-82). The murine Abca1-/- phenotype corroborate the human 
Tangiers disease and also show placental malformation and altered steroidogenesis (83,84). 
The huABCA4 protein is restricted to the photoreceptor cells and facilitates transport of vitamin 
A derivatives in the outer segments of rod photoreceptor cells and performs a crucial step in the 
vision cycle. The murine Abca4-/- displays delayed adaptation to dark and is a model for juvenile 
macular degeneration (85,86). 
ABCB  
The ABCB subfamily is unique among the ABC subfamilies in two ways. First, the 
complement of ABCB genes is identical in all mammals characterized to date, except that the 
gene encoding P-glycoprotein (Abcb1) is duplicated in the rodent genomes. This suggests that 
the ABCB genes have important, conserved functions that are similar in all mammals. Second 
ABCB subfamily is unique as it contains both full and half transporters.  
The human ABCB subfamily comprises 11 transporters. ABCB1 is the first human ABC 
transporter cloned and characterized for its ability to confer multi drug resistance (MDR) 
phenotype to cancer cells. The ABCB2 and ABCB3 (TAP) genes are half transporters which 
heterodimerize to transport peptides into the endoplasmic reticulum, which then complex with 
HLA class I molecules for presentation on the cell surface (87-89). The ABCB4 and ABCB11 
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proteins are both located in the liver and are involved in the secretion of bile acids (90-92). 
Mutation in ABCB4 leads to cholethiasis while mutation in ABCB11 leads to cholestasis (90,91).  
The ABCB9 half transporter, homolog of the TAPs, has been localized to lysosomes (93). The 
remaining four half transporters, Abcb6, ABCB7, ABCB8, and ABCB10, localize to the 
mitochondria, where they function in iron metabolism, heme biosynthesis and transport of Fe/S 
protein precursors (28,94-97). 
ABCC 
The ABCC subfamily contains 13 full transporters of diverse functions that include ion 
transport, cell-surface receptor, and metabolite secretion activities. The ABCC7/CFTR gene 
encodes for a chloride channel that is mutated in patients with cystic fibrosis (11). ABCC8 and 
ABCC9 proteins regulate potassium channels involved in modulating insulin secretion. The rest 
of the subfamily (ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC6, ABCC10 and ABCC13) is 
composed of nine multidrug resistance associated proteins (MRPs) which are involved in the 
cellular export of toxic compounds and therapy drugs either complexed with glutathione or co-
transported with glutathione   
ABCD  
The ABCD subfamily contains four genes encoding half transporters. All ABCD 
members are localized in the peroxisome. ABCD1 and ABCD2 function as homo- and/or 
heterodimers and regulate the transport of very long chain fatty acids (97). Homozygous 
deletion of  ABCD1 and ABCD2 gene in mice lead to accumulation of  very long chain fatty acid 
resulting in the  development of  late onset  neurodegenerative disease (98). Physiological 
function of ABCD3 and ABCD4 is not known yet. 
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ABCE and ABCF  
The ABCE and ABCF subfamilies are unique because they have no TMD and are not 
known to be involved in any membrane transport functions. The ABCE subfamily is solely 
composed of the oligo-adenylate-binding protein. Mice homozygous for the Abce gene 
disruption exhibit embryonic lethality at embryonic day E7. ABCF1 is associated with the 
ribosome and appears to play a role in the activation of elf2α kinase similar to its yeast homolog 
GCN20 (99,100). 
ABCG 
The human ABCG subfamily is composed of six “reverse” half transporters that have an 
NBD at the N terminus and a TMD at the C-terminus. The mammalian ABCG1 protein is 
involved in cholesterol transport (18). ABCG2, one of the well characterized members of this 
family, was originally identified as a gene overexpressed in several drug-resistant cell lines. The 
protein is found in the intestine, placenta, and liver and regulates the transport of drugs and 
toxins into and out of these tissues. Recent studies suggest that ABCG2 may also play a role in 
heme and porphyrin homeostasis (64,101).  
The remaining ABCG family genes are involved in transporting cholesterol and other 
sterols. The ABCG5 and ABCG8 are both required for transporting sterols, such as cholesterol 
and plant and shellfish sterols, out of intestinal cells and from the liver in to the bile (102-104). 
ABCG1 and ABCG4 are closely related genes that are both induced by cholesterol. ABCG1 is 
predominantly found in macrophages and ABCG4 in the brain (105,106). However, both genes 
have several alternatively spliced transcripts some of which are exclusively expressed in other 
tissues such as the lung and thymus (107).   
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1.4d. ABC genes and human genetic disease 
Many ABC genes were originally discovered during the positional cloning of human 
genetic disease genes. To date, 17 ABC genes have been linked to disorders displaying 
Mendelian inheritance (19) (Table 1.3). As expected from the diverse functional roles of ABC 
genes, the genetic deficiencies that they cause also vary widely. Because ABC genes typically 
encode structural proteins, all of the disorders are recessive or X-linked recessive and are 
attributable to a severe reduction or lack of function of the protein. However, heterozygous 
variants in ABC gene mutations are being implicated in the susceptibility to specific complex 
disorders. 
Few ABC gene mutations are lethal. Untreated cystic fibrosis (ABCC7 /CFTR) is typically 
lethal in the first decade, and adrenoleukodystrophy (ABCD1 /ALD) can also be fatal in the first 
10 years of life (108-110). The only mutations described in ABCB7 are missense alleles, and 
the yeast homolog is essential to mitochondria, suggesting that this gene is essential. The only 
developmental defect ascribed to an ABC gene is the congenital absence of the vas deferens 
that occurs in both cystic fibrosis patients and patients with less severe alleles that present male 
sterility as their only phenotype (111,112). Thus, most ABC genes do not play an essential role 
in development. 
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Table 1.3. ABC genes: human ABC genes and mendelian disorders 
Gene Mendelian disorder Complex disease Animal model 
ABCA1 Tangier disease, FHD   HDL levels Mouse, chicken 
ABCA3  Surfactant deficiency   
ABCA4 Stargardt/FFM, RP, CRD AMD Mouse 
ABCA12  Lamellar ichthyosis   
ABCB1 Ivermectin susceptibility Digoxin uptake Mouse, dog 
ABCB2 Immune deficiency   Mouse 
ABCB3 Immune deficiency   Mouse 
ABCB4 PFIC3 ICP  
ABCB7 XLSA/A    
ABCB11 PFIC2    
ABCC2 Dubin-Johnson Syndrome   Rat, sheep, monkey 
ABCC6 Pseudoxanthoma elasticum   Mouse 
ABCC7 Cystic Fibrosis, CBAVD Pancreatitis, 
bronchiectasis 
Mouse 
ABCC8 FPHHI   Mouse 
ABCC9 DCVT   
ABCD1 ALD   Mouse 
ABCG5 Sitosterolemia   Mouse 
ABCG8 Sitosterolemia   Mouse 
FHD, familial HDL deficiency; FFM, fundus flavimaculatis; RP, retinitis pigmentosum 19; CRD, 
cone-rod dystrophy; AMD, age-related macular degeneration; PFIC, progressive familial 
intrahepatic cholestasis; ICP, intrahepatic cholestasis of pregnancy; XLSA/A, X-linked 
sideroblastosis and anemia; CBAVD, congential bilateral absence of the vas deferens; FPHHI, 
Familial persistent hyperinsulinemic hypoglycemia of infancy; ALD, adrenoleukodystrophy, 
DCVT, dilated cardiomyopathy with ventricular tachycardia 
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1.4e. Mouse ABC genes and knockouts 
Mice have 52 ABC genes and most of the human genes have a clear mouse ortholog, 
indicating that the functions of the mouse genes should be highly similar to human genes; 
however, there are several exceptions (Table 1.4). Biological functions of some of these 
transporters has been facilitated by both genetic defects, so called ‘accidents of nature’ and the 
adventitious discovery of their role in causing chemotherapeutic drug resistance.  
A number of ABC genes have been disrupted in the mouse including those mutated in 
human diseases (Table 1.4). The Abca1–/–, Cftr–/–, Abce1–/– and Abcc4–/– mice show 
compromised viability; however, the remaining knockouts are viable and fertile, and many show 
either no phenotype or a phenotype only under stressed conditions. 
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Table 1.4. ABC genes: mouse ortholog for human gene 
Human gene Mouse gene Location Knockout 
ABCA1 Abca1 4, 23.1 cM Y  
ABCA2 Abca2 2, 12.6 Y 
ABCA3 Abca3 Unknown Y 
ABCA4 Abca4 3, 61.8 Y 
ABCA5 Abca5 Unknown Y 
ABCA6 Abca6 Unknown N 
ABCA7 Abca7 10, 44 Y 
ABCA8 Abca8a Unknown N 
  Abca8b 11, 69 N 
ABCA9 Abca9 Unknown N 
ABCA10  Abca10     
ABCA12 Abca12 1C1  Y 
ABCA13 Abca13 11A1   
ABCB1 Abcb1a 5, 1 Y  
  Abcb1b 5, 1 Y 
ABCB2 Abcb2 (Tap1) 17 Y 
ABCB3 Abcb3 (Tap2) 17 N 
ABCB4 Abcb4 5, 1 Y 
ABCB5 Abcb5 12, 60   
ABCB6 Abcb6 1, C3 Y 
ABCB7 Abcb7 X, 39 N 
ABCB8 Abcb8 Unknown N 
ABCB9 Abcb9 5, F N 
ABCB10 Abcb10 8, 67 Y 
ABCB11 Abcb11 2, 39 Y 
ABCC1 Abcc1 16 Y 
ABCC2 Abcc2 19 Y  
ABCC3 Abcc3 Unknown Y 
ABCC4 Abcc4 13, E4 Y 
ABCC5 Abcc5 16, 14 Y 
ABCC6 Abcc6 7, B3 Y 
ABCC7 Abcc7 (Cftr) 6, 3.1 Y 
ABCC8 Abcc8 7, 41 Y 
ABCC9 Abcc9 6, 70 Y 
ABCC10 Abcc10 Unknown N 
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Table 1.4. (continued) 
Human gene Mouse gene Location Knockout 
ABCC11 Abcc11 8, 44-45   
ABCC12       
ABCD1 Abcd1 X, 29.5 Y 
ABCD2 Abcd2 15, E-F N 
ABCD3 Abcd3 3, 56.6 N 
ABCD4 Abcd4 12, 39 N 
ABCE1 Abce1 8, 36 N 
ABCF1 Abcf1 17, 20.5 N 
ABCF2 Abcf2 13, 40 N 
ABCF3 Abcf3 16, 22 N 
ABCG1 Abcg1 17, A2-B N 
ABCG2 Abcg2 6, 28.5 Y 
  Abcg3 5, 59 N 
ABCG4 Abcg4 9, syntenic N 
ABCG5 Abcg5 17, syntenic N 
ABCG8 Abcg8 17, syntenic N 
Y= Yes; N= No 
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1.5. Mitochondrial ATP binding cassette transporter Abcb6  
Mitochondria are dynamic organelles that play a pivotal role in energy metabolism. 
Mitochondria are also involved in regulation of heme biosynthesis, iron homeostasis and 
biogenesis of iron–sulfur clusters. In addition, mitochondria play a major role in the regulation of 
apoptosis and are the major source of reactive oxygen species (ROS). Because of its central 
role in several vital processes, mitochondrial dysfunction is linked to human diseases. Reduced 
ATP level is associated with neurological disorders and mutations in mitochondrial DNA can 
cause MELAS (Mitochondrial Encephalopathy and Lactic Acidosis with Stroke like episodes) or 
Leigh's syndrome (113). Dysfunctional mitochondrial ATP binding cassette (ABC) proteins are 
also linked to human diseases.  
There are four mitochondrial ABC transporters known to date, Abcb6, Abcb7, Abcb8, 
and Abcb10. All of them play a role in some aspect of heme and iron homeostasis 
(28,94,95,97). Abcb7 localizes to the mitochondrial inner membrane and regulates 
mitochondrial iron homeostasis by forming iron–sulfur clusters (95). Defect in ABCB7 causes a 
rare type of X-linked sideroblastic anemia with cerebella ataxia (XLSA/A) (95,114). ABCB8 is 
involved in mitochondrial iron export, is essential for baseline cardiac function and appears to 
protect cells against ischemia and oxidative stress (94, 97). Genetic deletion of ABCB8 in 
mouse hearts results in mitochondrial iron accumulation and cardiomyopathy. Abcb10 localizes 
to mitochondrial inner membrane and exports ALA from the mitochondria into the cytosol. 
Abcb10 also plays important role in oxidative stress response and improves cardiac recovery 
after ischemia–reperfusion (94). Abcb6 localizes to the outer mitochondrial membrane and is 
shown to transport COPIII into mitochondria to complete heme biosynthesis (28). Several 
mutations in Abcb6 gene has been reported and linked to diseases like ocular coloboma, 
Dyschromatosis Universalis Hereditaria and dominant familial pseudohyperkalamia (115-117).  
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1.5a. History and cloning of Abcb6 
Abcb6 was initially cloned while screening for novel drug resistance-related genes in the 
liver using the nucleotide-binding domain of P-glycoprotein as a probe. The partial cDNA 
sequence isolated from the rat liver was referred to as PRP for Pgp-related protein. The 
transcript for this gene is ubiquitously expressed with specific induction during 
hepatocarcinogenesis (118).  Subsequent to the initial cloning, Hirsch-Ernst et al. and 
Mitsuhashi et al. independently cloned the full length rat cDNA, UMAT (ubiquitously expressed 
mammalian ABC half-transporter) and the human cDNA, MTABC3 (mammalian mitochondrial 
ABC protein 3) respectively (119,120). However, to conform with the ABC transporter 
nomenclature, all forms of the protein are now referred to as Abcb6. The human Abcb6 is 
localized to chromosome 2q36, a locus initially thought to encode a defective gene causing 
GRACILE syndrome, a defect associated with abnormal mitochondrial iron metabolism. 
However, sequence and quantitative expression analysis subsequently excluded Abcb6 as the 
primary cause of this syndrome (121).  
1.5b. Structure of Abcb6 
Abcb6 is a transmembrane protein with 11 predicted transmembrane helices arranged in 
two TMDs and a NBD. Abcb6s’ NBD is located on the cytosolic side of the membrane (122). 
Abcb6 is a ‘half-transporter’ and needs to either homodimerize or heterodimerize to form a 
functional unit of four Membrane spanning domains and two NDBs. Recently, the crystal 
structure of  Abcb6’s NBD has been determined in the apo form and in complexes with ATP, 
ADP and Mg2+. Nucleotide binding appears to induce notable structural changes through the 
highly conserved Tyr599 and the Walker A motif (122). The overall structure of the NBD of 
human Abcb6 is similar to the NBD structures of other ABC transporters. 
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1.5c. Localization of Abcb6 
 Multiple laboratories have confirmed that in many cell types, Abcb6 is primarily a protein 
localizing on the outer mitochondrial membrane and the plasma membrane (28,29,123). 
Interestingly the rat Abcb6 was demonstrated to localize to vesicular membrane, specifically that 
of the lysosome, suggesting either a species-specific difference in Abcb6 localization or a mis-
localization due to overexpression (124,125). However, unlike other mitochondrially targeted 
ABC transporters, which possess a signal sequence to target them to the mitochondria, Abcb6 
lacks a bona fide inner mitochondrial matrix-targeting sequence. This finding may explain why it 
has been reported to localize to both the plasma and mitochondrial membranes. Alternatively, 
Abcb6 may be subject to species- and/or tissue-specific splice variants (multiple Abcb6 splice 
variants have been described and are found at 
http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cig?exdb=AceView&db=36a&term=abcb
6) that produce this unique pattern of localization. 
1.5d. Physiological function(s) of Abcb6 
Abcb6 shares sequence similarity to the yeast mitochondrial transporters HMT1 (~39% 
identity) and ATM1p (~46% identity). Because of this similarity, Abcb6 was thought to play a 
role in iron transport and cellular iron homeostasis. In complementation studies, Abcb6 rescued 
yeast harboring a defective ATM1p from the respiratory effects of mitochondrial iron 
accumulation (120). While these studies suggested that Abcb6 is a functional orthologue of 
ATM1p, additional experiments revealed that, paradoxically, a non-functional mutant of Abcb6 
provided similar protection. Further, identification of ABCB7, an inner mitochondrial ABC 
transporter, as the true functional orthologue of ATM1p confirmed the distinction between Abcb6 
and ATM1p (114).  
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Orthologues of Abcb6 span multiple phyla from humans to C. elegans. Among the four 
mitochondrial ABC transporters, only Abcb6 and ABCB8 are found in C. elegans, suggesting 
that they have an evolutionarily conserved function. C. elegans requires dietary heme for 
survival because of incapability to synthesize heme. Abcb6 is highly expressed in the gut of C. 
elegans, and this location is important for the uptake of dietary heme (101). Based on this 
observation Abcb6 was thought to play a role in heme or porphyrin homeostasis.  
Abcb6 in porphyrin biosynthesis 
Recently, Krishnamurthy et al. showed that Abcb6 plays a pivotal role in porphyrin 
biosynthesis. The concentration of intracellular PPIX increased in multiple cell lines expressing 
Abcb6, but not in those expressing the nonfunctional mutant (28). Moreover, silencing of the 
Abcb6 gene expression prevented the increase in porphyrin biosynthesis (28). Abcb6 
expression not only increased PPIX biosynthesis but also activated the expression of genes 
important for heme biosynthesis (28). Thus, Abcb6 appeared to represent a previously 
unrecognized rate-limiting step in porphyrin biosynthesis. 
Initial studies suggested that heme is a transport substrate of Abcb6. However, it 
appears that Abcb6 transports other tetrapyrole-containing molecules as well, as the binding of 
Abcb6 to a heme-affinity resin could be disrupted by specific tetrapyrole-containing molecules 
such as hemin, but not by monopyroles such as porphobilinogen (28,68,101). Moreover, COPIII 
(the oxidized form of COPIII, the final cytosolic protoporphyrin precursor) was highly effective in 
disrupting Abcb6 interaction with hemin- agarose [12]. These studies suggested that COPIII is a 
good candidate for an endogenous Abcb6 substrate. COPIII, the last cytoplasmic heme 
biosynthesis intermediate, must be transported into the mitochondria, by an energy dependent 
mechanism, to complete heme biosynthesis [71]. Abcb6 appears to regulate heme biosynthesis 
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in cells by increasing the uptake of heme precursors (e.g., COPIII). This level of regulation 
affects the physiology of the cell substantially, as heme is involved in many different cell 
processes, and the activity and expression of a number of hemoproteins is altered both inside 
and outside the mitochondria in response to changes in the amount of heme. 
Abcb6 in cell growth and proliferation 
Abcb6 was first identified as a gene that was upregulated in a rodent model of 
hepatocarcinogenesis. Abcb6 mRNA increased during liver regeneration in a pattern that 
paralleled the wave of DNA synthesis [45]. Expression of the transcription factor c-myc shows a 
similar pattern of increase during liver regeneration, suggesting that c-myc regulates Abcb6. A 
genome-wide chromatin immunoprecipitation (ChIP) analysis of a Burkitt’s lymphoma cell line 
supported this possibility by showing direct interaction between c-myc and the human Abcb6 
promoter [60]. Although c-myc is an oncogenic transcription factor, it also plays a prominent role 
in regulating proliferative and metabolic genes. Many genes harboring c-myc binding sites have 
roles in DNA replication, protein synthesis, cell respiration, and energy metabolism [61-63]. 
Therefore, given the role of Abcb6 in regulating heme synthesis, regulation of Abcb6 by a 
transcription factor such as c-myc that controls multiple constitutive cell process is reasonable. 
A ChIP-on-ChIP analysis found that the Abcb6 promoter is also bound by the transcriptional 
repressor complex p130-E2F4 under conditions of cell cycle arrest [64], a finding suggesting 
that Abcb6 is switched off by p130-E2F4 when cells stop replicating. The authors of this study 
developed a motif-scanning algorithm to identify conserved regions in the promoters bound by 
p130-E2F4 and discovered that some of these promoters, including the Abcb6 promoter, also 
harbored consensus nuclear respiratory factor-1 (NRF1) binding sites. NRF1 both contributes to 
mitochondrial biogenesis and transcriptionally activates nuclear-encoded mitochondrial genes 
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with respiratory functions (e.g., cytochrome c oxidase) [65]. These findings fit well with Abcb6’s 
ability to regulate biosynthesis of the oxygen-sensing molecule heme.  
1.5e. Pathologies associated with Abcb6 
An increasing number of human inborn diseases are found to be caused by defects in 
ABC transporter genes. Abcb6 appears to be a part of this group with several studies reporting 
an association between non-functional mutations in the Abcb6 gene and human inborn 
diseases.  
Ocular Coloboma 
Ocular coloboma is a developmental defect of the eye and results from an abnormal or 
incomplete closure of the optic fissure. This disorder displays genetic and clinical heterogeneity 
and its prevalence ranges from 0.5 – 0.75 per 10,000 births. Most interestingly, genes 
associated with coloboma play important roles in the early development of the human body, 
especially in the development of the CNS. To date approximately 50% of coloboma cases are 
associated with genetic mutations (117).  
Using a positional cloning approach, Wang et al., identified Abcb6 as the causative gene 
in a Chinese family affected by autosomal-dominant coloboma (117). A non-functional mutation 
in the Abcb6 gene was identified in seven affected members of the family and was absent in six 
unaffected members from three generations. Abcb6s’ pathology in coloboma was confirmed in 
zebra fish where morpholino knockdown of Abcb6 produced a phenotype characteristic of 
coloboma that replicated the clinical phenotype observed in humans (117). More importantly, 
the knockdown phenotype in zebra fish, could be corrected with co-injection of the wild-type, but 
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not mutant Abcb6 mRNA, suggesting that the phenotype observed in zebra fish are due to 
insufficient abcbc6 function (117).  
Abcb6 in Langereis blood group 
The International Society of Blood Transfusion has recognized 30 blood group systems 
as a major concern in transfusion and obstetrics. Among these blood group systems, the high-
prevalence blood group antigen Lan, first reported in 1962, can cause acute transfusion 
reactions and fatal hemolytic disease of the fetus and the newborn (HDFN) (126,127). Until 
recently, the biochemical and genetic basis of Lan had not been elucidated. However, using a 
human monoclonal antibody specific to Lan, Arnaud et al., identified Abcb6 as a novel genetic 
locus encoding for the Lan phenotype (128). Abcb6 was present in the membrane of Lan+ 
erythrocytes while no Abcb6 was detected in Lan- erythrocytes, suggesting that null alleles of 
Abcb6 may be responsible for the Lan-phenotype (128). Further, targeted sequencing of Abcb6 
in 12 unrelated Lan- individuals identified 10 different null mutations, confirming that null alleles 
of Abcb6 are responsible for the Lan-phenotype (128).  
Familial Pseudohyperkalemia  
Familial Pseudohyperkalemia (FP) is a dominant red cell trait characterized by increased 
serum [K+] in whole blood stored at or below room temperature (129). This dominantly inherited 
trait is not accompanied by clinical symptoms or biological signs except for borderline 
abnormalities of red cell shape. Functional gene mapping and sequencing analysis of the 
candidate genes by Andolfo et al. identified Abcb6 as the causative gene for the FP phenotype 
(130). Two genomic substitutions altered two adjacent nucleotides within codon 375 of Abcb6 
that are predicted to alter protein structure (130). This alteration in Abcb6 structure could 
potentially lead to red cell K+ leak that is characteristic of the FP phenotype.   
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Dyschromatosis Universalis Hereditaria  
Dyschromatosis universalis hereditaria (DUH) is a rare autosomal dominant pigmentary 
genodermatosis characterized by a mixture of hyper-and hypo-pigmented macules distributed 
randomly over the body. Until recently the causative gene for DUH had not been identified. 
Using genome-wide linkage analysis coupled with exome sequencing Zhang et al. identified 
mutation in exon 3 of Abcb6 as a contributing factor for DUH (115). Immunohistological 
examination of biopsy specimens showed that Abcb6 is expressed in the epidermis and had a 
diffuse cytoplasmic distribution. Subcellular localization of Abcb6 in B16 mouse melanoma cell 
line revealed that wild type Abcb6 localized to endosome-like compartment and dendrite tips, 
whereas DUH-causing mutations of Abcb6 resulted in its retention in the Golgi apparatus (115).   
Multi Drug resistance 
Drug resistance remains one of the primary causes of suboptimal outcomes in cancer 
therapy. A growing body of evidence has implicated ABC transporters as potential mediators of 
drug resistance. Gene amplification and consequent overexpression of Abcb6 has been 
observed in a considerable number of drug resistant cell lines, suggesting that it has a dominant 
effect in tumor cells.  In addition, treatment of cancer cells with artesunate resulted in increased 
Abcb6 expression and cross-resistance to cisplatin (41,131,132). These results suggest that 
Abcb6 could function as a protein capable of conferring multidrug resistance phenotype to cells. 
However, a role for Abcb6 in substrate efflux across the plasma membrane has not yet been 
unequivocally demonstrated. 
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2.1. Objectives of the study 
There is a growing awareness of the functional significance of ATP-binding cassette 
(ABC) transporters in pathophysiological conditions. Most of these ABC transporters are 
expressed in the plasma membrane and are well characterized. However, the ABC transporters 
in the intracellular organelles are incompletely understood with respect to their cellular roles. 
Because of the mitochondria’s important role in cellular energy and apoptosis, we have focused 
on a mitochondrial ABC transporter Abcb6 that is involved in porphyrin transport for two 
reasons. First, Abcb6 expression regulates cellular heme synthesis. Heme, a complex of iron 
and PPIX, senses and utilizes oxygen in nearly all living cells and is an essential component of 
various hemoproteins, including those involved in oxygen transport and storage, electron 
transfer, drug and steroid metabolism and signal transduction. Second, loss of function 
mutations in the Abcb6 gene is associated with developmental disorders including improper 
development of the eye and stunted growth. In contrast, overexpression of functional Abcb6 
leads to increased cell growth and proliferation, tumorigenesis and therapy related drug 
resistance. Thus, the physiological and pathological significance of Abcb6 represents a 
substantial role in public health-focused research. However, our understanding of Abcb6 
appears to be rudimentary at best and several questions remain unanswered, which require 
further evaluation. The major questions that remain undefined are a) the mechanisms that 
regulate Abcb6 expression and the significance of such expression to cellular function, b) 
transport substrates of Abcb6 and their relationship to pathologies associated with Abcb6 
expression or loss thereof, and c) the existence and the precise localization of differentially 
targeted Abcb6 and its functional significance. Answering these questions and understanding 
their significance is crucial to our ability to evaluate the physiological functions and 
pathophysiological significance of Abcb6.  
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As a first step in unraveling the complexity of Abcb6s’ biology in its mechanistic detail 
the dissertation explores the functional consequences of Abcb6 as a regulator of heme 
synthesis to cellular heme homeostasis.   
Specific Aim 1 tests the hypothesis that Abcb6 expression is regulated by signals that promote 
heme synthesis. This hypothesis was tested in both tissue culture (in vitro) and mouse models 
(in vivo) of heme synthesis. In the proposed studies, exposure to xenobiotics, which promotes 
cellular heme synthesis, essential to support the function and activity of hemoproteins, was 
used as a model of heme synthesis.  
Specific Aim 2 tests the hypothesis that Abcb6 is a determinant of hemoprotein expression and 
activity in vitro and evaluates the consequences of Abcb6 deficiency to cellular heme 
homeostasis. Studies were conducted in vitro in Abcb6 expressing and non-expressing cells to 
i) determine the significance of Abcb6 expression to xenobiotic mediated heme synthesis; and 
ii) determine the significance of Abcb6 expression to heme dependent cellular functions, with 
special emphasis on drug induced porphyria and oxidative stress response.  
Specific Aim 3 tests the in vivo significance of loss of Abcb6 expression to heme dependent 
cellular functions. Towards this end, experiments were designed to develop an Abcb6 gene 
deleted mouse model (Abcb6-/- mouse) to evaluate, a) loss of Abcb6 expression to hepatic heme 
homeostasis, and b) loss of Abcb6 expression to heme dependent hepatic functions, with 
special emphasis on metabolism and disposition of endo and xenobiotics.  
Studies proposed in specific Aim 4 were designed to define the transport kinetics and substrate 
specificity of Abcb6 in the absence of contaminating ATPases and carriers/transporters. The 
rationale for these studies was based on the problems associated with analyzing transport 
process of mitochondrial proteins because of difficulties associated with the two-membrane 
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architecture of the mitochondria and the high abundance of other ATPases and 
carriers/transporters. Thus, the development of an in vitro system with pure and active protein, 
was thought to be a prerequisite toward understanding the mechanistic relationships between 
ATP binding and hydrolysis and coupling of these events to translocation of substrates across 
the lipid membranes. Towards this end, in vitro liposomal transport system with pure and active 
Abcb6 protein was developed which allowed biochemical characterization of the ATPase 
including (i) substrate stimulated ATPase activity (ii) transport kinetics of its proposed 
endogenous substrate COPIII and (iii) transport kinetics of substrates identified using a HTS 
assay. 
2.2. Significance of the proposed study 
Studies assessing the molecular expression and function of transport proteins in the liver have 
helped to define the adaptive responses of hepatocytes to certain physiological states and to 
liver injury (133). A growing number of specific transport proteins present at the sinusoidal and 
canalicular membrane domains of hepatocytes and cholangiocytes have been cloned and 
functionally characterized (134). These studies have led to our understanding of the molecular 
basis of several forms of inherited cholestatic liver diseases (135,136). Results from such 
studies have helped in the development of better diagnostic tools and have resulted in the 
design of new therapeutic strategies (137-139).  However, despite the fact that mitochondrial 
dysfunction is a major mechanism of liver injury, very little is known about the role of 
mitochondrial transport proteins in liver function. In particular, the physiological significance of 
mitochondrial ATP binding cassette transporters to liver function is poorly understood. My 
contribution will be to demonstrate that the mitochondrial transporter Abcb6, which regulates 
heme synthesis, plays an important role in hepatic drug metabolism and oxidative stress 
response. This contribution will be significant because it bridges the gap in our knowledge about 
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the relationship between mitochondrial ABC transporter Abcb6 and liver function. As this 
information becomes available, translational clinical trials, specifically targeting Abcb6, can be 
developed to establish therapeutic approaches to minimize hepatic injury associated with 
oxidative stress. There is also the potential of specifically targeting Abcb6 to predict adverse 
drug reactions that are precipitated by alteration to P450 activity mediated by Abcb6. In this 
context, it is significant to note that variation in P450 expression is believed to influence the 
therapeutic index of up to one-third of all drugs, and may contribute to inter-individual 
differences in the generation and elimination of environmental toxins and carcinogens. 
However, the factors responsible for variation in P450 expression between individuals are 
unclear. I expect that the studies described in the dissertation will help explain some of these 
inter-individual differences associated with drug metabolism and disposition. In addition, the 
research described in the dissertation will be significant because what is learned will contribute 
not only to our fundamental understanding of the mechanisms that control porphyrin 
biosynthesis, but also into the manner in which the mitochondrial transporter Abcb6 is integrated 
into hepatic drug metabolism and disposition. 
2.3. Innovation 
The research proposed in this dissertation is innovative, because it is the first study to 
evaluate the role of mitochondrial ABC transporters in liver function. Further, the studies provide 
a unique opportunity to use the Abcb6 deficient and Abcb6 over-expressing cell culture and 
mouse models that were developed as a part of the dissertation, to predict adaptive responses 
of liver, to injury precipitated by pharmacological drugs and environmental chemicals. Further, 
the development of an in vitro cell free system (liposome reconstituted Abcb6) carrying purified 
Abcb6 provides an opportunity to evaluate Abcb6 transport functions in the absence of 
contaminating ATPases and carriers/transporters. 
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MATERIALS AND METHODS 
 
Materials 
8-Azido-[α-32P] ATP was purchased from MP Biomedicals (Solon, OH). 
Coproporphyrinogen III, Protoporphyrin IX, Hemin and Porphobilinogen were purchased from 
Frontier Scientific (Logan, UT). N-octyl-β-D-glucopyranoside, Phosphatidylcholine, 
Phosphatidylethanolamine, Phosphatidylserine and Ergosterol were from Avanti Polar Lipids 
(Alabaster, AL). Handee spin cups were from Pierce (Rockford, IL). All other chemicals and 
reagents were obtained from either Sigma-Aldrich or Fluka unless otherwise indicated. 
 
Cell culture 
Human liver-derived cell lines Hep3B, Huh7 and HepG2 were from the American Type 
Culture Collection (Manassas, VA). Hep3B and HepG2 cells were cultured in modified Eagle’s 
medium supplemented with 10% fetal bovine serum (FBS) and 100 units/ml penicillin. HepG2 
Huh7 and Hep3B cells were engineered to overexpress human Abcb6 as described (28). 
Abcb6-overexpressing cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% FBS, 100 units/ml penicillin, 2 mM Lglutamine, and 0.6 μg/ml 
puromycin. 
 
Overexpression in HEK293 cells for purification 
To construct Abcb6-FLAG expressing lentiviral plasmid, the human Abcb6/pcDNA3.1 
Topo vector carrying FLAG-tagged Abcb6 was cut with restriction enzymes XbaI and EcoRI, 
and the Abcb6-FLAG containing fragment was ligated into corresponding restriction sites of 
Lentiviral vector; pLenti PGK Puro. HEK 293 cells overexpressing the Abcb6-FLAG lentiviral 
plasmid was generated by infecting cells with filtered viral supernatants followed by selection 
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with 0.5 μg/mL puromycin. 293 cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, penicillin and streptomycin. The non-functional 
mutant of Abcb6 was generated as previously described (28). Briefly, the critical lysine residue 
in the Walker A domain of Abcb6, which is the nucleotide binding domain in ATP binding 
cassette transporters that is essential for transport function was changed to alanine by site 
directed mutagenesis as described (28). 
 
RNA Interference 
The small interfering RNA (siRNA) oligonucleotide and negative control scrambled 
oligonucleotide were custom synthesized by Dharmacon (Lafeyette, CO). Both siRNA and 
control oligonucleotides were used at a final concentration of 150nM and were added to cells 
using lipofectamine following the manufacturer’s protocol. 
siRNA 1: 5’ GCGCAUACUUUGUCACUGACA 3’ 
   3’ UUCGCGUAUGAAACAGUGACUP 5’ 
siRNA 2: 5’ CCGAAUAGAUGGGCAGGACAU 3’ 
   3’ UUGGCUUAUCUACCCGUCCUGP 5’ 
Scrambled oligo: 5’ UAGCGACUAAACACAUCAA 3’ 
Abcb6-shRNA and scrambled shRNA viral particles were obtained from Sigma. Stable cell lines 
harboring either Abcb6-shRNA or the scrambled shRNA were generated by transduction of viral 
particles following the manufacturer's protocol, followed by selection in puromycin (0.6 μg/ml for 
HepG2, Huh7 and Hep3B cells) as described . Loss of endogenous Abcb6 expression was 
confirmed by RT-PCR and immunoblot using gene-specific primers and protein-specific 
antibody. 
The siRNA specific for AhR and a scrambled siRNA were a kind gift from Dr. Hongbing 
Wang (University of Maryland, Baltimore, MD). HepG2 cells at ∼60% confluence were 
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transfected with AhR siRNA or scrambled siRNA (40 pmol/well) using Lipofectamine 2000 
reagent (Invitrogen, CA) following the manufacturer's instructions. Twenty-four hours after 
siRNA transfection, cells were treated with either DMSO or 5 μM B[a]P and incubated for an 
additional 16 h before harvesting. Total RNA isolated from transfected cells as described below. 
 
Primary mouse hepatocyte culture 
Hepatocytes from the liver were isolated using the collagenase perfusion method as 
described previously (140). Briefly, under pentobarbital anesthesia (50 mg/kg intraperitoneally), 
liver was perfused with 50 ml of calcium- and magnesium-free Hanks' balanced salt solution 
supplemented with 0.5 mM EGTA, 5.5 mM glucose, and penicillin-streptomycin, followed by 40 
ml of calcium- and magnesium-free Hanks' balanced salt solution supplemented with 1.5 
mMcalcium chloride, 5.5 mM glucose, penicillin-streptomycin, and 0.02 g of Type IV 
collagenase. Liver was removed, and the digested product was centrifuged at 50 × g for 2 min 
to pellet the hepatocytes. The hepatocytes were washed three times with Williams' medium E 
and then cultured in Williams' medium E containing 10% FBS and penicillin-streptomycin. After 
a 3-h attachment period, the medium with unattached cells was removed, and fresh medium 
was added. The viability of isolated hepatocytes was >90% by the criterion of trypan blue 
exclusion. Cells were cultured for ∼16 h before the addition of drugs. 
 
Animals housing 
Mice were housed in polycarbonate cages (four per cage), provided normal diet and 
water ad libitum, and maintained on a 12–12 h light-dark cycle at 22 ± 5°C and 50 ± 20% 
relative humidity.  
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Animals’ treatment  
Study 1: Nrf2 gene-deleted mice (Nrf2-/-) was a kind gift from Dr. Curtis Klaassen 
(Professor, Department of Medicine-Gastroenterology, University of Kansas Medical Center, 
USA). Wild-type mice were C57BL/6J from Jackson’s Laboratory. At 8 weeks of age, Nrf2+/+ and 
Nrf2-/- mice (four mice per group) were fed sodium arsenite (10 ppm) in drinking water for 24 h.  
Study 2: Effect of sodium arsenite on Abcb6 expression was measured in 8-week-old 
C57BL/6J mice. Mice (four per group) were fed sodium arsenite (0, 1, 10, or 100 ppm; As(III)) in 
drinking water for 1 day or with 10 ppm of sodium arsenite for 1, 3, or 5 days. All mice survived 
sodium arsenite treatment.  
Study 3: AhR gene-deleted mice (AhR−/−) were a kind gift from Dr. Curtis Klaassen 
(Professor, Department of Medicine-Gastroenterology, University of Kansas Medical Center, 
USA). At 8 weeks of age, AhR+/+ and AhR−/− (4 mice per group) were given 37 μg/kg TCDD or 
an equal volume of vehicle (corn oil) intraperitoneally for 4 days.  
Study 4: Abcb6+/+, Abcb6+/- and Abcb6-/- mice (six mice per group) were sacrificed at 8 
weeks of age. At the end of treatment, animals were sacrificed, livers were harvested, and RNA, 
mitochondria or microsomes were isolated immediately as described below. 
  
RNA isolation, reverse transcription and real-time PCR 
RNA isolation from liver tissue or cells were done using TRIZOL® reagent (Invitrogen, 
CA). 1 μg of RNA was used for reverse complementation using iScriptTM cDNA synthesis kit 
according to manufacturer’s protocol (BioRad, CA). Real-time PCR was performed using 
CFX384TM Real Time PCR System as described previously by using primer sets specific for the 
mouse genes enlisted in Appendix 1.1.  
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Immunoblot analysis 
For Western analysis, cell lysates were prepared as described previously (64) and 50 µg 
of total protein, mitochondrial protein, or microsomes was analyzed by polyacrylamide gel 
electrophoresis (PAGE). Blots were probed with mono- and/or polyclonal anti-Abcb6 antibody, 
monoclonal anti-HO-1 (Assaydesigns, MI), and monoclonal anti-porin (Mitosciences, OR), 
mouse P450 oxidoreductase (POR); Cyp2e1 (Abcam, MA) Cyp2b10 (Millipore, MA), Gapdh 
(Cell Signaling, MA). The polyclonal antiserum to mouse Cyp3a and Cyp1a were a kind gift from 
Dr. Xiaochao Ma (Associate Professor, University of Pittsburgh, USA).  
We detected the secondary antibody by using a chemiluminescence detection kit (Amersham 
Biosciences, NJ). Abcb6 antibodies were generated using a portion of the Abcb6 protein (aa 
592–894) that is predicted to localize to the cytosol and is unique among the Abc transporters. 
The antibody was affinity purified and characterized for its ability to recognize the native Abcb6 
protein. 
 
Cell viability studies 
Trypan blue exclusion assay was used to determine cell viability. Briefly, we exposed 106 
HepG2 or Hep3B vector cells or Abcb6-expressing cells to increasing concentration of sodium 
arsenite in water for 24 or 48 h at 370C and then counted the living cells (that were able to 
exclude the dye). Results are expressed as a percentage of cells surviving from the total plated. 
 
Cytotoxicity assay 
For arsenic toxicity studies, in 96-well plates, we incubated Hep3B or HepG2 cells that 
express either an empty vector or an Abcb6-expressing vector at 37O C for 24 h. Sodium 
arsenite in a dilution series was added and incubation continued for 2–4 days. 
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For TCDD and B[a]P toxicity, cell viability was measured in logarithmically growing mouse 
primary hepatocytes, HepG2 and Huh7 cells. Cells were plated onto 96-well plates at a starting 
density of 104 cells and treated with increasing concentrations of TCDD, B[a]P, or the respective 
solvents.  
Cell viability was determined at 24, 48, and 72 h using 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl-tetrazolium bromide. Absorbance at 570 nm was measured with a kinetic microplate 
reader (BioTek, VT) and was used as a measure of cell viability. 
 
Measurement of ROS 
Cells treated with sodium arsenite (25µM) for 24 h were incubated with 3µM 2, 7-
dichlorodihydrofluorescein diacetate (DCF; Molecular Probes, OR) for 15 min at 370C. After 
incubation, cells were washed with PBS, trypsinized, and resuspended in PBS solution. DCF 
fluorescence was measured using FACScan flow cytometer (excitation at 488 nm, emission at 
515–545 nm). Data were analyzed with CellQuest software. 
 
Isolation and purification of mitochondria 
Cells were pelleted in 13 Hanks buffered saline solution (Life Technologies, CA), 
resuspended in buffer A (10 mmol/l NaCl, 1.5mM MgCl2, and 10 mmol/l Tris [pH 7.4]) 
containing 13 protease inhibitor cocktail (Roche Applied Science, IN), swollen on ice, and 
disrupted with a type B Dounce homogenizer. Buffer B (525 mmol/l mannitol, 175 mmol/l 
sucrose, 12.5 mmol/l Tris [pH7.4], and 2.5 mmol/l EDTA) was added in a ratio of 4:10 
homogenate/buffer B. The supernatant was collected after centrifugation at 1500 x g for 10 min. 
The supernatant was centrifuged at 17,000 x g for 15 min to pellet mitochondria. The crude 
mitochondria were purified from the endoplasmic reticulum as previously described (28). 
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Preparation of microsomes 
Microsomes were prepared from Abcb6+/+, Abcb6+/- and Abcb6-/- mice liver tissues. 
Briefly, 0.3-0.5 g of liver tissue was homogenized in 1X PBS and centrifuged at 17000 x g for 30 
min at 4°C. The supernatant was subjected to centrifugation at 100000 x g for 90 min at 4°C. 
The resulting microsome pellet was resuspended in 1X PBS. Microsomal protein concentrations 
were determined using the Bio-Rad protein assay reagent. Microsomes were stored at –80 °C 
until used for western blot analysis or P450 activity assays. 
 
Catalase inhibition and catalase activity 
Catalase inhibition was achieved by using 3-aminotriazole (3-AT) as described (141). 
Briefly, cells were exposed to 20 mmol/l of 3-AT in PBS for the duration of the experiments. For 
catalase activity, cells (5 x 105) were washed twice with PBS, resuspended in PBS, sonicated 
for 10 s, and centrifuged at 14,000 rpm for 10 min. The supernatants from the centrifugation 
were subjected to the catalase activity assay. Catalase activity was determined by monitoring 
the rate of decomposition of H2O2, as assessed by the decrease in absorbance at 240 nm. One 
unit of activity represents the consumption of 1 mmol H2O2/min/ mg protein. The assay mixture 
(1 ml) contained 19 mmol/l H2O2 and defined amounts of cell extract in 50 mmol/l phosphate 
buffer (pH 7) at 250C.  
 
Cellular protoporphyrin IX measurement 
Intracellular PPIX concentration was measured as described previously (28,142). Briefly, 
cells were harvested and washed once with PBS. PPIX concentration was measured by using a 
Vantage flow cytometer (BD Biosciences, NJ). To induce PPIX fluorescence, the excitation 
wavelength was set at 405 nm, and the emission filter was set at 695 nm/40 nm. 
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Heme measurement 
Heme measurement was done using liver tissue from Abcb6+/+, Abcb6+/- and Abcb6-/- 
mice. Briefly, 5 mg of liver tissue was homogenized in 100 µl of 1X phosphate buffer saline (pH 
7.4). Heme extraction was performed using double the volume of Ethyl acetate and acetic acid 
mixture (4:1). Sample was vortexed briefly and centrifuged at 20000x g for 5 min. Each 
supernatant was diluted 5 times with 50% acetonitrile and transferred to an auto sampler vial, of 
which 5.0 µl was injected onto the UPLC-TOFMS system for heme analysis. 
 
Mass spectrometry based P450 assay 
Microsomal incubation reaction was performed 1X phosphate-buffered saline (pH 7.4), 
containing 3µM Midazolam (MDZ) or 20µM Chloroxazone with 0.03 mg of mouse liver 
microsomes. The final volume of reaction was 200 μl. After 5min of pre-incubation at 37°C, the 
reaction was initiated by adding NADPH (final concentration 1.0mM). The reactions were 
shaken at 37°C for 10 min for MDZ and 15 min for Chloroxazone. Incubations were terminated 
by adding 200 µl of ice cold acetonitrile and vortexing for 10 seconds and centrifuging at 18000x 
g for 10 min. Each supernatant was transferred to an auto sampler vial, and 5.0 µl was injected 
onto the UPLC-TOFMS (Waters, MA) system for metabolite analysis. 
 
UPLC-TOFMS analysis 
Ultra-performance liquid chromatography (UPLC)-time-of-flight mass spectrometry 
(TOFMS) analyses were performed as described previously (143). A 100mm × 2.1mm (Acquity 
1.7 μm) UPLC BEH C-18 column (Waters, MA) was used to separate metabolites. The flow rate 
of the mobile phase was 0.3ml/min with a gradient ranging from 2 to 98% aqueous acetonitrile, 
containing 0.1% formic acid in a 10-min run. TOFMS was operated in a positive mode with 
electrospray ionization. The source temperature and desolvation temperature were set at 120°C 
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and 350°C, respectively. Nitrogen was applied as the cone gas (10 l/h) and desolvation gas 
(700 l/h) and argon as the collision gas. TOFMS was calibrated with sodium formate and 
monitored by the intermittent injection of lock mass leucine enkeophalin in real time. The 
capillary voltage and cone voltage were set at 3.5kV and 35V in positive ion mode. Identification 
of major metabolite were performed using MakerLynx software (Waters, MA), based on 
accurate mass measurement (mass errors less than 10ppm). All the incubations were 
performed in duplicate. 
 
Pentobarbital induced sleeping time  
Abcb6+/+ and Abcb6-/- mice were used in these studies. The animals were injected with 
40 mg/kg body weight of pentobarbital by intra peritoneal route. The time for animals to sleep 
was noted as sleep latency and time difference between the animal completely losing their 
reflexes after pentobarbital administration and the time they regained their reflexes was taken 
as the pentobarbital-induced sleeping time. 
 
ABCB6/Abcb6 promoter analysis 
Promoter analysis was performed as described previously (64). Briefly, HepG2 cells at 
∼60% confluence were transfected with 1.5 μg/well of either pGL2-luciferase, pLightSwitch-
Abcb6-luciferase (Switchgear Genomics, CA), pGL2-Abcb6-luciferase, or pGL2-HO-1-luciferase 
constructs using Lipofectamine reagent following the manufacturer's protocol. All transfections 
included Renilla luciferase (100 ng/well) as an internal transfection control. In a subset of 
experiments, we introduced aryl hydrocarbon-responsive element (AhRE) mutations into 
the Abcb6 promoter by using a site-directed mutagenesis kit (Stratagene, CA). Briefly, two 
nucleotide mutations (consensus motifs 5′-GCGTG-3′ mutated to 5′-ATGTG-3′) were introduced 
into the AhR binding site of the Abcb6 promoter at base pairs −102 bp, −115 bp, and −123 bp 
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relative to the transcription start site (Figure 4.1.5D). All mutations were confirmed by 
sequencing using pGL2-basic and pLightSwitch-Abcb6-luciferase primers (Promega, WI). The 
relative activity of the promoter constructs was determined after subtraction of the values 
obtained for pGL2-luciferase, and the results were expressed in relative terms (ratio of vehicle 
control value to treatment value). All experiments were performed at least three times with a 
minimum of four replicates per experiment. 
 
Electrophoretic mobility shift assay (EMSA) 
Electrophoretic mobility shift assay was performed as described previously (64). Briefly, 
HepG2 cells at ∼90% confluence were treated with vehicle or 5 μM B[a]P for 2 h, and nuclear 
protein was extracted using the NE-PER nuclear extraction kit (Pierce, IL). To detect AhRE 
interaction, 20 fmol of biotinylated DNA segments containing either 1) the three AhREs of 
human Abcb6 (CGTACGTGCCCTGCGTGAGTGCGTGGCGGCGGCGCGTGCG; the core 
AhRE is underlined (Figure 4.1.5D), 2) only the two distal AhREs 
(CGTACGTGCCCTGCGTGAGTGCGTGGCGGCGG; underlined and in boldface type (Figure 
4.1.5D and 4.1.6D), or 3) the two distal AhREs where the sequences flanking the core AhRE 
were changed to random bases (Figure 4.1.5D) were incubated with 2 μg of nuclear extracts 
with or without excess amounts (4 pmol) of similar or mutant 
(CGTACGTGCCCTATGTGAGTATGTGGCGGCGGCATGTG; mutations shown in italic type) 
unbiotinylated DNA oligonucleotides. Rabbit polyclonal antibody against AhR (Santa Cruz 
Biotechnology, CA) was used to probe the AhRE complexes, and anti-FXR polyclonal antibody 
(Santa Cruz Biotechnology, CA) was used as a nonspecific negative control in the experiment. 
A 25-bp biotinylated DNA motif containing human CYP1A1 AhRE (5′-
CGAGTTGCGTGAGAAGAGCCAGATC- 3′; the core AhRE is underlined) and the 
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mutant CYP1A1 AhRE (5′-CGAGTTGATTGAGAAGAGCCAGATC- 3′; mutations shown in italic 
type) was used as a positive control in these experiments. 
 
Chromatin immunoprecipitation (ChIP) assay 
Chromatin immunoprecipitation was performed using HepG2 cells treated with vehicle or 
B[a]P (5 μM) for 2 h. Approximately 2 × 106 cells were cross-linked with 1% formaldehyde for 15 
min at room temperature and washed with ice-cold PBS containing a protease inhibitor mixture. 
Chromatin derived from isolated nuclei was fragmented to an average size of 0.5–2 kb using a 
Vibra-cell ultrasonic processor (Sonics, CT). Following centrifugation, supernatants containing 
sheared chromatin were immunoprecipitated overnight at 4 °C with anti-AhR antibody (M-20 
from Santa Cruz Biotechnology, CA, and AhR-31635 from Aviva System Biology, CA) or isotype 
control IgG. The immunocomplex was precipitated using protein A coupled to Sepharose beads 
and decross-linked for 6 h. The immunoprecipitated DNA fragments were recovered by 
QIAquick PCR purification kit. Quantitative RT-PCR was performed using a specific set of 
primers (sense, 5′-CAGAGCCAGCGGGGCCGTGCTG-3′; antisense, 5′-
GGCGCGGACATCCGGGTGCC-3′) spanning the region between −20 and −193 bp around the 
putative AhR binding site within the Abcb6 promoter. PCR products were also resolved on a 
1.5% agarose gel and visualized by ethidium bromide staining. 
 
Purification of Abcb6 from total lysate 
HEK 293 cells (70% confluent) were harvested with 1X PBS and lysed (10 min at 4° C 
with gentle shaking ) in buffer A (1X PBS; 0.2% Triton X100) containing EDTA-free complete 
protease inhibitor mixture (Roche Applied Science, IN). Soluble and insoluble fractions were 
separated by centrifugation (10 min at 10,000 rpm, 4°C) and the supernatant was incubated 
with sepharose conjugated anti-M2 beads (EZviewTM Red Anti-FLAG M2 affinity gel) overnight 
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at 4°C with gentle shaking. The supernatant with the sepharose conjugated M2-beads were 
transferred to handee spin cups (paper filter) and separated by centrifugation (2,000 RPM for 5 
min at 4°C). The beads were washed twice with buffer A, twice with buffer B (10 mM Tris; 0.2% 
Triton-X-100) and five times with Hepes buffer [Hepes-EGTA-1% n-Octyl-β-D-glucopyranoside 
(OGP)]. Proteins bound to the affinity column were eluted using elution buffer (Hepes-EGTA-1% 
OGP-0.5 mg FLAG peptide). The eluted protein was identified by immunoblotting using Abcb6 
specific and FLAG-epitope specific antibody (Sigma, MO) followed by matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) peptide mass fingerprint analysis after trypsin 
digestion, using Mascot (data base NCBInr 20040521) 
 
Purification of Abcb6 from mitochondria 
Mitochondria were isolated as previously described (11). Isolated mitochondria were 
solubilized in buffer A (1X PBS; 0.2% Triton X100) containing EDTA-free complete protease 
inhibitor mixture (Roche Applied Science, IN) for 30 min at 4°C with gentle shaking. Soluble and 
insoluble fractions were separated by ultracentrifugation (100,000 x g, 30 min, 4°C) and the 
supernatant was incubated with anti-M2 sepharose beads as described above for whole cell 
lysate. Proteins bound to the affinity column was washed and eluted as described above for 
total cell fraction using FLAG-peptide in elution buffer. The bound protein was identified by 
immunoblotting and matrix-assisted laser desorption/ionization time-of-flight peptide mass 
fingerprint analysis after trypsin digestion, using Mascot (data base NCBInr 20040521) 
 
Nucleotide binding assay 
Nucleotide binding was measured by 8-azido-[α-32P]ATP photo cross-linking 
experiments. Cross-linking reactions were performed in a 96-well microtiter plate in a final 
volume of 25 uL/reaction. Purified wild-type Abcb6 (2 μM final concentration) was incubated for 
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5 min on ice with 8-azido-[α-32P]ATP (0.05 – 16 μM) in reaction buffer (100 mM KCl, 2.5 mM 
MgCl2, 50 mM Tris-HCl, pH 7.4). For competition experiments, 0.1 μM to 10 mM unlabeled ATP 
was included in the buffer. Subsequently, samples were irradiated with UV light (254 nm, 8 
watts) for 5 min at 4°C, separated by SDS-PAGE, Coomassie blue-stained, dried, and exposed 
to Kodak SO230 phosphor screen. Photo cross-linked protein was quantified by 
phosphorimaging (Phosphor-Imager 445Si, Molecular dynamics) and bands were quantified 
using ImageJ software (version 1.43u). Intensities were plotted against the 8-azido-ATP 
concentration and apparent Kd values for 8-azido-[α-32P]ATP were obtained from the best fit of 
the data to a hyperbolic curve using GraphPad Prism software (version 5, CA). The half-
maximal inhibitory concentration (IC50) for ATP was derived by plotting labeling intensities 
corresponding to Abcb6 as a function of unlabeled ATP concentrations. The Kd(azidoATP) 
values and the IC50 values were used to calculate Kd(ATP) by applying the Cheng-Pursoff 
equation. 
 
ATP hydrolysis assay 
ATPase activity was determined essentially as described by measuring the release of 
inorganic phosphate (Pi). Briefly, purified Abcb6 (5 μM final concentration) was incubated at 
37°C in 100 μL of an ATP buffer containing 50 mM Tris-MOPS; 70 mM KCl; and 2 mM EGTA, 
pH 7.5, and the ATPase reaction was started by the addition of 12 mM MgATP. The reaction 
was stopped by the addition of 100 μL of 10% SDS solution, and the amount of inorganic 
phosphate was determined immediately. ATPase activity was estimated by the difference 
obtained in Pi levels between ATP buffer alone and ATP buffer containing the purified protein. 
Inorganic phosphate was measured by a sensitive colorimetric reaction. The SDS-containing 
samples were supplemented with 200 μL of freshly prepared reagent A containing a final 
concentration of 5.5% ascorbic acid; 5 mM ammonium molybdate and 2 mM zinc acetate and 
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the reduced complex was measured at an optical density of 850 nM. A similar protocol was 
used to determine the ATPase activity of liposome reconstituted Abcb6. For substrate 
stimulated ATPase activity, indicated drugs were added in dimethyl sulfoxide (DMSO). The final 
concentration of DMSO in the assay medium was 1%. Control experiments indicated that 
DMSO at this concentration had no appreciable effect on the ATPase activity. 
 
Reconstitution of Abcb6 
For reconstitution of functional (WT) and non-functional (mutant; MT) Abcb6 into lipids, 
protein bound to the FLAG-affinity column as described above was washed with Hepes-EGTA-
1% n-Octyl-β-D-glucopyranoside (OGP) 5 times, and eluted using Hepes-EGTA-1% OGP-0.5 
mg FLAG peptide. Lipid solutions (5 mg/mL Phosphatidylcholine (PC), 5 mg/mL 
Phosphatidylserine (PS), 5 mg/mL Phosphatidylethanolamine (PE), and 10 mg/mL Ergosterol 
(ES) were dissolved in chloroform, and the solvent was evaporated under a gentle stream of 
argon and evacuated overnight in a desiccator under vacuum to remove any residual 
chloroform. The lipid film was rehydrated in 1 mL of reconstitution buffer (15 mM HEPES, 0.5 
mM EGTA, pH 7.4) to produce a 1 mM lipid solution. FLAG-tagged WT and MT Abcb6 protein at 
a concentration of 3.3 μg/μL was added to the rehydrated liposomes and incubated for 1 h at 
4°C with gentle agitation. The lipid-protein suspension mixture was sonicated using an 
ultrasonic cleaner (Avanti polar lipids Inc) for 20 sec; 3 times at 4°C. This procedure resulted in 
a nearly uniform suspension of relatively unilamellar liposomes. Protein-free liposomes were 
prepared similarly by replacing purified protein with elution buffer. Unincorporated materials and 
detergent were removed by dialysis using 1L of reconstitution buffer changed every 24 h for a 
total duration of 48 h. The resultant proteoliposomes were collected, flushed quickly with argon, 
and stored at -80°C until used. 
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Liposome flotation assay 
Proteoliposomes were floated in a discontinuous Nycodenz density gradient in a buffer 
containing 100 mM KCl and 10 mM MOPS/Tris, pH 7.0. Nycodenz and proteoliposomes were 
solubilized in the same buffer and mixed to a final nycodenz concentration of 40%. Subsequent 
layers of decreasing Nycodenz concentration (20, 10, 5, and 2%) were layered onto the 40% 
nycodenz-proteoliposomes mixture. Percentages indicated in the figures are the final 
concentrations of Nycodenz. The gradient was centrifuged at 4°C for 60 min at 100,000 x g. 
Subsequently, the gradient was fractionated by taking equal volumes from the top. Fractions 
were analyzed by SDS-PAGE and western blotting. 
 
Hemin agarose affinity chromatography 
The assay was performed as described previously. Briefly, Abcb6-FLAG 
proteoliposomes (5 μg), was incubated at room temperature for 15 min in the presence of 167.5 
nM hemin-agarose (Sigma, MO). The reaction mixture was centrifuged at 4°C. The hemin-
agarose-Abcb6-FLAG proteoliposome complex was washed thrice with 1 mL lysis buffer, 
resuspended in 50 μL of 2 X SDS sample-loading buffer, and then centrifuged. The supernatant 
from the final spin was analyzed on a 4-15% gradient gel, transferred to a nylon membrane, and 
probed with a monoclonal antibody to the FLAG epitope to identify Abcb6-FLAG. 
 
Coproporphyrinogen (COPIII) transport assays 
COPIII transport assays were performed as previously described (28) with slight 
modification to accommodate the use of liposomes. Control, Abcb6-WT and Abcb6-MT 
liposomes (25 to 50 μg for Abcb6 liposomes and equal volume of control liposomes) were 
resuspended in reconstitution buffer (final volume of 50 μL). Transport reaction was started by 
adding 50 μL of a reaction mixture (50 mM MOPS-Tris, 70 mM KCl, 10mM MgCl2, and either 4 
67 
 
mM AMP, 4 mM AMP:PNP or 4 mM ATP) and incubated at 37°C for the duration of the 
experiment as described in the respective figures. Reactions were stopped by diluting the 
reaction with 1 mL of ice-cold reconstitution buffer. In early experiments using nitrocellulose 
filters (pore size 0.45 μM) to measure COPIII uptake, we observed that a significant proportion 
of the proteoliposomes passed through the filters. To avoid this problem, an affinity purification 
method employing FLAG-affinity columns using anti-M2 magnetic beads was used to separate 
proteoliposomes from free COPIII. The affinity columns were washed three times with cold 
reconstitution buffer to remove any free COPIII not transported into the proteoliposomes. The 
affinity-purified proteoliposomes were lysed by incubation for 10 min in 10% SDS with vortexing. 
COPIII fluorescence was measured at excitation wavelength 405 nm and emission wavelength 
630 nm. Concentration of COPIII was determined from a standard curve of COPIII in 10% SDS. 
The rate of active transport was calculated as the difference between ATP-dependent and 
independent uptake. 
 
Verteporfin and tomatine transport assays 
The assay was performed as previously described (69). Briefly, following uptake of 
tomatine and verteporfin into proteoliposomes, the reaction was stopped at the indicated time 
and liposomes were separated by affinity purification employing FLAG-affinity columns as 
described above (COPIII transport assay). The affinity column was washed three times with cold 
reconstitution buffer to remove any free tomatine or verteporfin not transported into 
proteoliposomes. The affinity-purified proteoliposomes were resuspended in 100 μL of 
acetonitrile and the amount of verteporfin or tomatine taken up into proteoliposomes was 
analyzed using Ultra Performance Liquid Chromatography-time-of-flight mass spectrometry 
(UPLC-TOFMS) as previously described (143). Concentration of verteporfin and tomatine was 
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determined from a standard curve of verteporfin and tomatine in acetonitrile. The rate of active 
transport was calculated as the difference between ATP-dependent and independent uptake. 
 
Determination of transport kinetics 
Transport kinetics was estimated by non-linear curve-fitting using GraphPad Prism 5.0 
software. The Michaelis-Menten equation was used to calculate apparent Km and Vmax values. 
 
Microarray analysis 
Abcb6+/+ and Abcb6-/- mice (n=3) liver samples were used for gene expression analysis 
using the Affymetrix Genechip System (Affymetrix, CA) in collaboration with the Genome 
sequencing facility, University of Kansas Medical Center. Briefly, 1µg of total RNA was used to 
synthesize complementary DNA (cDNA) using the One-Cycle cDNA Synthesis kit. Biotinylated 
complementary RNA (cRNA) was synthesized following the IVT labeling kit and purified using 
the GeneChip Sample Cleanup Module. Subsequently, Biotinylated cRNA was fragmented and 
hybridized to the Genechip Mouse430A 2.0 microarrays. Hybridization was followed by washing 
of the chip and then scanned using the GeneChip Scanner 3000. The fluorescent signal 
corresponding to the intensity of hybridization for each transcript was determined using the 
Gene Chip Operating Software (GCOS 1.4). 
 
Functional and pathways analysis by ingenuity pathway analysis (IPA) 
The genes with significantly different expression (p value ≤0.05) and fold change 
upregulated or downregulated by ≥ 1.5 fold were used for IPA. The dataset of such genes 
containing information about Affymetrix probe ID and fold change was uploaded onto the IPA 
System. For functional and canonical pathway analysis, Fischer's exact test was used to 
calculate the p-value determining the probability that the association between the genes in the 
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dataset and the biological function and the canonical pathway is due to chance alone. P-values 
≤ 0.05 were considered as significant. The Biofunction and Canonical Pathways Analysis 
identified the pathways in our dataset with most significant association to pathways in the 
Ingenuity Knowledge Base. For Biofunction analysis Activation z-score was calculated as a 
measure of significance. An absolute z-score of below (inhibited) or above (activated) 2 was 
considered as significant. For canonical pathway analysis Fischer's exact p- value were used for 
significance and a ratio measure was used for pathway overlap. A ratio was calculated by the 
number of differentially expressed genes from our dataset that map to the pathway divided by 
the total number of molecules that exist in the canonical pathway. A ratio of 1 implies complete 
overlap. 
 
Statistical analysis  
Statistical analysis of the observed values was performed using Student's t-test. All 
calculations were performed with the SPSS statistical software package. All values are 
expressed as mean ± S.D. Significant differences between the groups were determined with 
SPSS 10.0 software (SPSS Inc., IL). A difference was considered significant at the p < 0.05 
level. 
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Chapter 4. XENOBIOTICS MEDIATED REGULATION OF ABCB6 
 
4.1. Polycyclic aromatic hydrocarbons (PAHs) mediate transcriptional 
activation of the ATP binding cassette transporter Abcb6 gene via 
the aryl hydrocarbon receptor (AhR) 
4.2. Xenosensor CAR and PXR regulates ATP binding cassette 
transporter Abcb6 gene 
4.3. Arsenic mediated transcriptional activation of Abcb6
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4.1. POLYCYCLIC AROMATIC HYDROCARBONS (PAHs) MEDIATE 
TRANSCRIPTIONAL ACTIVATION OF ABCB6 GENE VIA THE 
ARYL HYDROCARBON RECEPTOR (AhR) 
 
Abstract 
In the present study, we demonstrate that polycyclic aromatic hydrocarbons (PAHs), the widely 
distributed environmental toxicants up-regulate Abcb6 expression in both mice and humans. 
Moreover, in vivo studies in aryl hydrocarbon receptor (AhR) knock-out mice demonstrate that 
PAH induction of Abcb6 is mediated by AhR. Promoter activation studies combined with 
electrophoretic mobility shift assay and chromatin immunoprecipitation assay demonstrate direct 
interactions between the AhR binding sites in the Abcb6 promoter and the AhR receptor, 
implicating drug activation mechanisms for Abcb6 similar to those found in inducible P450s. 
These studies are the first to describe direct transcriptional activation of both mouse and human 
Abcb6 by xenobiotics. 
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Introduction 
Heme is indispensable for mammalian life. It is an essential component of numerous heme 
proteins, with functions including oxygen transport, energy metabolism, and drug 
biotransformation (144-146). Under normal physiological conditions, intracellular free heme 
levels are extremely low because increased levels of free heme are cytotoxic, and accordingly 
heme biosynthesis is tightly regulated (5,8,147). However, the rate of heme biosynthesis must 
also be responsive to increased demands, for instance, during induction of drug-metabolizing 
P450s, which is required to assure an adequate and apparently coordinated supply of heme for 
the generation of functional cytochrome holoprotein (40,148,149). Under these conditions, heme 
biosynthesis is swiftly up-regulated to provide sufficient heme to nascent apocytochromes. 
The two major sites of heme synthesis are bone marrow, where hemoglobin is produced, 
and liver, where various hemoproteins (in particular, microsomal P450s) rely on prosthetic heme 
to catalyze the oxidation of endogenous and exogenous compounds. The rate of heme 
synthesis in both the bone marrow and the liver is controlled at the first committed step, the 
condensation of glycine and succinyl-CoA to 5-aminolevulinate (150). This committed step is 
catalyzed by ALAS, which exists as two isoforms: ALAS1, which regulates heme synthesis in 
liver and other organ systems, and ALAS2, which regulates heme synthesis in hematopoietic 
tissues (44,151,152). The regulatory role of ALAS in heme synthesis is underlined by the fact 
that ALAS mRNA is markedly increased under physiological conditions demanding more heme, 
such as exposure to drugs and environmental toxicants, whereas expression levels of the other 
enzymes in the pathway do not change significantly (153). Recent studies have shown that this 
increase in ALAS expression in response to heme demand is not a consequence of heme 
feedback regulation but a direct activation of ALAS transcription by xenobiotic-sensing nuclear 
receptors similar to those found in inducible P450s (154). 
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Although ALAS-mediated regulation of heme synthesis is considered the key step in heme 
biosynthesis, recent reports have identified a second regulatory step in heme biosynthesis 
mediated by the mitochondrial ATP binding cassette transporter Abcb6 (28). Abcb6 is highly 
expressed in fetal liver, erythroid cells, and adult tissues that have substantial heme 
requirements because of their high metabolic activity (e.g. heart and skeletal muscle) (28). 
Further, Abcb6 expression is directly related to enhanced de novo porphyrin biosynthesis, 
and Abcb6 overexpression activates the expression of genes important for heme biosynthesis 
(28). Thus, Abcb6 represents a previously unrecognized rate-limiting step in heme biosynthesis. 
Supporting this hypothesis, recent observations demonstrate that Abcb6 mRNA, like ALAS 
mRNA, is markedly increased under physiological conditions demanding more heme 
(28,155,156). Despite these observations, very little is known about the mechanisms that 
regulate Abcb6 expression both under normal physiological conditions and conditions of 
increasing demand for heme. 
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Results 
4.1.1. PAH increases hepatic porphyrin levels in mice and humans 
PAHs are potent atmospheric pollutants that are classified as either being nontoxic or 
being extremely toxic based on their structure (157-159). The three prototypical PAHs used in 
the studies described here, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),  benzo[a]pyrene 
(B[a]P), and 3-methylcholanthrene (3-MC) are classified as teratogens by the environmental 
protection agency (EPA) and are considered to be extremely toxic (160-162). Thus in these 
studies, we first established the toxicity profile for TCDD, B[a]P and 3-MC in mouse primary 
hepatocytes and human hepatoma cells. Mouse primary hepatocytes and human hepatoma 
cells (HepG2 and Huh7) were treated with increasing concentrations of either B[a]P (0, 2.5, 5 
and 10 µM), TCDD (0, 1 and 2 nM) or 3-MC (0, 5, 10 and 20  µM) for 16 hr and viability was 
evaluated by trypan blue exclusion assay (to measure necrosis) and annexin V staining (to 
measure apoptosis). We found that B[a]P was non-lethal upto a concentration of 10 µM, TCDD 
was non-lethal upto a concentration of 2 nM and 3-MC wan non-lethal upto a concentration of 
20 µM, for a maximum exposure time of 16 hours (data not shown). Based on these initial 
observations an exposure regimen of 0, 2.5, 5 and 10 µM for 16 hr for B[a]P, 0, 1 and 2 nM for 
16 hr for TCDD, and 0, 5, 10 and 20 µM for 3-MC was considered as non-lethal to both mouse 
primary hepatocytes and human hepatoma cells, and was employed as treatment regimen in 
the rest of the studies. 
Previous studies have shown that exposure to PAHs such as B[a]P, 3-MC, and TCDD 
induces the expression and activity of P450s. This increase in P450 expression would require a 
co-ordinate increase in cellular porphyrin levels to compensate for the increased heme demand 
required for increased P450 activity (163-166). To test this we evaluated the effect of B[a]P, 3-
MC and TCDD on hepatic PPIX levels, as a measure of heme,  using the non-lethal 
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concentrations of B[a]P, 3-MC and TCDD described above. In these studies, both dose and 
time dependent effects of B[a]P, 3-MC and TCDD on hepatic PPIX levels were evaluated. In the 
dose dependent studies mouse primary hepatocytes and human hepatoma cells were exposed 
to increasing concentration of either B[a]P (0 μM to 10 μM), or 3-MC (0 µM to 20 µM), or TCDD 
( 0 nM to 2 nM) for 16 hr. In the time dependent studies mouse primary hepatocytes and human 
hepatoma cells were exposed to a single concentration of either 10 μM B[a]P, 10 µM of 3-MC, 
or 2 nM TCDD for 0, 2, 4, 8 and 16 hr. We found that both B[a]P and 3-MC increased cellular 
PPIX levels in a dose dependent and time dependent manner in both primary hepatocytes and 
in hepatoma cells (Figure 4.1.1 A-F, data not shown for 3-MC). Maximum increase in cellular 
PPIX was observed after 16 hr of exposure to 10 μM B[a]P or 20 µM 3-MC. Percent fold 
increase in PPIX levels in response to B[a]P and 3-MC treatment was comparable between 
mouse primary hepatocytes and human hepatoma cells suggesting similar effect of B[a]P and 3-
MC on protoporphyrin levels in both mice and humans. In contrast to B[a]P and 3-MC, TCDD 
did not increase hepatic PPIX levels (data not shown) consistent with previous observations 
(36). 
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Figure 4.1.1. 
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Figure 4.1.1. (continued) 
Polyaromatic hydrocarbon benzo[a]pyrene increases hepatic PPIX levels.  
Exposure to B[a]P increases protoporphyrin IX levels in both mouse primary hepatocytes 
(A and B) and human hepatomas (C–F), in a dose-dependent (A, C, and E) and time-dependent 
(B, D, and F) manner. Values represent mean ± S.D. (error bars) (n = 4). Results shown are 
representative of three independent experiment with n = 4 per experiment. *, significantly 
different from vehicle control (p < 0.01); #, significantly different from cells treated with 2.5 
μM B[a]P in dose-dependent studies and significantly different from 4-h treatment (hepatomas) 
in time-dependent studies (p < 0.01). $, significantly different from cells treated with 5 μM B[a]P 
in dose-dependent studies and significantly different from 8-h treatment (hepatomas) in time-
dependent studies (p< 0.01). **, significantly different from cells exposed to B[a]P for 8 h 
(mouse primary hepatocytes) (p < 0.01). 
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4.1.2.  PAH exposure induces the key regulators of hepatic heme synthesis, 
ALAS1 and Abcb6/Abcb6 
B[a]P and 3-MC-mediated increase in PPIX could be due to either an increase in 
porphyrin synthesis or a block in porphyrin metabolism or both. To evaluate this further, we first 
tested whether B[a]P- and 3-MC-induced increase in cellular PPIX levels was a result of 
increased porphyrin biosynthesis. Because hepatic porphyrin biosynthesis is predominantly 
regulated by the two key regulatory proteins ALAS1 and Abcb6, we measured the expression of 
these two genes in response to B[a]P and 3-MC as a measure of increased porphyrin 
biosynthesis. Both time- and dose-dependent effects of B[a]P and 3-MC on porphyrin 
biosynthesis were evaluated in these studies. In the dose-dependent studies, mouse primary 
hepatocytes and hepatoma cells were treated with increasing concentrations of B[a]P or 3-MC 
for 16 h. In the time-dependent studies, cells were exposed to one single dose of 10 μM B[a]P 
for 0, 2, 4, 8, and 16 h. As shown in Figure 4.1.2, B[a]P induced both Abcb6 and ALAS1 mRNA 
in a dose- and time-dependent manner in both mouse primary hepatocytes (Figure 4.1.2, A and 
B) and human hepatoma cells (Figure 4.1.2, C–F). Similarly, 3-MC also induced Abcb6 
expression in a dose- and time-dependent manner (data not shown). Significant induction of 
both of the genes was found at concentrations as low as 5 μM and 16 h of treatment. Further, 
we found that B[a]P- and 3-MC-mediated increase in Abcb6 mRNA correlated well with B[a]P- 
and 3-MC-mediated increase in Abcb6 protein expression (Figure 4.1.2G and data not shown 
for 3.MC). Cytochrome P450 subfamily 1a1 (Cyp1a1) gene known to be induced in response to 
B[a]P and 3-MC, were used as a positive control in these studies (35). Cyp1a1 expression 
increased with increasing concentration of B[a]P and 3-MC and with increasing time of exposure 
(Figure 4.1.2 and data not shown for 3-MC), demonstrating treatment effectiveness. Taken 
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together, results presented in Figure 4.1.2 demonstrate that B[a]P- and 3-MC-induced hepatic 
expression of the key regulators of porphyrin synthesis, ALAS1 and Abcb6. 
 
 
80 
 
Figure 4.1.2. 
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Figure 4.1.2. (continued) 
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Figure 4.1.2. (continued) 
 
 
B[a]P induces Abcb6 and ALAS1 expression in a dose- and time-dependent manner. 
Exposure to B[a]P induces Abcb6 and Alas1 expression in mouse primary hepatocytes (left 
panels; A and B) and human hepatomas (left panels;C–F) in a dose-dependent (left 
panels; A, C, and E) and time-dependent manner (left panels;B, D, and F). Right panels (A–F), 
B[a]P-mediated induction of CYP1A1. CYP1A1, a gene known to be induced by B[a]P in liver, is 
used as a positive control in these experiments. G, Abcb6 protein expression in response to 
B[a]P treatment in human hepatomas. Abcb6 expression was measured in isolated 
mitochondria using an Abcb6-specific antibody. Values represent mean ± S.D. (error bars) (n = 
4). Results shown are representative of three independent experiments with n = 4/experiment. *, 
significantly different from cells exposed to 2.5 μM B[a]P in dose-dependent studies and 
significantly different from cells exposed to B[a]P for 4 h (hepatomas) in time-dependent studies 
(p < 0.01). #, significantly different from cells treated with 5 μM B[a]P in dose-dependent studies 
and significantly different from 8-h treatment (hepatomas) in time-dependent studies (p < 0.01). 
 
  
G  
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Although TCDD did not increase cellular PPIX levels, previous studies have demonstrated that 
TCDD treatment induces ALAS1 expression probably as a feedback regulation to increased 
heme demand required for P450 activity (167-169). Based on these observations, we 
hypothesized that TCDD might induce Abcb6 expression similar to what has been reported for 
ALAS1. To test this hypothesis, we exposed both mice and human hepatoma cells to TCDD and 
measured Abcb6/Abcb6 expression. Mice were treated with 37 μg/kg/day TCDD for 4 
consecutive days in corn oil. In contrast, hepatoma cells were treated with a single dose of 2 
nM TCDD for 16 h. We found that TCDD induced Abcb6 expression in both mice (Figure 
4.1.3A) and hepatoma cells (Figure 4.1.3, C and D). As before, expression of Cyp1a1, a gene 
known to be induced in response to TCDD (170,171), was used as a positive control in these 
studies. As with B[a]P and 3-MC treatment, Cyp1a1 expression increased with TCDD treatment 
(Figure 4.1.3, B–D), demonstrating treatment effectiveness. Together these results suggest that 
TCDD induces Abcb6 expression in a manner similar to its effect on ALAS1 expression. 
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Figure 4.1.3. 
 
 
TCDD induces Abcb6 expression in both mice and humans.  
Exposure to TCDD induces Abcb6 expression in mouse (A) and human hepatomas (C and D). 
B, TCDD-mediated induction of Cyp1a1, a gene known to be induced by TCDD in the liver, is 
used as a positive control in these experiments. Values represent mean ± S.D. (error bars); n = 
3 for mice, and n = 4 for cell culture. Results shown are representative of three independent 
experiments. *, significantly different for vehicle-treated mice in animals and human hepatomas 
(p < 0.01). 
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4.1.3.  PAH-mediated induction of Abcb6/Abcb6 is AhR-dependent 
Recent discoveries have implicated the nuclear receptor AhR in PAH-mediated induction 
of target genes (172,173). Thus, in this study, we evaluated the involvement of the AhR 
pathway in PAH-mediated up-regulation of Abcb6. Toward this end, we examined Abcb6 mRNA 
expression in response to TCDD and B[a]P treatment both in vivo and in vitro. In the in vivo 
studies, AhR wild type and AhR knock-out mice were exposed to TCDD as described under 
“Experimental Procedures.” In the in vitro studies, AhR endogenous knock-down and AhR-
expressing hepatoma (HepG2) cells were exposed to B[a]P as described under “Experimental 
Procedures.” Loss of AhR expression in the AhR knock-out mouse and AhR knock-down cells 
was confirmed by real-time PCR analysis of the AhR transcript using gene-specific primers 
(Figure 4.1.4C). Abcb6 expression was evaluated by real-time PCR using gene-specific primers. 
As before, CYP1A1 induction in response to AhR ligands was used as a positive control. We 
found that in both the AhR knock-out mice and in AhR knock-down hepatoma cells, AhR-
responsive gene CYP1A1 was not activated, whereas it was activated in the AhR wild type 
mouse and hepatoma cells (Figure 4.1.4, B and C). More importantly, we found that TCDD and 
B[a]P induced a marked increase in the expression of Abcb6 mRNA in AhR proficient mice 
(Figure 4.1.4A) and hepatomas (Figure 4.1.4C), but TCDD and B[a]P had no effect on Abcb6 
expression in AhR-deficient mice and hepatomas (Figure 4.1.4, A and C). Taken together, these 
results suggest that PAH-mediated increase in Abcb6/ Abcb6 transcript is AhR-dependent. 
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Figure 4.1.4. 
 
 
A functional AhR pathway is required for B[a]P-mediated up-regulation of Abcb6.  
Mouse (A) and HepG2 (C) cells lacking AhR are unable to up-regulate Abcb6 expression, 
whereas mouse (A) and HepG2 (C) cells with functional AhR up-regulate Abcb6 expression in 
response to TCDD and B[a]P. Cyp1a1, a gene known to be induced by TCDD and B[a]P, is 
used as a positive control in these experiments. Values represent mean ± S.D. (error bars); n = 
4 for mice, and n = 3 for HepG2. Results representative of three independent experiments. *, 
significantly different from scrambled siRNA transfected cells; p < 0.01 in hepatomas and 
AhR+/+ vehicle-treated mice. #, significantly different from AhR siRNA-transfected cells treated 
with B[a]P. p < 0.01. 
A B 
C 
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4.1.4.  AhR activates transcription of Abcb6 by binding to the AhR response 
element (AhRE) in the Abcb6/Abcb6 promoter  
Previous studies have demonstrated that in the absence of its ligand, AhR is localized to 
the cytoplasm. However, upon binding the ligand, AhR translocates from the cytoplasm to the 
nucleus, where it interacts with specific DNA response elements in target gene promoters and 
activates gene transcription (174,175). Thus in these studies, we first confirmed that B[a]P 
treatment results in the redistribution of AhR from the cytoplasm to the nucleus (Data not 
shown). We next tested whether PAH-induced expression of Abcb6/Abcb6 is mediated by AhR-
dependent activation of the Abcb6 promoter. For this purpose, both human and mouse Abcb6 
promoters were cloned in frame in a luciferase reporter vector, and the promoter-luciferase-
reporter constructs were transfected into HepG2 cells as described (64). Using the heme 
oxygenase-1 (HO-1) promoter luciferase- reporter construct, known to be activated by AhR, as 
a positive control, we evaluated the effect of PAH on the transcriptional activation of the 
Abcb6/Abcb6 promoter. Because both TCDD and B[a]P are known to activate target genes in a 
similar manner, via the AhR receptor (174,175), only B[a]P treatment was used in the promoter 
activation studies. We found that B[a]P activated both the human and mouse Abcb6 promoter 
(Fig. 4.1.5, A and B) in a manner that corresponded well with Abcb6 transcriptional up-
regulation seen in Figure 4.1.2. Together, these results suggest that the B[a]P-mediated 
increase in Abcb6 expression is mediated by activation of the Abcb6 promoter by AhR. 
The apparent similarity in AhR-mediated activation of both the mouse and human Abcb6 
promoter suggests similarities in the genomic organization of their AhR-binding response 
elements. In an effort to identify the existence of such elements in the Abcb6/Abcb6 promoter, 
we used a computer algorithm (Transfac) to analyze the 5′-flanking sequence of the human and 
mouse gene encoding Abcb6. Transfac analysis found three putative AhREs located at 102, 
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115, and 123 bp upstream of the transcription start site in the human and at 168, 185, and 195 
bp upstream of the transcription start site in the mouse Abcb6 promoter (Figure 4.1.5C). For 
clarity, the three AhR binding sites are labeled according to their occurrence in the gene, with 
the farthest upstream from the transcription start site referred to as Abcb6-ARE1 (123 bp in the 
human and 195 bp in the mouse promoter) and the one closest to the start site referred to as 
Abcb6-ARE3 (102 bp in the human and 168 bp in the mouse promoter (Figure 4.1.5D). 
The existence of three putative AREs in the 5′-flanking region of both the human and 
mouse Abcb6 promoter suggests that AhR could interact with any of these AREs to induce 
Abcb6 expression. To test this assertion and to assess the relative contribution of the three 
AREs to Abcb6 promoter transactivation by B[a]P, we generated mutations in each of the three 
AREs by site-directed mutagenesis (Figure 4.1.5D) and transfected HepG2 cells with these 
promoter constructs followed by treatment with B[a]P. Because the three AREs appeared to be 
conserved in both the mouse and human promoter, and because the activation of these mouse 
and human promoters appear to be similar (Figure 4.1.5, A and B), only the human promoter 
was used to explore the relative contribution of the three AREs to B[a]P-mediated activation. We 
found that mutations in the two proximal AREs at 115 and 102 bp (Abcb6-M2 and Abcb6-M3, 
respectively) did not affect B[a]P-mediated activation of the human Abcb6 promoter (Figure 
4.1.5E). In contrast, mutation of the distal ARE at123 bp (Abcb6-M1) or mutation of all the three 
AREs (Abcb6-M1M2M3) completely abolished B[a]P-mediated activation of the human Abcb6 
promoter (Figure 4.1.5E). Taken together, these results suggest that the most distal ARE in the 
human Abcb6 promoter (Abcb6- ARE1; at 123 bp) is responsible for B[a]P-mediated induction 
of Abcb6, whereas the two proximal AREs (Abcb6-ARE2 and Abcb6-ARE3, at 115 and 102 bp) 
are dispensable for B[a]P-mediated induction of Abcb6. In all of these studies, the heme 
oxygenase-1 promoter-luciferase-reporter construct was used as a positive control to confirm 
treatment effectiveness (Figure 4.1.5). 
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Figure 4.1.5. 
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Figure 4.1.5. (continued) 
Active AhR response element in human and mouse 5′-flanking region.  
Shown is activity of human (A) and mouse (B) 5′-flanking sequence in the Abcb6 gene in 
response to B[a]P. C, schematic representation of the 5′-flanking region of human and mouse 
Abcb6 genes. Core AREs are shown as boxes with respective locations of the 5′ end base from 
the reported transcription start sites. D, schematic representation of the human Abcb6 promoter, 
used in the transactivation studies, showing the introduction of mutations in the ARE. Gray 
shaded boxes show the AhR sequence motif that was mutated by site-directed mutagenesis on 
the human Abcb6 promoter.E, mutation of either the distal ARE or all of the three AREs does 
not activate the promoter-luciferase reporter in response to B[a]P. Values represent mean ± 
S.D. (error bars) (n = 3). Results representative of six independent experiments. *, significantly 
different from empty vector-transfected cells treated with B[a]P and Abcb6 promoter-transfected 
cells treated with vehicle. p < 0.01. #, significantly different from Abcb6-WT, Abcb6-M1, and 
Abcb6-M2 promoter-transfected cells treated with B[a]P. p < 0.01. 
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4.1.6.  AhR binds and interacts with the distal AhR response element in the Abcb6 
promoter 
To confirm and extend our promoter transactivation analysis and to demonstrate that 
AhR interacts with the distal promoter element of the human Abcb6 promoter, we performed an 
EMSA with oligonucleotide probe containing the human Abcb6 AREs. Although both AREs at 
102 and 115 bp failed to activate the Abcb6 promoter in response to B[a]P (Figure 4.1.5E), we 
decided to include these in our EMSA studies to confirm and extend the results from the 
promoter transactivation studies (Figure 4.1.5). Further, because of the close proximity of the 
AREs at 115 and 123 bp, a single oligonucleotide probe carrying both of these two sites were 
used in EMSA. Following EMSA, we found that nuclear extracts of HepG2 cells exposed to 
B[a]P caused an intense band with the 123 to 115 bp Abcb6-ARE oligonucleotide probe, 
retarded on the gel, indicative of a ARE-AhR protein complex at either 123 or 115 bp (Figure 
4.1.6C). In contrast, ARE at 102 bp did not demonstrate any retarded bands on the gel, 
suggesting the absence of ARE-AhR protein complex interaction at the 102 bp site (data not 
shown). Further, we found that the binding affinity of B[a]P-treated nuclear extract with the 
oligonucleotide probe (carrying both 123 and 115 bp) could be competed with the use of either 
excess unlabeled oligonucleotide probe (carrying 123 and 115 bp) or excess unlabeled 
oligonucleotide probe carrying mutations in the 115 bp AhRE (Abcb6-M2) but not with unlabeled 
oligonucleotides carrying mutations in Abcb6-M1 (123 bp) or mutations in both 115 and 123 bp 
(Abcb6-M1M2) (Figure 4.1.6C). These results suggest that an intact core AhRE at 123 bp in the 
Abcb6 promoter is required to form this DNA-protein complex. The fact that co-incubation with 
an antibody specific for AhR was capable of reducing the intensity of the 123 bp retarded band 
on the gel confirms the presence of AhR in this DNA-protein complex (Figure 4.1.6C). Instead of 
a supershifted band, studies have shown a reduction of AhR/ARNT-response element complex 
formation in the presence of an AhR antibody (176). Previous studies have demonstrated B[a]P-
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mediated interaction of AhR with the CYP1A1-ARE and the ability of AhR-specific antibody to 
disrupt this interaction. Thus, in our studies, CYP1A1-ARE interaction with AhR was used as a 
positive control (Fig. 4.1.6A).  
Although the EMSA studies demonstrate AhR interaction with the AhRE in the Abcb6 
promoter, we observed a significant difference in the migration pattern of Abcb6 promoter- AhR 
protein complex compared with CYP1A1 promoter-AhR protein complex (Figure 4.1.6, A and 
C). Further, the intensity of Abcb6 promoter-AhR protein complex on the EMSA was noticeably 
lighter compared with the interacting complex seen with CYP1A1 (Figure 4.1.6, A and C). We 
hypothesized that the difference in the migration pattern of the Abcb6-AhR protein complex 
could be due to DNA binding proteins, activated in response to B[a]P, that interact with the 
Abcb6 promoter at sites independent of AhR interaction with the ARE. To test this hypothesis, 
we synthesized a Abcb6-AhRE oligonucleotide probe where the sequence flanking the AREs 
(123 and 115 bp) was changed to random bases (Figure 4.1.6D) while keeping the core Abcb6-
ARE intact (Figure 4.1.6D). EMSA analysis of the core sequence and the two randomly altered 
probes demonstrates that changing the ARE flanking sequence to random bases restores the 
migration pattern of the Abcb6-ARE protein complex similar to what was seen with the CYP1A1-
AhR protein complex (Figure 4.1.6A and E). Further, these studies also demonstrate that the 
ARE in the Abcb6 promoter is sufficient for AhR interaction with the Abcb6 promoter because 
changing the flanking sequence did not alter overall AhR binding to the Abcb6-oligonucleotide 
probe (Figure 4.1.6E). These studies were confirmed further by competition assays using 
unlabeled and mutant oligonucleotide probes as described above (Figure 4.1.6F). 
Taken together, our findings suggest that the Abcb6 promoter is directly activated by 
AhR and that the ARE at 123 bp (Abcb6-ARE3) is essential and sufficient for the transcriptional 
activation of the human Abcb6 promoter. The predicted AhR response element at AREs in the 
Abcb6 promoter was further evaluated for its ability to bind AhR in the physiologically relevant 
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cellular environment. For this purpose, we performed chromatin immunoprecipitation 
experiments in HepG2 cells treated with B[a]P (5 µM). As shown in Figure 4.1.6, G and H, AhR 
protein was recruited to the ARE-containing regions of the Abcb6 promoter. Further, the AhR 
protein interaction with the Abcb6 promoter was significantly increased after B[a]P treatment 
(Figure 4.1.6, G and H). These results indicate that AhR activates the Abcb6 promoter through 
direct interaction with the AREs in the presence of B[a]P in vivo. 
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Figure 4.1.6.
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Figure 4.1.6. (continued)
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Figure 4.1.6. (continued) 
 
 
AhR is recruited to the distal AhR response element in the human Abcb6 promoter.  
A, electrophoretic mobility shift assay of AhR complex binding to the ARE element in the 
CYP1A1 promoter. B, schematic representation of the human Abcb6 promoter used in EMSA 
studies. C, electrophoretic mobility shift assay of AhR complex binding to the ARE element in 
the human Abcb6 promoter. D, schematic representation of the changes introduced in the ARE 
flanking sequence. Letters highlighted in blue show the altered bases introduced in the ARE 
flanking sequence, and letters in red show the core ARE. E and F, electrophoretic mobility shift 
assay of AhR complex binding to the human Abcb6-WT promoter and to the human Abcb6 
promoter carrying changes to the ARE flanking sequence. In all EMSA assays (A, C, E, and F), 
biotinylated DNA probes containing ARE were incubated with nuclear extracts of HepG2 cells 
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treated with either vehicle or 5 μM B[a]P in the presence or absence of excess unlabeled probe 
or the mutant AREs. Polyclonal antibody against AhR was used to show antibody-induced 
reduction in the intensity of the AhR-protein complex band. Incubation with equal amounts of a 
nonspecific polyclonal antibody did not reduce the band intensity. Results are representative of 
four independent experiments. G and H, chromatin immunoprecipitation analysis shows 
recruitment of AhR to the ARE in the Abcb6 promoter. Histograms (G) represent real-time PCR 
values of promoter amplification, whereas H shows conventional PCR analysis (28 cycles) for 
AREs of Abcb6 to confirm the specificity of PCR amplification and quantitation in SYBR green 
real-time PCR. Immunoprecipitation was carried out with two anti-AhR antibodies (M-20 and 
AhR-31635) or isotype control IgG. Values represent mean ± S.D. (error bars) of three 
independent experiments. Arrows indicates desired band. *, significantly different from B[a]P-
treated isotype IgG control values. p < 0.01. 
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Discussion 
All PAHs are potent inducers of microsomal monooxygenases, which require heme for 
their activity (5,177). Hence, heme demand is higher in animals exposed to PAH (42,154,178). 
When heme demand is high, the preferred response of cells to increased heme demand is to 
increase heme synthesis. Abcb6 is a mitochondrial transporter that regulates heme synthesis 
(28). Thus, in this study, we investigated the role of Abcb6 in PAH-mediated increase in heme 
synthesis and characterized the mechanism that regulates Abcb6 expression under these 
conditions.  
Previous studies have shown that exposure to TCDD induces the expression of ALAS1, 
the rate-limiting enzyme in heme biosynthesis, suggesting a feedback regulation of heme 
synthesis to compensate for the increased heme demand (154). However, this increase in 
ALAS1 does not result in an increase in heme or its precursor PPIX but results in the 
accumulation of uroporphyrins (167,169). This is because TCDD inhibits UROD, the enzyme 
that catalyzes the conversion of uroporphyrinogen to COPIII (167). Our studies confirm these 
observations showing no increase in PPIX levels in mice or tissue culture cells treated with 
TCDD. However, as with ALAS1 expression, both mouse and human Abcb6 expression were 
induced in response to TCDD treatment. This response appears to be a coordinated induction 
mediated by AhR to support the increased expression and activity of induced monooxygenases. 
In contrast to TCDD, the effect of B[a]P and 3-MC exposure on hepatic porphyrin levels 
is not known. We show here that exposure to B[a]P or 3-MC results in increased PPIX levels in 
both mouse primary hepatocytes and human hepatoma cells, suggesting that the B[a]P and 3-
MC effect on UROD activity is not the same as that of TCDD. Our results confirm previous 
observations in leukocytes, where B[a]P has been show to increase PPIX accumulation (179). 
Again, in response to B[a]P and 3-MC exposure, both ALAS1 and Abcb6 expression were 
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induced, supporting the hypothesis that in response to cellular heme demands, the heme 
biosynthetic pathway is up-regulated. 
Recent studies have demonstrated that the induction of P450s by drugs is mediated by 
several orphan nuclear receptors, members of a superfamily of DNA-binding proteins that act as 
transcription factors (163). With respect to PAH, the key transcription factor is AhR, which binds 
the DNA consensus sequence 5-GCGTG-3 (also known as ARE) in the gene promoters, thus 
inducing transcription. Here we demonstrate that B[a]P-mediated induction of Abcb6 expression 
is regulated by the AhR pathway. The up-regulation of Abcb6 promoter by AhR and the 
requirement that a functional AhR be present to ensure up-regulation of Abcb6 expression 
reveal a novel mechanism whereby a cell can, on demand, induce Abcb6 expression to promote 
heme biosynthesis to meet the increasing heme demands under these conditions. 
In our studies, although three potential ARE elements were identified by algorithm-based 
analysis of the Abcb6 promoter, only one of these ARE elements appeared to be important for 
AhR-mediated activation of Abcb6. Interestingly, mutation of the ARE element at 115 bp 
(Abcb6-M2) showed an increase in promoter activation in response to B[a]P that was 
significantly higher than the one seen with the unmutated native sequence. We speculate that 
this observation suggests the potential existence of repressor motifs in close proximity to the 
ARE motif at 115 bp. Observations such as these are not uncommon and have given rise to the 
idea that enhancer and repressor motifs often exist in close proximity to one another and might 
serve as crucial recruitment sites for transcriptional activation machinery that functions to either 
promote or suppress gene activation in response to external stimuli. In this context, it is 
interesting to note that the ARE sequence 5-GCGTG-3 is similar to the HIF-1response element 
sequence (consensus 5-RCGTG-3), suggesting a potential role of HIF and hypoxia in regulating 
Abcb6 expression.  
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It is interesting to note that in our studies treatment with B[a]P led to additional DNA-
protein complex formation in the Abcb6 promoter. However, this interaction appeared to be 
independent of AhR interaction with the Abcb6 promoter. At present, it is not clear what these 
interacting proteins are and what if any is the significance of these interactions to Abcb6 
expression and function.  
Previous studies have shown that the expression of membrane- bound efflux 
transporters mediated by AhR in response to environmental contaminants is not uniform 
between mice and humans (176). For example, breast cancer resistance protein, a transporter 
important in cellular detoxification and multidrug resistance, is induced in an AhR-dependent 
manner in humans but not in mice (176). However, in our studies, we found that TCDD and 
B[a]P induced both mouse and human Abcb6 in an AhR-dependent manner that appears to be 
comparable, suggesting a common underlying mechanism of PAH-mediated activation of Abcb6 
in humans and mice.  
The results from our studies presented in this work have both pharmacological and 
toxicological significance. In addition to their ability to precipitate porphyria, PAHs are 
carcinogenic in many animal species (158,180-182). Following their conversion to dihydrodiol 
epoxides and epoxide hydrolase by CYP1A1, these compounds interact with DNA and form 
PAH-DNA adducts (183,184). These epoxides are highly reactive electrophiles and cause 
mutations and cytotoxicity in both prokaryotic and eukaryotic cells. In this context, it is 
interesting to note that Abcb6 expression promotes cell growth and proliferation in hepatoma 
cells, and Abcb6 expression is induced during the development of hepatocellular carcinoma 
(185-187). Thus, Abcb6 induction by PAHs could be a potential contributing factor in PAH 
carcinogenicity. In addition, it is also possible that PAH-mediated activation of Abcb6 could 
enhance CYP1A1 activity and accelerate the metabolism of PAHs to epoxide hydrolase, thus 
promoting carcinogenesis.  
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In conclusion, this is the first report to illustrate that an important regulator of heme 
synthesis, Abcb6, is transcriptionally regulated by AhR. The resultant enhancement of Abcb6 
function represents an essential requirement coordinated by AhR to support the increased 
heme demand that occurs when animals are exposed to xenobiotics and therapeutic drugs. The 
observation that this AhR-induced expression of Abcb6 is common to both mice and humans 
highlights the importance and significance of this process. 
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4.2. XENOSENSOR CAR AND PXR REGULATES ATP BINDING 
CASSETTE TRANSPORTER ABCB6 GENE 
 
Abstract 
In the present study, we demonstrate that 1, 4-bis [2-(3, 5-dichloropyridyloxy)] benzene 
(TCPOBOP) a prototypical inducer of CAR and 5-pregnen-3β-ol-20-one-16α-carbonitrile (PCN) 
a prototypical ligand of PXR, up-regulate Abcb6 expression. Moreover, in vivo studies in CAR 
null mice demonstrate that TCPOBOP induction of Abcb6 is mediated by CAR. Similarly, 
studies with PXR null mice demonstrate that PCN mediated induction of Abcb6 is mediated 
through PXR. In silico analysis of Abcb6 promoter demonstrates the existence of CAR and PXR 
response elements. However, the significance of these elements to CAR and PXR mediated 
activation of Abcb6 promoter needs further investigation.  
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Introduction 
P450s constitute a superfamily of heme-proteins that play an important role in the 
activation of chemical carcinogens, detoxification of numerous xenobiotics as well as in the 
oxidative metabolism of endogenous compounds such as steroids, fatty acids, prostaglandins, 
and leukotrienes. In addition, some P450s have important roles in physiological processes, such 
as steroidogenesis and the maintenance of bile acid and cholesterol homeostasis. Given their 
importance, the molecular mechanisms of P450 gene regulation have been intensely studied. 
Direct activation by nuclear receptors represents one of the primary means by which the 
expression of these genes is controlled. However, because P450 are heme dependent enzymes 
that require heme for their activity, the availability of heme represents an important factor in the 
regulation of P450 activity. This requires coordinate synthesis of heme and a P450 apoprotein 
moiety. Despite these observations our understanding of the role of nuclear receptors in the 
regulation of heme synthesis is not completely understood.  
The xenosensing nuclear receptors CAR and PXR have been previously shown to 
regulate heme synthesis by regulating ALAS1 (188). ALAS1 regulates the rate of heme 
synthesis by controlling the first committed step, the condensation of glycine and succinyl-CoA 
to 5-aminolevulinate.  Although ALAS-mediated regulation of heme synthesis is considered the 
key step in heme biosynthesis, recent reports have identified a second regulatory step in heme 
biosynthesis mediated by the mitochondrial ATP binding cassette transporter Abcb6. Abcb6 
regulates heme biosynthesis by controlling the transport of COPIII, an intermediate in heme 
synthesis, from the cytoplasm into the mitochondria to complete heme synthesis. However, 
despite this knowledge little if any information is available on the role of nuclear receptors, the 
predominant regulators of P450s, in the regulation of Abcb6. 
In the present study, we demonstrate that Abcb6 expression is induced by both 
TCPOBP and PCN, two of the most common canonical activators of CAR and PXR, 
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respectively. We show that TCPOBOP and PCN mediated induction of Abcb6 is transcriptionally 
regulated and requires functional CAR and PXR.  
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Results 
 
4.2.1. Abcb6 expression in mouse hepatoma cells and mice treated with 
TCPOBOP 
Mouse hepatoma cells (Hepa1c1c7) were treated with increasing concentration of CAR 
ligand, TCPOBOP (0, 0.25, and 0.5μM) for 24 h. TCPOBOP treatment resulted in a dose-
dependent induction of Abcb6 mRNA (Figure 4.2.1A). Cyp2b10, a gene whose expression is 
induced by TCPOBOP, was used as a positive control (Figure 4.2.1A). 
We next evaluated if TCPOBOP induces Abcb6 expression in mice (C57BL/6J). Mice 
were exposed to TCPOBOP (0.3 mg/kg/day in corn oil) intra peritoneal for 4 days. Change in 
hepatic Abcb6 expression was determined by quantitative real time PCR and western blot 
analysis. TCPOBOP induced Abcb6 mRNA and protein levels in mice liver (Figure 4.2.1 B – C). 
Expression of Cyp2b10, a gene known to be induced in response to TCPOBOP, was used as 
positive control. Cyp2b10 expression increased with TCPOBOP treatment, demonstrating 
treatment effectiveness (Figure 4.2.1 B – C). Actin was used as a loading control in these 
experiments. Taken together, results presented in Figure 4.2.1 demonstrate that TCPOBOP 
induced hepatic expression of Abcb6. 
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Figure 4.2.1. 
 
 
TCPOBOP induces Abcb6 expression. 
Exposure to TCPOBOP induces Abcb6 expression in mouse hepatoma (A) in a dose-dependent 
manner and in mice liver (B).  Abcb6 protein expression in response to TCPOBOP treatment in 
mice livers (C). Abcb6 expression was measured using an Abcb6-specific antibody. TCPOBOP-
mediated induction of Cyp2b10, a gene known to be induced by TCPOBOP in liver, is used as a 
positive control in these experiments. Values represent mean ± S.D. (error bars) (n = 4). Results 
shown are representative of three independent experiments with n = 4/experiment. *, 
significantly different from vehicle treated control (p < 0.01). 
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4.2.2. TCPOBOP mediated Induction of Abcb6 is CAR-dependent  
Recent discoveries have implicated the nuclear receptor CAR in TCPOBOP-mediated 
induction of target genes. Thus, in this study, we evaluated the involvement of the CAR pathway 
in TCPOBOP-mediated up-regulation of Abcb6. CAR wild type and CAR knock-out mice were 
exposed to TCPOBOP (0.3 mg/kg/day in corn oil) intra peritoneal for 4 days. Abcb6 expression 
was evaluated by real-time PCR using gene-specific primers and western blot analysis using 
protein specific antibody. Mrp4 and Cyp2b10, genes known to be induced in response to CAR 
activation, were used as positive controls. We found that in CAR knock-out mice CAR-
responsive genes Mrp4 and Cyp2b10 were not activated, whereas they were activated in the 
CAR wild type mouse (Figure 4.2.2 A – D). More importantly, we found that TCPOBOP induced 
a marked increase in the expression of Abcb6 mRNA and protein in CAR wild type mice (Figure 
4.2.2 A and C), but TCPOBOP had no effect on Abcb6 expression in CAR-deficient mice 
(Figure 4.2.2 B and D). Taken together, these results suggest that TCPOBOP-mediated 
increase in Abcb6 transcript and protein is CAR-dependent. 
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Figure 4.2.2. 
 
TCPOBOP mediated Induction of Abcb6 is CAR-dependent.  
Real time PCR analysis for Abcb6 expression in mouse with functional CAR (A) and mouse 
lacking CAR (B), TCPOBOP up-regulates Abcb6 expression in CAR wild type mouse and not in 
CAR null mouse. Immunoblot analysis for Abcb6 expression in mouse with functional CAR (C) 
and mouse lacking CAR (D), TCPOBOP up-regulates Abcb6 expression in CAR wild type 
mouse and not in CAR null mouse. CAR dependent and TCPOBOP-mediated induction of Mrp4 
and Cyp2b10 genes is used as a positive control in these experiments. Values represent mean 
± S.D. (error bars); n = 4 for mice. Results representative of three independent experiments. *, 
significantly different from mice exposed to vehicle treatment (p < 0.01). 
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4.2.3. PCN induces Abcb6 expression in a PXR-dependent manner 
Recent studies demonstrate that nuclear receptors, chicken CXR, human PXR and 
mouse PXR regulate ALAS1 gene expression, the rate-limiting enzyme in heme biosynthesis, in 
response to xenobiotics. In the present study, we investigated the role of PXR in the regulation 
of Abcb6, the newly discovered rate-limiting protein in heme biosynthesis.  
PXR wild type and PXR knock-out mice were exposed to PCN (200 mg/kg/day in corn 
oil) intra peritoneal for 4 days. Abcb6 expression was evaluated by real-time PCR using gene-
specific primers and western blot analysis using protein specific antibodies. Oatp1a4 and 
Cyp3a, genes known to be induced in response to PXR activation, were used as positive 
controls. We found that in PXR knock-out mice PXR-responsive genes Oatp1a4 and Cyp3a 
were not activated, whereas they were activated in the PXR wild type mouse (Figure 4.2.3 A – 
D), demonstrating treatment effectiveness. More importantly, we found that PCN induced a 
marked increase in the expression of Abcb6 mRNA and protein in PXR wild type mice (Figure 
4.2.3 A and B), but PCN had no effect on Abcb6 expression in PXR-deficient mice (Figure 4.2.3 
C and D). Taken together, these results suggest that PCN-mediated increase in Abcb6 
transcript and protein is PXR-dependent. 
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Figure 4.2.3. 
 
PCN induces Abcb6 expression in PXR-dependent manner.  
Real time PCR analysis for Abcb6 expression in mouse with functional PXR (A) and mouse 
lacking PXR (C), Pregnenolone-16-carbonitrile (PCN) up-regulate Abcb6 expression in PXR 
wild type mouse and not in PXR null mouse. Immunoblot analysis for Abcb6 expression in 
mouse with functional PXR (B) and mouse lacking PXR (D), PCN up-regulates Abcb6 
expression in PXR wild type mouse and not in PXR null mouse. PXR dependent and PCN-
mediated induction of Oatp1a4 and Cyp3a genes is used as a positive control in these 
experiments. Values represent mean ± S.D. (error bars); n = 3 for mice. *, significantly different 
from mice exposed to vehicle treatment (p < 0.01). 
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4.2.4. CAR and PXR response element in the Abcb6 Promoter  
Our results demonstrate transcriptional activation of Abcb6 in the presence of ligands for 
nuclear receptors CAR and PXR. To test whether ligand-induced expression of Abcb6 is 
mediated by CAR or PXR-dependent manner, mouse Abcb6 promoters were cloned in frame in 
a luciferase reporter vector. First we did in silico analysis for potential cis-elements that may be 
capable of binding PXR or CAR using ‘Nubiscan’ which uses the known consensus sequences 
for nuclear receptor binding sites. Further, the promoter-luciferase-reporter constructs were 
transfected into Hepa1c1c7 cells as described (64). We evaluated the effect of CAR – ligand 
TCPOBOP on the transcriptional activation of the Abcb6 promoter (Figure 4.2.4). Although 
nubiscan analysis found several putative CAR and PXR binding sites (Figure 4.2.4A) in the 
Abcb6 promoter, we did not see any activation of Abcb6 promoter (1.2 kb upstream of the 
transcription start site) (Figure 4.2.4B). These results suggest that the CAR activation sites 
could be upstream of the 1.2 kb promoter region used in these studies. Analysis of PXR 
mediated activation of Abcb6 promoter will be done in future studies. 
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Figure 4.2.4. 
A 
 
B 
 
Nuclear receptors PXR and CAR response elements in Abcb6 Promoter.  
A, The consensus sequences for nuclear receptor binding sites were searched using ‘Nubiscan’ 
which identified potential cis-elements that may be capable of binding PXR or CAR. ‘number +’ 
for example ‘140+’ represents the nucleotide base and the strand orientation (+strand). B, 
activity of mouse 5′-flanking sequence in the Abcb6 gene in response to TCPOBOP. Values 
represent mean ± S.D. (error bars) (n = 3).  
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Discussion 
 
In response to endo and xenobiotic exposure, hepatic detoxification mechanisms are 
activated to prevent liver injury that accompanies such exposure. The efficient functioning of this 
detoxification mechanism requires fully active P450s, the predominant detoxification system in 
the liver. However, because P450s are heme dependent enzymes we envisioned a pathway in 
which P450 induction is coordinated with heme synthesis to support P450 function.  We had 
previously proposed that this coordinated induction of heme synthesis could involve 
mechanisms that complement P450 induction. Consistent with this proposal we demonstrate 
that Abcb6 expression is transcriptionally induced by TCPOBOP and PCN the two prototypical 
inducers of P450s, potentially to support the increased heme demand.  
In our studies TCPOBOP and PCN mediated regulation of Abcb6 appear to require 
functional CAR and PXR, as Abcb6 expression was not induced in CAR and PXR knockout 
animals.  In contrast, although PCN mediated induction of ALAS the rate limiting enzyme in 
heme synthesis is dependent on PXR, TCPOBOP mediated induction of ALAS appears to be 
independent of CAR (42,178). The basis for this differential regulation of Abcb6 and ALAS by 
TCPOBOP remains unclear.  
An evaluation of the Abcb6 5’ flanking region revealed several nuclear response 
elements (DR1-5, ER6) within the first 1.2-kb upstream of the Abcb6 transcription start site, 
nevertheless Abcb6 promoter was not activated by either CAR or PXR ligands. However, this is 
not unusual as other genes that are CAR and PXR targets (CYP2B6, CYP3A4, MDR1 and 
Mrp4) all have distal (>7 kb) upstream nuclear receptor binding sites. Again consistent with this 
observation a nuclear receptor site computer scanning algorithm (Nubiscan, 
www.nubiscan.unibas.ch) used to probe for putative upstream nuclear receptor binding sites 
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(upstream of 1.2 kb) of the Abcb6 gene identified several nuclear receptor sites preferred by 
CAR (i.e. DR3, DR4, and ER6). Therefore, future studies using this region between 1.2 and 10 
kb upstream of the transcription start site in promoter activation studies should help identify the 
response elements responsible for CAR mediated activation of Abcb6. 
CAR and PXR ligands include endogenous bile acids, therapeutic drugs, dietary 
constituents, and environmental pollutants. All or some of these chemicals are substrates for 
P450s. Thus through CAR activation, xenobiotics can induce Abcb6 expression that can 
increase heme synthesis to support increased expression and function of P450 activity. 
However, variation in Abcb6 expression either due to non-functional mutations in the gene or 
existence of splice variants of Abcb6 with altered function could affect P450 function and might 
have a significant impact on the metabolism of a wide range of pharmacological agents and 
other foreign compounds. Thus, identifying and defining Abcb6 mutations, splice variants, and 
the specific effect of these changes to Abcb6 expression and function in the human population 
should provide insight into this important xenobiotic response.   
Although CAR and PXR were initially characterized as xenosensors that coordinated 
hepatic responses to xenobiotics, recent evidence indicates that they are also important 
regulators of hepatic energy metabolism. In liver, both receptors regulate expression of genes in 
pathways that control lipid and carbohydrate metabolism. Both lipid and carbohydrate 
metabolism require a functional mitochondria with optimally functioning mitochondrial respiratory 
complexes. Given that most if not all mitochondrial respiratory complexes are hemoproteins and 
require heme for their activity, CAR and PXR mediated regulation of Abcb6 might have broader 
implications in mitochondrial function and cellular energy metabolism.  
In summary, we demonstrate that the ABC transporter, Abcb6, a regulator of heme 
synthesis, is induced by the nuclear receptors CAR and PXR, as is ALAS1, the rate-limiting 
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enzyme in heme synthesis. The up-regulation of Abcb6 and ALAS1 by CAR and PXR, the two 
canonical inducers of P450, suggests coordinate regulation of heme synthesis with P450 
expression. The upregulation of Abcb6 and ALAS1 by CAR and PXR also implicates them as 
bona fide members of hepatic detoxification cascade. Moreover, because hepatic hemoproteins 
include not only P450s but also enzymes involved in oxidative stress response, the results 
suggest that Abcb6 and ALAS1 expression might be induced in response to oxidative stress 
and might play a potentially important role in oxidative stress response.  
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4.3. ARSENIC MEDIATED TRANSCRIPTIONAL ACTIVATION OF 
ABCB6 
 
Abstract 
Arsenic is an environmental carcinogen and a major health hazard. Inspite of extensive 
efforts, the mechanism of arsenic induced toxicity and tumorigenicity is not yet clearly 
understood. Of importance, exposure to pro-oxidants such as arsenic, also results in the 
induction of a gene expression program, whose primary function is to protect cells from 
oxidative stress. However, little is known about the components of arsenic induced mammalian 
oxidative stress response and its regulatory logic. In the present study, we show that sodium 
arsenite, a major biohazard following environmental or occupational exposure, induces Abcb6 
expression in a dose-dependent manner both in mice fed sodium arsenite in drinking water and 
in cells exposed to sodium arsenite in vitro. Arsenite-induced Abcb6 expression was 
transcriptionally regulated, but this induction was not mediated by the redox-sensitive 
transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2). Collectively, these results, 
suggest that Abcb6 expression is transcriptionally regulated by sodium arsenite in a Nrf2 
independent manner. 
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Introduction 
Arsenic is a ubiquitous environmental pollutant. Chronic exposure of humans to 
inorganic arsenic results in formation of tumors of the liver and kidney and probably skin, lung, 
and urinary bladder (101,189). In addition to its carcinogenic effect, epidemiological studies 
have associated chronic arsenic exposure with an increased risk in many human nonmalignant 
diseases, such as peripheral vascular disease, diabetes, and chronic lung disease (190). 
Evidence suggests that arsenic exerts its chronic toxicity by interacting with sulfhydryl groups 
and generating reactive oxygen species (ROS) that cause damage to cellular macromolecules 
via oxidative stress (191-195). Of importance, exposure to pro-oxidants such as arsenic also 
results in the induction of a gene expression program whose primary function is to protect cells 
from oxidative stress (196-199).  
The 97-kDa Abcb6 protein is a member of the ATP-binding cassette (ABC) superfamily 
of transport proteins that was originally identified while screening for novel drug-resistant genes 
in the liver (118). Initial cloning and homology-modeling studies revealed that Abcb6 is related to 
the heavy metal tolerance factor 1 (HMT1) of Caenorhabditis elegans and 
Schizosaccharomyces pombe (200-202). HMT1 is a half transporter that confers tolerance to 
heavy metal toxicity in S. pombe (200) and tolerance to cadmium in C. elegans (202). These 
homology-modeling studies suggest a possible role for Abcb6 in metal tolerance. However, 
Abcb6 expression and metal tolerance in cell culture is conflicting. Recent studies by Annereau 
et al. and Paterson et al. suggest a direct correlation between arsenic resistance and Abcb6 
expression in various human and mouse cell lines (203,204). They suggest that cell lines 
selected for resistance to arsenite have elevated levels of Abcb6 messenger RNA (mRNA) and 
protein. In contrast, studies by Gebel et al. demonstrate no increase in Abcb6 mRNA in HepG2 
cells that were selected for arsenic resistance (205). 
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Thus, the present study was conducted to determine whether arsenic could induce 
Abcb6 expression. We report that sodium arsenite induces upregulation of Abcb6. Abcb6 
expression appears to be transcriptionally regulated, but this expression is not mediated by the 
redox-sensitive transcription factor Nrf2. 
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Results 
4.3.1.  Abcb6 expression in mice fed sodium arsenite 
Abcb6 expression was measured in mice (C57BL/6J) fed increasing concentrations of 
sodium arsenite (0, 1, 10, and 100 ppm) in drinking water for 24 h. Sodium arsenite induced 
both Abcb6 mRNA and protein levels in a dose-dependent manner (Figure 4.3.1, A – B). 
Highest induction of Abcb6 was seen in mice fed 100 ppm of sodium arsenite. Expression of 
heme oxygenase 1 (HO-1), a gene known to be induced in response to sodium arsenite, was 
used as positive control. HO-1 expression increased with increasing concentration of sodium 
arsenite, demonstrating treatment effectiveness (Figure 4.3.1, A – B). Mitochondrial protein 
porin whose expression is not altered in response to sodium arsenite was used as loading 
control in these experiments. 
We next evaluated whether Abcb6 expression was regulated by sodium arsenite in a 
time-dependent manner. Mice were exposed to 10 ppm of sodium arsenite for 1, 3, or 5 days. 
Sodium arsenite exposure induced Abcb6 expression throughout the 5-day treatment period 
(Figure 4.3.1C). However, the magnitude of Abcb6 expression on day 3 and day 5 following 
sodium arsenite treatment was similar to expression levels seen on day 1 (Figure 4.3.1C). As in 
the dose-dependent studies, expression of HO-1 and porin were used as positive and negative 
controls, respectively. Cumulatively results presented in Figure 4.3.1 demonstrate that sodium 
arsenite induces Abcb6 expression in a dose-dependent manner in mice fed sodium arsenite in 
drinking water. 
  
120 
 
Figure 4.3.1. 
 
Abcb6 expression in mice fed sodium arsenite in drinking water.  
Abcb6 expression in mice fed sodium arsenite in drinking water. (A) Immunoblot analysis of 
Abcb6 expression in mice (C57BL/6J) fed increasing concentrations (0, 1, 10, and 100 ppm) of 
sodium arsenite for 24 h. Abcb6 expression was measured in isolated mitochondria (100 μg) 
using Abcb6-specific antibody. Results are representative of three independent experiments 
with n = 4 mice per treatment group. (B) Real-time PCR analysis of Abcb6 mRNA levels in livers 
of mice fed increasing concentrations (0, 1, 10, and 100 ppm) of sodium arsenite for 24 h. 
Abcb6 expression was measured using gene-specific primers. Values represent mean ± SD; n = 
6. Results are representative of three independent experiments. “*” Significantly different from 
untreated controls. p < 0.01. (C) Immunoblot analysis of Abcb6 expression in mice fed sodium 
arsenite (10 ppm) for 1, 3, or 5 days. Abcb6 expression was measured in isolated mitochondria 
(100 μg) using Abcb6-specific antibody. Results are representative of three independent 
experiments with n = 4 mice per treatment group. 
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4.3.2.  Abcb6 expression in human hepatoma cells treated with sodium arsenite 
Human hepatoma cells (HepG2 and Hep3B) were treated with increasing concentration 
of sodium arsenite (0–5μM) for 24 h. These cells were selected because sodium arsenite elicits 
stress response, initiates ROS production, and induces apoptosis in these cells (205-207). 
Sodium arsenite treatment resulted in a dose-dependent induction of Abcb6 mRNA (Figure 
4.3.2, B – C) and Abcb6 protein (Figure 4.3.2A) in both HepG2 and Hep3B cells. 
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Figure 4.3.2. 
 
Abcb6 expression in hepatoma cells treated with sodium arsenite.  
(A) Immunoblot analysis of Abcb6 expression in HepG2 and Hep3B cells treated with increasing 
concentrations (0, 1, and 5μM) of sodium arsenite for 24 h. Abcb6 expression was measured in 
isolated mitochondria (100 μg) using Abcb6-specific antibody. Results are representative of 
three independent experiments. (B and C) Real-time PCR analysis of Abcb6 mRNA levels in (B) 
Hep3B and (C) HepG2 cells treated with increasing concentrations (0, 0.1, 1, and 5μM) of 
sodium arsenite for 24 h. Abcb6 expression was measured using gene-specific primers. HO-1 
expression was used as positive control. Values represent mean ± SD. Results are 
representative of three independent experiments. “*” Significantly different from untreated 
controls. p < 0.01. 
123 
 
4.3.3.  Abcb6 expression in Nrf2+/+ and Nrf2−/− mice fed sodium arsenite in drinking water 
Arsenic-mediated regulation of gene transcription is believed to be governed by redox-
sensitive transcription factors that are activated in response to oxidative stress. Among the 
many redox-sensitive transcription factors, Nrf2 (208) appears to play a key role in arsenic-
mediated activation of downstream genes (196,209,210). Because Abcb6 transcript was found 
in our studies to be upregulated by sodium arsenite, we tested whether this induction was 
mediated by Nrf2. We used the Nrf2 wild-type (Nrf2+/+) and Nrf2 gene-deleted (Nrf2−/−) mice for 
these studies. We did not see any difference in basal Abcb6 expression 
between Nrf2+/+ and Nrf2−/− mice (Data not shown). Sodium arsenite treatment induced Abcb6 
expression to a similar extent in both Nrf2+/+ and Nrf2−/− mice (Figure 4.3.3, A – B; ∼3.5-fold 
increase in Abcb6 mRNA in arsenite-treated vs. vehicle control mice), suggesting that sodium 
arsenite–dependent induction of Abcb6 is not mediated by Nrf2. HO-1, a gene whose 
expression is activated by Nrf2 (101,189,211), was used as a positive control (Figure 4.3.3, A – 
B). HO-1 expression was induced approximately two fold in arsenite-treated Nrf2+/+ mice but not 
in Nrf2−/− mice. 
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Figure 4.3.3. 
 
Abcb6 expression in the liver of Nrf2 wild-type (Nrf2+/+) and Nrf2 gene-                        
deleted (Nrf2−/−) mice fed sodium arsenite in drinking water.  
(A) Nrf2 wild-type (Nrf2+/+) and (B) Nrf2 gene-deleted (Nrf2−/−) mice were treated with 10 ppm 
sodium arsenite for 24 h. Abcb6 expression was measured by real-time PCR using gene-
specific primers. Expression of HO-1 was used as positive control in these studies. Values 
represent mean ± SD with n = 4 mice per treatment group. Results are representative of three 
independent experiments. “*” Significantly different from control mice (vehicle treated). p < 0.01. 
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Discussion 
Inorganic arsenic is a ubiquitous environmental pollutant, and chronic exposure in 
humans has devastating health effects, including the formation of tumors of the liver, kidney, 
skin, lung, and bladder (101,189). Its ubiquity in the environment has led to the evolution of 
arsenic defense mechanisms in all living organisms studied, from Escherichia coli to man (212). 
These defense mechanisms work either alone or in concert to reduce cellular oxidative stress. 
In this study, we determined whether arsenic can induce Abcb6 expression and further 
investigated the role of Abcb6 to arsenic toxicity (Chapter 5.2). We find that in vitro sodium 
arsenite induces Abcb6 expression in hepatoma cells at a concentration as low as 1 μM. This 
low-dose induction suggests that Abcb6 expression is an adaptive response to arsenite toxicity, 
a phenomenon commonly termed as preconditioning that allows cells and tissues to resist future 
toxic insults to similar stressors (213). In vivo Abcb6 expression is induced in a dose-dependent 
manner within a day following arsenite treatment, which suggests that Abcb6 is an early 
response gene activated in response to injury. 
As noted earlier, the redox-sensitive transcription factor Nrf2 provides a predominant 
pathway of oxidant-mediated induction of downstream genes. In our initial analysis, Abcb6 
expression did not appear to be regulated by Nrf2. This suggests that pathways independent of 
Nrf2 might be involved in regulating Abcb6 expression. Alternatively, arsenite-induced Abcb6 
expression might be regulated posttranscriptionally. Interestingly, recent studies by Hubner et 
al. (214) demonstrated induction of Abcb6 mRNA in humans in response to cigarette smoking. 
In these studies, Nrf2 did not mediate Abcb6 expression induced by smoking-related oxidative 
stress. Our studies support these findings, demonstrating that Nrf2 does not regulate Abcb6 
expression. In addition to Nrf2, arsenic exposure has been shown to activate several 
transcription factors including p53, Sp1, activator protein 1 (AP-1), and NF-kappaB (215-220). 
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Preliminary analysis of the human and mouse Abcb6/Abcb6 promoter using a pattern search 
program (nubiscan) reveals several putative cis-elements that may be capable of binding AP-1, 
NF-kB, and p53. Our future studies will evaluate the mechanism of sodium arsenite–mediated 
activation of Abcb6 and will address the role of these transcription factors in the activation of 
Abcb6. 
In summary, the present studies demonstrate that sodium arsenite induces Abcb6 
expression both in vitro and in vivo. Abcb6 expression is transcriptionally regulated by sodium 
arsenite in an Nrf2 independent manner. Future studies will focus on the mechanisms by which 
arsenic induces Abcb6 expression. 
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Chapter 5. SIGNIFICANCE OF ABCB6 TO XENOBIOTIC INDUCED 
PORPHYRIA AND OXIDATIVE STRESS – IN VITRO 
 
5.1. Role of Abcb6 in PAH mediated porphyria 
5.2. Role of Abcb6 in arsenic cytotoxicity 
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5.1. ROLE OF ABCB6 IN PAH MEDIATED PORPHYRIA  
Abstract 
Porphyrias are inherited or acquired disorders in which clinical manifestations are 
attributable to a disturbance in heme synthesis. Porphyrias are characterized by elevation in 
heme synthesis accompanied by elevations of heme precursors (porphyrins) in blood, urine 
and/or stool. A number of chemicals, particularly metals and halogenated hydrocarbons, induce 
disturbances of heme synthesis in experimental animals leading to porphyria. In the present 
study, we demonstrate that Abcb6 the second rate limiting protein in heme synthesis is an 
important component of environmental toxicant induced hepatic porphyria. Using a model of 
environmental toxicant induced hepatic porphyria we demonstrate that loss of Abcb6 expression 
in vitro in tissue culture or ex vivo in primary hepatocytes (isolated from Abcb6 knockout mouse) 
results in decreased accumulation of porphyrins, suggesting a role for Abcb6 in the 
manifestation of porphyria due to prolonged exposure to environmental toxicants.  
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Introduction 
The acute porphyrias are a group of disorders that result from inherited defects in the 
enzymes of the heme biosynthetic pathway, which lead to accumulation of porphyrin 
intermediates. The main clinical manifestations of porphyrias are intermittent attacks of 
neuropsychiatric dysfunction and/or sensitivity of the skin to sunlight (221,222). Affected 
patients are prone to potentially fatal acute attacks, which are frequently precipitated by 
exposure to pharmacological chemicals and/or environmental contaminants (222,223). It has 
been observed that for several of these pharmacological chemicals and/or environmental 
contaminants soon after their administration or exposure there is an overproduction of heme 
precursors and their accumulation in certain tissues. A sequence of events has been suggested 
in which the chemical decreases the activity of specific enzyme(s) in the heme synthesis 
pathway, usually in association with stimulation of heme synthesis. 
In the body, heme synthesis is regulated at two steps. The rate-limiting enzyme ALAS, 
which catalyzes the condensation of Glycine and Succinyl CoA to produce delta-Aminolevulinic 
acid, mediates the first rate-limiting step (21,22). The second rate-limiting step is mediated by 
the mitochondrial ABC transporter Abcb6 that regulates the energy dependent transport of 
COPIII from the cytoplasm into the mitochondria. It is now well established that induction of 
ALAS1 following exposure to environmental contaminants plays an important role in 
porphyrogenicity. Our studies described in Chapter 4.1 demonstrate that similar to ALAS, Abcb6 
expression is induced following exposure to environmental contaminants. However, the 
significance of such induction to drug-induced porphyria is not known.  
PAHs are potent environmental pollutants and have been shown to be associated with 
the induction of porphyria in humans and in experimental animals. In the present study, we used 
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PAH exposure as a model of porphyria to examine the relationship between Abcb6 induction 
and accelerated heme synthesis to manifestation of porphyria.  
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Results 
5.1.1. Abcb6 expression is required for PAH-mediated porphyrin synthesis 
 We observed increased hepatic porphyrin levels in mouse primary hepatocyte and 
human hepatoma cells with PAH treatment (Figure 4.1.1). To evaluate the functional importance 
and the relative contribution of Abcb6 expression to B[a]P induced porphyrin synthesis, we 
blocked endogenous Abcb6 expression in HepG2 and Huh7 cells and measured porphyrin 
synthesis following exposure to B[a]P. Reduced Abcb6 expression was achieved in these cells 
using Abcb6-specific shRNA, which resulted in greater than 80% reduction of endogenous 
Abcb6 relative to shRNA vector cells (185). PPIX levels were measured in these cells by flow 
cytometry as described under “Experimental Procedures” (28). We found that reduced Abcb6 
expression per se did not decrease PPIX levels under physiological conditions, confirming our 
earlier observations (Figure 5.1.1, A and B) (20). Interestingly, in the presence of 5 µM B[a]P, 
cellular protoporphyrin IX levels were decreased significantly in both of the hepatoma cells 
(Figure 5.1.1, A and B).  
Although a significant decrease in B[a]P-mediated cellular PPIX levels was observed in 
the hepatoma cells in the absence of Abcb6, this decrease was not as dramatic as one would 
have expected if Abcb6 were to play a significant role in porphyrin biosynthesis. To test this 
further and to evaluate the full impact of Abcb6 on B[a]P-induced porphyrin biosynthesis, we 
isolated primary hepatocytes from Abcb6+/+ and Abcb6-/- mice and measured protoporphyrin 
levels in these hepatocytes in the presence and absence of B[a]P. We found that complete loss 
of Abcb6 expression significantly compromised the ability of Abcb6-/- primary hepatocytes to 
respond to B[a]P-mediated increase in cellular PPIX levels (Figure 5.1.1E). 
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Figure 5.1.1. 
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Figure 5.1.1. (continued) 
Loss of Abcb6 expression compromises B[a]P-induced hepatic porphyrin levels.  
Endogenous knockdown of Abcb6 expression results in decreased PPIX levels in both HepG2 
(A) and Huh7 (B) cells exposed to B[a]P. In contrast, exposure to B[a]P does not affect PPIX 
levels in HepG2 (C) and Huh7 (D) cells overexpressing Abcb6. E, loss of Abcb6 expression 
results in decreased PPIX levels in mouse primary hepatocytes isolated from Abcb6−/− mice 
exposed to B[a]P. Values represent mean ± S.D. (error bars) (n = 3). Results are representative 
of three independent experiments with n = 3 per experiment. *, significantly different from 
shRNA vector control cells exposed to B[a]P for 16 h in (A and B) and significantly different from 
vector control cells (C and D). p < 0.05. E, *, significantly different from B[a]P-treated wild-type 
mouse primary hepatocytes. p < 0.01. #, significantly different from B[a]P-treated wild-type 
mouse primary hepatocytes. p < 0.001. 
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We next evaluated the effect of B[a]P treatment on porphyrin biosynthesis in cells 
engineered to overexpress Abcb6. Abcb6 overexpression was achieved by engineering stable 
expression of Abcb6 under a constitutively active CMV promoter as described previously 
(28,185). In contrast to the porphyrin phenotype seen in response to B[a]P treatment of Abcb6-
depleted cells, in Abcb6-overexpressing cells, B[a]P treatment did not increase porphyrin 
biosynthesis beyond the levels already exhibited by increased Abcb6 overexpression in these 
cells (Figure 5.1.1, C and D). 
Based on the results presented in Figure 5.1.1, A, B, and E, which demonstrate 
significant decrease in hepatic porphyrin levels in the absence of Abcb6 in response to B[a]P 
treatment, we hypothesized that B[a]P-induced CYP1A1 activity might be altered in cells that 
have a loss of Abcb6 expression. However, despite our efforts, we were not able to detect any 
CYP1A1 activity in these cell culture systems. Thus, evaluation of this aspect requires in vivo 
studies using Abcb6 gene-deleted mouse.  
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Discussion 
A number of halogenated hydrocarbons have been experimentally demonstrated to be 
porphyrinogenic in exposed animals, and in in vitro tests. There is little question that individuals 
who are genetically predisposed to porphyria can have both neurological and cutaneous 
manifestations of porphyria triggered by exogenous chemicals. It is also clear that certain 
exogenous chemicals activate mechanisms that regulate heme synthesis. However, it is not 
apparent as to the degree that clinical manifestations of environmentally induced porphyria 
might be attributable (if at all) to the associated induction in heme synthesis, apart from potential 
direct toxic effects of inhibition of enzymes in the heme synthesis pathway. The results 
presented here provide evidence suggesting that disturbed expression or function of proteins 
that regulate heme synthesis may have a contributing role in chemical induced porphyria.  
A basic pathogenic event in PAH-induced porphyria is the accumulation of porphyrins. In 
many cases, the porphyria remains latent until clinical manifestations (phototoxicity, neural or 
visceral symptoms, elevation in urinary porphyrins) occur because of pharmacological exposure 
to chemicals and therapeutic drugs, which precipitates an acute attack because of increased 
heme synthesis (13,40,148,168). In this regard, increased Abcb6 expression in response to 
environmental contaminants and therapeutic drugs might contribute to the manifestation of 
porphyria. In this scenario, increased Abcb6 expression in response to environmental 
contaminants could enhance heme synthesis in patients compromised in the activity of enzymes 
of the heme synthetic pathway. This would result in a progressive increase in the accumulation 
of porphyrin intermediates that leads to clinical manifestation of the latent disease. Consistent 
with this observation in our studies loss of Abcb6 expression resulted in decreased 
accumulation of porphyrins in response to PAH exposure.  
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Porphyrias have historically been classified based on the specific enzyme principally 
involved and the principal origin(s) of the excess heme precursors. Among these is hereditary 
coproporphyria (HCP), which results in the accumulation of coproporphyrinogen. (224). 
However, it has to be acknowledged that loss of Abcb6 function could also be predicted to 
precipitate coproporphyria. Abcb6 has been proposed to promote heme synthesis by regulating 
the energy dependent transport of coproporphyrinogen from the cytoplasm into the mitochondria 
to complete heme synthesis (224). Ironically, in the absence of Abcb6 loss of 
coproporphyrinogen transport into the mitochondria could lead to accumulation of 
coproporphyrinogen in the cytosol precipitating coproporphyria. In this context, it is interesting to 
note that pesticides such as oxadiazon or oxyfluorfen induce hepatic porphyria whose etiology 
is not clearly understood. One could speculate that oxadiazon or oxyfluorfen induced hepatic 
porphyria could potentially involve interference with Abcb6 mediated porphyrin transport.  
It has recently been proposed that a variety of chemical-associated illnesses for which 
there are no widely accepted specific diagnostic tests or etiologic explanations – such as 
multiple chemical syndrome, Persian gulf war illnesses, conditions associated with silicone 
breast implants, and various fatigue syndromes – may represent either mild chronic cases of 
porphyria, and in part could be manifestations of acquired abnormalities in heme synthesis. 
Thus in cases involving these otherwise unexplained illnesses; it would be interesting to test 
whether Abcb6 expression and/or function is compromised. As we gain additional knowledge, 
therapeutic manipulation of Abcb6 could provide an alternative way of treating these porphyric 
phenotypes of unknown etiology.  
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5.2. ROLE OF ABCB6 IN ARSENIC CYTOTOXICITY  
Abstract 
Arsenic is an inorganic carcinogen and a major hazard after environmental or 
occupational exposure. Current treatments for arsenic toxicity are limited. Consideration of 
endogenous protective pathways activated by cells in response to arsenic will potentially reveal 
novel pharmacological targets. In the present study, we evaluated the significance of Abcb6 
expression to arsenic toxicity in cell culture. We demonstrate that, in HepG2 and Hep3B cells, 
knockdown of Abcb6 expression using Abcb6-specific small interfering RNA sensitized the cells 
to arsenite toxicity. In contrast, stable overexpression of Abcb6 conferred a strong survival 
advantage toward arsenite-induced oxidative stress. Collectively, these results, obtained by 
both loss of function and gain of function analysis, suggest that Abcb6 expression might be an 
endogenous protective mechanism activated to protect cells against arsenite-induced oxidative 
stress. 
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Introduction 
Arsenic is a ubiquitous environmental pollutant. Chronic exposure of humans to 
inorganic arsenic results in formation of tumors of the liver and kidney and probably skin, lung, 
and urinary bladder. In addition to its carcinogenic effect, epidemiological studies have 
associated chronic arsenic exposure with an increased risk in many human nonmalignant 
diseases, such as peripheral vascular disease, diabetes, and chronic lung disease. Evidence 
suggests that arsenic exerts its chronic toxicity by interacting with sulfhydryl groups and 
generating reactive oxygen species (ROS) that cause damage to cellular macromolecules via 
oxidative stress. Of importance, exposure to pro-oxidants such as arsenic also results in the 
induction of a gene expression program whose primary function is to protect cells from oxidative 
stress. Understanding this protective program of adaptation and acquired tolerance to arsenic 
could potentially open up new therapeutic avenues for prevention and intervention strategies 
against the toxic effects of arsenic. 
We recently characterized Abcb6 and found that this transporter localizes to the 
mitochondria and regulates de novo porphyrin biosynthesis (28). Abcb6 overexpression 
increases the concentration and activity of hemoproteins, including the heme-dependent 
antioxidant defense enzyme catalase. Abcb6’s ability to increase catalase activity protects cells 
against hydrogen peroxide (H2O2)–mediated oxidative stress (225). Thus, Abcb6 expression 
protects against oxidative stress. However, based on the studies reported by Paterson et al. and 
Gebel et al., it is not clear whether Abcb6 can protect against arsenic-mediated oxidative stress 
(204,205). 
Thus, the present study was conducted to determine whether arsenic could protect cells 
against arsenic-induced oxidative stress.  We demonstrate that loss of Abcb6 expression 
sensitizes cells to the toxic effects of arsenite. Finally, we provide convincing evidence that 
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Abcb6’s ability to reduce arsenite-induced oxidative stress is a contributing mechanism by which 
Abcb6 protects against arsenite toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
  
140 
 
Results 
5.2.1. Effect of sodium arsenite on cell survival in the presence and absence of 
Abcb6 
The functional importance of Abcb6 to arsenite toxicity was evaluated by blocking 
endogenous Abcb6 expression in two human cell lines (hepatoma cells Hep3B and HepG2) 
(Figure 5.2.1). Reduced Abcb6 expression was achieved in these cells using Abcb6-specific 
siRNA, which resulted in greater than 70% reduction of endogenous Abcb6 (Figure 5.2.1, A and 
B, bottom panel) compared with scrambled siRNA. Arsenic toxicity was evaluated in these cells 
by measuring cell viability. Reduced Abcb6 expression in Abcb6-specific siRNA-treated cells 
sensitized both HepG2 and Hep3B cells to arsenite toxicity compared with vector control cells or 
cells transfected with the scrambled siRNA (inhibitor concentration IC50 of 19.6 and 18.7μM in 
the presence of Abcb6-specific siRNA vs. 27.3 and 27.4μM in the absence of siRNA in Hep3B 
and HepG2 cells, respectively (Figure 5.2.1 A and B). 
Based on the results presented in Figures 5.2.1A and B, it is conceivable that Abcb6 
overexpression is cytoprotective against arsenite toxicity. To test this hypothesis, we developed 
Abcb6-overexpressing cell lines using HepG2 and Hep3B cells as described (28). Abcb6 
expression in these cells was confirmed by immunoblot analysis using Abcb6-specific antibody 
(Figure 5.2.1C and D, bottom panels). Abcb6’s ability to protect against arsenite toxicity was 
evaluated by measuring cell viability. We found that both HepG2 and Hep3B cells that 
overexpress Abcb6 demonstrate better survival in the presence of sodium arsenite compared 
with vector control cells (IC50 of 211μM vs. 15.8μM for Abcb6-expressing and empty vector 
Hep3B cells, respectively, and 236μM vs. 12.9μM for Abcb6-expressing vs. empty vector 
HepG2 cells, respectively; Figures 5.2.1C and D). More importantly, knockdown of Abcb6 
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expression using Abcb6-specific siRNA resulted in sensitization of Abcb6-overexpressing 
HepG2 and Hep3B cells to arsenite toxicity (Figure 5.2.1C and D). 
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Figure 5.2.1. 
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Figure 5.2.1. (continued) 
Effect of sodium arsenite on cell survival in Abcb6-expressing and Abcb6 knockdown 
cells.  
Survival of (A) Hep3B and (B) HepG2 cells treated with increasing concentrations of sodium 
arsenite for 48 h. Immunoblot analysis of Abcb6 expression in Hep3B and HepG2 mitochondria 
in cells transfected with Abcb6-specific and scrambled (nonspecific) siRNA is presented in the 
bottom panel (A and B). Survival of (C) Abcb6-overexpressing Hep3B and (D) Abcb6-
overexpressing HepG2 cells treated with increasing concentrations of sodium arsenite for 48 h. 
Immunoblot analysis of Abcb6 expression in Abcb6-expressing and siRNA knockdown cells is 
presented in the bottom panel (C and D). Porin expression is used as loading control in these 
experiments. Values represent the mean ± SD; n = 5. Results representative of three 
independent experiments; “*” Significantly different from siRNA knockdown cells and vector 
control cells at the respective time points. p < 0.01. 
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5.2.2. Effect of sodium arsenite on oxidative stress in cells expressing Abcb6 
It has been reported that arsenic toxicity is in part attributed to increased oxidative stress 
(191-195). To test the hypothesis that Abcb6 protects against arsenite-induced oxidative stress, 
we measured ROS in Abcb6-overexpressing HepG2 and Hep3B cells in response to sodium 
arsenite. We first evaluated the basal level of ROS in Abcb6-overexpressing and vector control 
cells. We found reduced basal ROS in Abcb6-overexpressing cells compared with vector control 
cells (Figure 5.2.2A and C). We next evaluated sodium arsenite–induced oxidative stress in the 
vector control and Abcb6-overexpressing cells. Sodium arsenite induced oxidative stress in both 
vector control and Abcb6-overexpressing cells. However, the magnitude of oxidative stress in 
Abcb6-overexpressing cells was significantly lower than that observed in vector control cells. 
(Figure 5.2.2B and D). These results suggest that Abcb6 expression reduces arsenite-induced 
oxidative stress. 
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Figure 5.2.2. 
 
Sodium arsenite–induced oxidative stress in Abcb6-overexpressing and vector control 
cells.  
Fluorescence-activated cell-sorting analysis of DCF fluorescence as a measure of oxidative 
stress in (A) Abcb6-overexpressing HepG2 and (C) Abcb6-overexpressing Hep3B cells in the 
absence of sodium arsenite treatment. Arsenite-induced oxidative stress in (B) Abcb6-
overexpressing HepG2 and (D) Abcb6-overexpressing Hep3B cells. Results are representative 
of three independent experiments. 
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We have previously demonstrated that the expression and activity of catalase is 
increased in cells that overexpress Abcb6. Furthermore, this increased catalase activity in 
Abcb6-expressing cells protects these cells against H2O2-mediated oxidative stress (156). 
Because arsenic toxicity is in part attributed to increased oxidative stress mediated by 
H2O2 (199,226,227), we tested the relative contribution of increased catalase activity in Abcb6-
overexpressing cells in protecting against arsenite toxicity. In the studies reported here, we first 
evaluated the ability of 3-Aminotriazole (3-AT) to inhibit catalase activity in Abcb6-expressing 
and nonexpressing cells. 3-AT at a concentration of 20 mmol/l was capable of inhibiting > 80% 
of Abcb6-induced catalase activity (Figure 5.2.3A). We next evaluated the contribution of 
catalase to Abcb6-mediated protection against sodium arsenite. Following pretreatment with the 
catalase inhibitor (3-AT), Abcb6-overexpressing and nonexpressing cells were exposed to 
sodium arsenite for 48 h. Pretreatment with the catalase inhibitor was essential to eliminate 
most of the steady-state catalase protein that is induced in Abcb6-overexpressing cells (156). 
Survival was evaluated at the end of 48 h by measuring cell viability. We found that, in vector 
control cells, blocking catalase activity increased arsenite-mediated cell death (63 and 45% at 
48 and 72 h, respectively, in the absence of 3-AT compared with 45 and 20% in the presence of 
3-AT; Figure 5.2.3B), which was statistically significant (p < 0.05). In contrast, in Abcb6-
expressing cells, blocking catalase activity increased significant (p < 0.05) arsenite-mediated 
cell death only after 72 h of treatment. Abcb6-overexpressing HepG2 cells showed 85 and 76% 
survival (48 and 72 h, respectively) in response to sodium arsenite in the absence of 3-AT 
compared with 76 and 60% survival in cells that were pretreated with 3-AT (Figure 5.2.3B). 
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Figure 5.2.3. 
 
Effect of sodium arsenite on cell survival in Abcb6-expressing cells in the presence and 
absence of the catalase inhibitor 3-AT.  
(A) Effect of 3-AT (20 mmol/l) on Abcb6-induced catalase activation in human hepatoma cells 
HepG2 in the absence of sodium arsenite treatment. (B) Effect of 3-AT on cell death in Abcb6-
expressing HepG2 cells treated with sodium arsenite (25μM) for 48 h. Values represent the 
mean ± SD; n = 5. Results are representative of three independent experiments. “*” Significantly 
different from their respective untreated groups. p < 0.05. 
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Discussion 
In our studies, Abcb6 expression protected cells against acute arsenic toxicity. These 
results are in agreement with the studies reported by (204) but are in contrast to the studies 
reported by (205). Paterson et al. suggest a direct correlation between Abcb6 expression and 
arsenic resistance, whereas Gebel et al. demonstrate no increase in Abcb6 expression in 
HepG2 cells that were selected for arsenic resistance (204,205). One clear distinction between 
the studies reported in the manuscript and the studies reported by Gebel et al. (205) is that 
Gebel et al. evaluated Abcb6 expression in arsenic-resistant and arsenic-susceptible cells, 
whereas studies presented in the manuscript use Abcb6 knockdown cells that could make these 
cells acutely susceptible to arsenic toxicity. Thus, taken together, the results from these studies 
suggest the possibility that Abcb6 expression is induced in response to short-term low-dose 
exposure to arsenic and that this increased expression could protect against short-term acute 
arsenic toxicity. In contrast, long-term exposure to acute arsenic toxicity might not induce Abcb6 
expression. In this context, additional studies are required to evaluate if Abcb6 expression is 
induced in response to long-term acute arsenic toxicity and if Abcb6 expression can provide 
prolonged protection against acute arsenic toxicity. 
Although our studies demonstrate protection against arsenic toxicity in in vitro cell 
culture, they do not provide any relevant information regarding Abcb6 expression to chronic 
arsenic–induced diseases in humans. The high dose of arsenic used in our study causes acute 
toxicity, whereas moderate doses of repetitive exposure are associated with human diseases 
such as cancer, diabetes, and cardiovascular diseases. Thus, the role of Abcb6 in arsenic-
induced diseases of humans requires confirmation in vivo. 
Arsenic is known to cause cellular injury by several mechanisms including the 
generation of ROS (191-194), and the metabolism of arsenic has an important role in this 
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process (228,229). Although high concentrations of inorganic arsenic can stimulate ROS 
production, most of the absorbed inorganic arsenic is biomethylated to its methylated species, 
which appear to stimulate ROS production more efficiently than inorganic arsenic 
(193,230,231). Thus, one adaptive mechanism that protects against arsenic toxicity is increase 
in the expression of stress-response genes that reduce cellular oxidative stress (197-199). 
Because we have previously demonstrated Abcb6-mediated protection against oxidative stress, 
we first evaluated whether Abcb6’s ability to protect against arsenic toxicity was associated with 
its ability to reduce oxidative stress. We found reduced arsenite-induced oxidative stress in 
Abcb6-expressing cells. Thus, one potential mechanism by which Abcb6 protects against 
arsenite toxicity is by reducing oxidative stress. 
Results from both in vivo and in vitro studies show that both superoxide and H2O2 are 
produced in humans and animals exposed to arsenite (198,227,232). The production of 
H2O2 appears to be involved in the induction of apoptosis by arsenite in cell culture 
(196,199,226). It is important to note that preincubation with catalase ameliorated arsenite-
induced ROS in human bladder cell culture (232), whereas treatment with 3-AT, an inhibitor of 
catalase, increased arsenite-induced micronuclei (226). We have previously demonstrated that 
Abcb6 expression protects cells against the toxic effects of H2O2, which is mediated by Abcb6’s 
ability to potentiate the expression and activity of catalase (156). In the studies described in the 
manuscript, we tested whether Abcb6 protection against sodium arsenite is mediated by its 
ability to potentiate catalase activity. Treatment of cells with the catalase inhibitor 3-AT blocked 
Abcb6-mediated activation of catalase but had only a modest effect on the survival of cells 
exposed to sodium arsenite. Thus, although H2O2 is reported to be involved in arsenite toxicity, 
this does not appear to be the sole mechanism by which Abcb6 protects against arsenite 
toxicity. 
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Increased Abcb6 expression occurs in drug-resistant cell lines (203,233,234). Elevated 
Abcb6 mRNA levels were reported in adriamycin, camptothecin, paclitaxel, and 5-fluorouracil–
resistant tumor cell lines (235). Based on these observations, it was speculated that Abcb6 
could be a multidrug resistance gene and that the multidrug resistance phenotype could be 
attributed to Abcb6’s ability to function as a transporter to reduce intracellular concentrations of 
the respective drug compounds. It is quite possible that a similar transport mechanism mediated 
by Abcb6 for inorganic arsenic or its metabolite could reduce cellular arsenic concentrations. 
Supporting this hypothesis in cells that are engineered to overexpress Abcb6, the transporter 
was shown to localize to the plasma membrane (204). However, in our studies reported here, 
we were not able to detect endogenous Abcb6 expression at the plasma membrane. It is quite 
possible that either the concentration of arsenite used in these studies was not sufficient or the 
analytical techniques used were not sensitive enough to detect endogenous Abcb6 expression 
at the plasma membrane. Thus, additional studies are required to evaluate endogenous 
expression of Abcb6 at the plasma membrane and its potential contribution to arsenic toxicity. 
Alternatively, because most of the chemotherapeutic drugs used in the studies described by 
Annereau et al., Szakacs et al., and Yasui et al. cause cellular stress (203,204,234) and based 
on the results presented in the manuscript, one could hypothesize that the mode of protection 
against drug-induced toxicity may be associated with Abcb6’s ability to protect against oxidative 
stress. 
In summary, the present studies demonstrate that sodium arsenite induces Abcb6 
expression both in vitro and in vivo. Moreover, this induction of Abcb6 is likely responsible for 
protection against arsenite toxicity in vitro. Future studies will focus on both the mechanisms by 
which arsenic causes induction of Abcb6 and the in vivo significance of Abcb6 expression to 
protection against oxidative stressors. 
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Chapter 6. SIGNIFICANCE OF ABCB6 TO XENOBIOTIC INDUCED 
PORPHYRIA AND OXIDATIVE STRESS – IN VIVO 
 
6.1. Generation and initial characterization of Abcb6 knockout 
mouse 
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6.1. GENERATION AND INITIAL CHARACTERIZATION OF ABCB6 
KNOCKOUT MICE 
 
Abstract 
 
Abcb6 is a mammalian mitochondrial ATP-binding cassette (ABC) transporter that is 
suggested to regulate de novo porphyrin synthesis. However, the role of Abcb6 in vivo remains 
undefined. To explore this role, we generated Abcb6 deficient mice. Unexpectedly, these mice 
showed altered metabolism of the classic P450 substrate pentobarbital. Further studies 
demonstrated that Abcb6 deficient mice have decreased expression and activity of specific 
P450 enzymes including Cyp2b10 and Cyp3a11, the two predominant detoxification enzymes in 
the liver. In addition, hepatic gene expression analysis revealed that loss of Abcb6 expression 
also results in altered expression of genes involved in cell death and survival, lipid metabolism 
and embryonic development. These results suggest that Abcb6, which was initially thought to 
play a role in heme synthesis, might have additional biological functions. Development of the 
Abcb6 deficient mice should provide an opportunity to explore the role of Abcb6 in normal and 
patho-physiology.  
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Introduction 
ATP binding cassette transporters belong to a family of integral membrane proteins that 
play a major role in many cellular processes and mediate the active transport of a vast variety of 
solutes across cellular membranes. Although many cellular ABC proteins have been 
characterized, mitochondrial ABC proteins are only beginning to emerge as important regulators 
of this organelle’s function. To date, four members of the ABC transport proteins have been 
identified in the mitochondria, however, only a fraction of them have a known function. ABCB7 
and ABCB8 are thought to play a role in the maturation of iron-sulfur clusters and iron 
homeostasis, while ABCB10 is thought to play a role in heme synthesis (94,236,237). 
Dysfunction of ABCB7 is involved in cellular iron homeostasis and causes a rare type of X-
linked sideroblastic anemia (114). Disruption of ABCB8 in mice leads to cardiomyopathy (236), 
while loss of ABCB10 expression results in oxidative stress and cell death (94).  Abcb6 is a half-
molecule ABC protein that localizes to the outer mitochondrial membrane, and contains single 
transmembrane- and nucleotide binding-domains. Abcb6 has been suggested to play a role in 
heme and porphyrin transport and protection against oxidant induced cell death in vitro 
(132,156); however, its primary function in vivo is not known.  
To characterize the function of Abcb6 in vivo, we generated a mouse model of whole 
body Abcb6 deficiency, and studied the effects of this deficiency on hepatic heme homeostasis, 
and hepatic global gene expression changes. We demonstrate that deletion of Abcb6 in mice 
results in mild hepatic heme deficiency confirming its role in regulating heme homeostasis. More 
importantly, we demonstrate that Abcb6 is required for maintenance of normal function of a 
specific set of P450s, influences cholesterol and lipid homeostasis, and plays a role in growth 
and proliferation.  
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Results 
6.1.1. Abcb6 knockout and heme content 
The murine Abcb6 knockout mice were generated on a C57BL/6N background. To 
disrupt the Abcb6 gene the region extending from exons 3 to 5 of Abcb6 was replaced with a 
neomycin-containing cassette by homologous recombination (Figure 6.1.1A). Gene disruption 
was confirmed by genotyping (Figure 6.1.1B), Real Time PCR analysis of RNA transcript 
(Figure 6.1.1C) and immunoblotting (Figure 6.1.1D). The amount of immunodetectable Abcb6 
was proportional to the amount of the Abcb6 transcript (Figure 6.1.1C and D). Aside from the 
Abcb6 monomer band of approximately 90 kDa, we observed 2 additional immunoreactive 
bands at ~ 80 and ~60 kDa (Figure 6.1.1D). The amount of all three immunodetectable proteins 
was proportional to the amounts of the Abcb6 transcript (Figure 6.1.1C and D). No 
immunoreactive protein band was detected in the Abcb6-/- mice (Figure 6.1.1D), suggesting that 
all three protein bands contain Abcb6.  
The Abcb6-/- mice were fertile, and litter sizes were normal. However, the Abcb6 null 
allele showed a non-mendelian inheritance with 10 % fewer mice of the Abcb6-/- genotype than 
expected. We also observed random events of relatively small Abcb6-/- mice among the 
littermates but this physical phenotype was inconsistent. Abcb6 has been proposed to play a 
role in heme synthesis. Thus, the significance of Abcb6 expression to hepatic heme synthesis 
was evaluated in Abcb6-/- mice. As shown in Figure 6.1.1E heme levels decreased in Abcb6+/+, 
Abcb6+/- and Abcb6-/- mice in a manner that was consistent with a gene dose effect but the 
values were not statistically significantly. 
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Figure 6.1.1. 
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Figure 6.1.1. (continued) 
Generation of Abcb6−/− mice and heme measurement.  
Construct used to generate Abcb6−/− mice (A). qPCR analysis of genomic DNA from Abcb6+/+, 
Abcb6+/− and Abcb6−/− mice (B). The wild-type allele amplifies a 0.47 kb fragment and the null 
allele a 0.62 kb fragment. Real-time PCR analysis of Abcb6 from liver tissue of 8 week old 
Abcb6+/+, Abcb6+/− and Abcb6−/− mice (C). Western blot analysis (D, upper panel) of Abcb6 in 
total cell lysate from liver tissue of 8 week old Abcb6+/+, Abcb6+/− and Abcb6−/− mice and non-
Mendelian inheritance (D, lower panel) of Abcb6 gene in mice.  E, Heme content measured 
using total liver cell lysate from Abcb6+/+, Abcb6+/− and Abcb6−/− mice and normalized to protein. 
Values represent mean ± S.D. (error bars); n = 3 mice per experiment. Results shown are 
representative of three independent experiments. *, significantly different from Abcb6+/+  (p < 
0.01). #, significantly different from Abcb6+/- (p < 0.01). 
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6.1.2. Global gene expression changes in Abcb6−/− mice 
To determine the effect of Abcb6 expression in vivo we compared transcript expression 
in the liver of Abcb6−/− and Abcb6+/+ by using an Affymetrix microarray. We focused on 496 
genes that were up- or down- regulated by a fold change of 1.5 with p value ≤ 0.05 in Abcb6−/− 
mice liver (317 down regulated and 179 upregulated genes). Functional networks and pathways 
analyses were generated through the use of Ingenuity Pathways Analysis (IPA) (Ingenuity 
Systems®, www.ingenuity.com).  
IPA analysis gave insights into the molecular processes and pathways altered in Abcb6 
knockout mice. The highest altered pathway according to IPA is organismal survival with 
increased prediction of organismal, perinatal and neonatal death based on 92-gene set altered 
in Abcb6-/- mice (Table 6.1). The increased organismal death could in part explain the reduced 
inheritance of the Abcb6-null allele (Figure 6.1.1D, lower panel). Additional important biological 
pathways that were altered in our gene set were related to lipid metabolism, steroid 
homeostasis, embryonic development and carbohydrate metabolism (Figure 6.1.2A and Table 
6.1). Consistent with the lipid metabolism pathway prediction we observed increased serum 
cholesterol levels in Abcb6 null mice fasted for 16 hr (Figure 6.1.3C).  
Further analysis of the data for alteration in canonical pathways (Figure 6.1.2B) showed 
subtle differences in  UDP-N-acetyl-D-galactosamine Biosynthesis I/II, PXR/RXR Activation, 
Prolactin Signaling, Endoplasmic Reticulum Stress Pathway, Retinol Biosynthesis, Thyroid 
Cancer Signaling, RAR Activation, IL-9 Signaling, Colanic Acid Building Blocks Biosynthesis, N-
acetylglucosamine Degradation I, Type II Diabetes Mellitus Signaling and Glutathione 
Biosynthesis.  
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Table 6.1. List of activated and inhibited functions by functional annotation analysis  
Category Functions Annotation p-Value 
Activation 
z-score 
# 
genes
Activated Functions 
Organismal Survival 
organismal death 1.57E-02 3.924 92 
perinatal death 9.99E-04 3.831 35 
neonatal death 5.23E-03 3.113 25 
Small Molecule Biochemistry 
concentration of 
cholesterol 
1.45E-02 2.774 13 
Molecular Transport 1.45E-02 2.774 13 
Lipid Metabolism 1.45E-02 2.774 13 
Small Molecule Biochemistry 
quantity of steroid 
1.49E-02 2.221 20 
Molecular Transport 1.49E-02 2.221 20 
Lipid Metabolism 1.49E-02 2.221 20 
Cell Death and Survival 
cell death of 
Neuroblastoma cell lines 
8.97E-03 2.219 5 
Metabolic Disease 
adiposity 
1.54E-02 2.213 8 
Connective Tissue Disorders 1.54E-02 2.213 8 
Small Molecule Biochemistry 
concentration of 
phospholipid 
4.80E-02 2.213 7 
Molecular Transport 4.80E-02 2.213 7 
Lipid Metabolism 4.80E-02 2.213 7 
Small Molecule Biochemistry 
concentration of lipid 
7.47E-03 2.110 32 
Molecular Transport 7.47E-03 2.110 32 
Lipid Metabolism 7.47E-03 2.110 32 
Cell Death and Survival 
cell death of neuroblasts 
1.67E-05 2.000 4 
Embryonic Development 1.67E-05 2.000 4 
Inhibited Functions 
Carbohydrate Metabolism 
synthesis of carbohydrate 6.58E-04 -2.180 13 
synthesis of D-glucose 7.23E-04 -2.200 6 
Small Molecule Biochemistry synthesis of D-glucose 7.23E-04 -2.200 6 
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Figure 6.1.2. 
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Figure 6.1.2. (Continued) 
 
C
 
 
Biofunction, Canonical pathway and Upstream regulators analysis by IPA software based 
on the Abcb6 null mice dataset.  
Comparative Biofunction analysis (A), Comparative canonical pathway analysis (B), Upstream 
regulators analysis (C) of Abcb6+/+ and Abcb6-/- group. Figure shows the top (most significant) 
bio-functional or canonical groups. Threshold is set at p= 0.05. Significance is expressed as a p-
value (≤ 0.05), which was calculated using the right-tailed Fisher's exact test. In canonical 
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pathways a ratio of the number of differentially expressed genes from our dataset that map to 
the pathway divided by the total number of molecules that exist in the canonical pathway was 
used for determining which pathways overlap the most. In upstream regulator analysis each ode 
represents a gene; red color denotes over-expressed genes and green color denotes down-
regulated genes. The color intensity appears according to the related expression level by fold 
change. Solid connections indicate direct regulatory interactions. Arrows are colored differently 
to ease the identification of each connection.  
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Figure 6.1.3. 
 
 
 
Increased serum cholesterol in Abcb6 knockout mice.  
Loss of Abcb6 expression results in increased serum cholesterol in mice fasted for 16 hr. (A & 
B) Triglyceride content in serum (A) and liver (B) of Abcb6-/- mice. (C & D) Cholesterol 
measurement in serum (C) and liver (D) of Abcb6-/- mice. Values represent mean ± S.D. (error 
bars); n = 3 per experiment. *, significantly different from WT control mice (p < 0.01). 
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6.1.3. Altered expression of specific P450 enzymes in the liver of Abcb6-/- mice 
One of the most interesting results from the affymetrix microarray analysis was the 
observation that loss of Abcb6 expression precipitates altered expression of specific P450 
enzymes in the liver. The panel of P450 enzymes altered in expression included Cyp2b10 and 
Cyp2c54 both of which have been proposed to participate in arachidonic acid and xenobiotic 
metabolism, Cyp2r1 the vitamin D 25-hydroxylase, and Cyp1a1 involved in phase I xenobiotic 
and drug metabolism. This observation was confirmed and extended further by targeted RT-
PCR analysis of a panel of 45 mouse P450s using gene specific primers. The RT-PCR analysis 
confirmed results from the affymetrix study, in addition to identifying alteration in the expression 
of additional P450s including Cyp3a11 that was not recognized by the microarray.  
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6.1.4. Abcb6-/- mice show decreased metabolism of the classic P450 substrate 
pentobarbital 
Mammalian hepatic P450s involved in the metabolism of therapeutic agents include 
members of the CYP1A, CYP2A, CYP2B, CYP2C, CYP2D, CYP2E and CYP3A subfamilies. 
Among these, quantitatively CYP3A and CYP2B forms account for nearly 30% and 19% of liver 
microsomal total CYP content respectively, with CYP3A forms involved in the metabolism of 
over 50% of available drugs (238). Thus, initial experiments were carried out to determine the 
effect of Abcb6 deficiency and the ensuing decrease in the Cyp3a and Cyp2b transcript to 
enzyme activity. For this purpose in vitro metabolism assays were performed using liver 
microsomes isolated from Abcb6+/+ and Abcb6-/- mice. Oxidation of midazolam to ketoconazole 
by Cyp3a11 and chloroxazone to pyridine by Cyp2e1 was used as specific markers for Cyp3a 
and Cyp2e1 activity respectively. Cyp2e1 activity was used as a negative control in these 
studies as Cyp2e1 expression was not altered in Abcb6-/- mice. Interestingly and consistent with 
the gene expression data we found that loss of Abcb6 expression compromised Cyp3a protein 
expression and basal Cyp3a activity but did not affect Cyp2e1 protein expression or activity 
(Figure 6.1.4, A and B and Figure 6.1.5, A and B ).  
Decreased Cyp3a activity in Abcb6-/- mice would be expected to alter the metabolism 
and hepatic clearance of Cyp3a substrates. Metabolism and hepatic clearance of classic 
xenobiotics pentobarbital have traditionally been used as an in vivo measure of altered 
pharmacokinetics/pharmacodynamics of Cyp3a substrate. Pentobarbital, an anesthetic, is 
inactivated by Cyp3a enzyme activity; therefore, the length of sedation following treatment with 
pentobarbital is indicative of Cyp3a activity.  As shown in Figure 6.1.4D most wild type animals 
treated with pentobarbital woke up from sleep in approximately 40 minutes. In contrast 
essentially all the Abcb6-deficient mice required ~52 minutes to wake up. Thus, the knockout 
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animals have dramatically decreased basal Cyp3a activity, in agreement with the gene 
expression and in vitro activity results, and indicate that loss of Abcb6 function significantly 
increases pentobarbital sensitivity. Taken together these results suggest that the activity of a 
subset of hepatic P450s is altered in the absence of Abcb6.  
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Figure 6.1.4. 
 
Loss of Abcb6 expression compromises hepatic P450 activity.  
Loss of Abcb6 expression results in decreased hepatic Cyp3a activity. (A & B), Oxidation of 
Midazolam (A) and Chloroxazone (B) is used to quantitate enzymatic activity of Cyp3a11 and 
Cyp2e1 levels in livers of Abcb6+/+, Abcb6+/− and Abcb6−/− mice. Enzymatic activity was 
normalized to protein content. (C & D), The length of time between pentobarbital administration 
and the loss (Sleep Latency, C) and subsequent recovery of righting reflex (Sleeping time, D) 
were recorded as marker for pentobarbital clearance in Abcb6+/+ and Abcb6−/− mice. Values 
represent mean ± S.D. (error bars); n = 3 mice per experiment. Results shown are 
representative of two independent experiments. *, significantly different from Abcb6+/+ control (p 
< 0.01). #, significantly different from Abcb6+/- (p < 0.01). 
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Figure 6.1.5. 
 
 
 
Loss of Abcb6 expression compromises hepatic P450 expression.  
Loss of Abcb6 expression results in decreased hepatic P450s expression (A) Real-time PCR 
analysis of Cyp3a11 and Cyp2e1 mRNA levels in livers of Abcb6+/+, Abcb6+/− and Abcb6−/− mice. 
P450s expression was measured using gene-specific primers and normalized to expression of 
Actin. (B) Immunoblot analysis (upper panel) of Cyp3a and Cyp2e expression in Abcb6+/+ and 
Abcb6−/− mice. ImageJ densitometry analysis (lower panel) of immunoblots panels from 2B. (C) 
Immunoblot analysis (upper panel) of Cyp2b10 and Cyp1a expression in Abcb6+/+ and Abcb6−/− 
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mice. ImageJ densitometry analysis (lower panel) of immunoblots panels from 2C. Gapdh and 
P450 oxidoreductase (POR) are used as loading control for the Immunoblot analysis. Gapdh 
used for the normalization of densitometric analysis. Values represent mean ± S.D. (error bars); 
n = 3 mice per experiment. Results shown are representative of three independent experiments. 
*, significantly different from Abcb6+/+ control (p < 0.01). #, significantly different from Abcb6+/− (p 
< 0.01). 
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6.1.5. Loss of Abcb6 expression alters human P450 expression in hepatomas 
Mechanisms that regulate human and mouse P450s are not always comparable. To test 
whether loss of Abcb6 expression has a similar phenotype on P450 expression in humans we 
measured P450 expression in human hepatoma cells where endogenous Abcb6 expression 
was knocked down using Abcb6 specific shRNA. Generation and characterization of Abcb6 
knockdown hepatoma cells has been described previously. Consistent with P450 expression in 
Abcb6 knockout mouse, in Abcb6 knockdown Hep3B and Huh7 cells loss of Abcb6 resulted in 
decreased expression of a specific subset of P450s including CYP 2B, 3A4 and 1A2 gene 
transcripts (Figure 6.1.6A and B). Overall, these results suggest that Abcb6 mediated regulation 
of P450 is similar in mice and humans.  
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Figure 6.1.6. 
 
Loss of Abcb6 expression compromises hepatic P450 expression in hepatoma cells.  
Loss of Abcb6 expression results in decreased P450s expression. (A & B) Real-time PCR 
analysis of CYP1A2, CYP2B, CYP3A4 and CYP2E1 mRNA levels in hepatoma cells Hep3B (A) 
and Huh7 (B). P450s expression was measured using gene-specific primers and normalized to 
Gapdh expression. Values represent mean ± S.D. (error bars); n = 3 per experiment. Results 
shown are representative of three independent experiments. *, significantly different from 
Scrambled shRNA control (p < 0.01). 
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6.1.6. Abcb6 overexpression results in increased expression of a subset of P450 
genes  
Results from mouse and cell culture studies clearly demonstrate that loss of Abcb6 
expression results in decreased expression of a specific subset of P450 genes. Based on these 
observations it is rationale to hypothesize that Abcb6 overexpression could lead to an increase 
in P450 expression and activity. To test this further, we measured P450 expression in cells 
engineered to overexpress Abcb6. Consistent with our hypothesis we found increased 
expression of a specific subset of P450s in Abcb6 overexpressing hepatomas including 
CYP1A2, CYP2B and CYP3A4 transcripts (Figure 6.1.7A). CYP2E1 expression, which we found 
to be unchanged in Abcb6 knockdown cells and knockout mouse models, was used as a control 
in these studies as well. Again consistent with previous observations Abcb6 overexpression did 
not affect CYP2E1 expression. Although we were able to demonstrate induced expression of 
P450s in Abcb6 overexpressing cells, we were unable to extend these studies to changes in 
P450 activity, because despite our extensive efforts the P450 activity assays used in these 
studies were not sensitive enough to detect P450 activity in these cell culture systems. 
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6.1.7. Heme independent P450 increase in Abcb6 overexpressing hepatoma 
Heme is not only an important prosthetic group that modulates the structure and activity 
of hemoproteins such as P450s but also a regulatory molecule that controls the biosynthesis of 
various proteins. Evidence suggests that increased cellular heme levels are associated with 
increased expression of three CYPS; Cyp3a, Cyp2a5 and Cyp2b10 but not other members in 
this family. In our studies, Abcb6 overexpression induced not only Cyp3a and Cyp2b10 but also 
other members in this family, suggesting that Abcb6 mediated induction of CYP450 gene 
expression is independent of cellular heme levels. However, to confirm this further, we 
evaluated the expression of Cyp3a11, Cyp2a5, and Cyp2b10 expression in Abcb6 
overexpressing cells in the absence of heme synthesis. Loss of heme synthesis in Abcb6 
overexpressing cells was achieved by blocking heme synthesis using succinylacetone, a potent 
inhibitor of ALA-dehydratase the second enzyme in heme synthesis. We found that 
succinylacetone at a concentration of 0.6 mM resulted in 50% reduction in cellular heme levels 
(Figure 6.1.7 D and E), however this reduction in heme levels did not decrease CYP3A4 
expression significantly (Figure 6.1.7C) suggesting that Abcb6 mediated induction of CYP3A4 is 
independent of cellular heme levels. 
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Figure 6.1.7. 
 
 
 
Effect of heme biosynthesis Inhibition on P450 expression in Abcb6 overexpressor 
hepatoma 
 
Inhibition of heme biosynthesis by succinyl acetone does not alter Abcb6 mediated induction of 
CYP3A4. (A & B) Real-time PCR analysis of Abcb6 (A) CYP1A2, CYP2B, CYP3A4 and 
CYP2E1 (B) levels in Hep3B cells overexpressing Abcb6. Real-time PCR analysis of CYP3A4 
and CYP2E1 mRNA levels in Hep3B cells overexpressing Abcb6 treated with 0.6 mM SA (C) for 
24 hr. Mean PPIX (D) and Heme (E) levels in Hep3B cells overexpressing Abcb6 treated with 
0.6 mM Succinyl acetone (SA) for 24 hr. Values represent mean ± S.D. (error bars); n = 3 per 
experiment. Results shown are representative of three independent experiments. *, significantly 
different from vector control (p < 0.01). 
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6.1.8. Increased accumulation of androstanols in Abcb6 deficient mice 
 Direct activation by nuclear receptors represents one of the primary mechanisms by 
which P450 expression is regulated. The classical nuclear receptors are activated by their 
cognate ligands, which include endogenous metabolites and exogenous chemicals. Given that 
Abcb6 is an ABC transporter we hypothesized that loss of Abcb6 expression could in theory 
affect the levels of endogenous metabolites that could represent potential ligands for nuclear 
receptors. To test this hypothesis we performed a global metabolomics analysis using livers 
isolated from Abcb6 wildtype and Abcb6 knockout mice. To our surprise, we found that loss of 
Abcb6 expression lead to a significant increase in several androstane metabolites (Table 6.1.2), 
shown to be the naturally occurring inverse agonists that reverse transcriptional activation by 
nuclear receptor CAR.  These results suggest that Abcb6 might regulate androstane 
homeostasis.  
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Table 6.1.2. List of androstanol and androrstenol derivatives 
  
Androstane derivative   Formula Mol. Wt.  
2α, 3α-(Difluoromethylene)-5α-androstan-17β-ol acetate C22H32F2O2 366.2370 
3α-Hydroxy-2α-methyl-5α androstan-17-one     C20H32O2 304.2402 
17-Methyl-5α-androst-2-ene-1α, 17β-diol       C20H32O2 304.2402 
17β-Hydroxy-4α-methyl-5α androstan-3-one     C20H32O2 304.2402 
3β-Methoxyandrost-5-en-16β-ol         C20H32O2 304.2402 
3α-Hydroxy-2α-methyl-5α androstan-17-one     C20H32O2 304.2402 
17-Methyl-5α-androst-2-ene-1α, 17β-diol       C20H32O2  304.2402 
17β-Hydroxy-4α-methyl-5α androstan-3-one     C20H32O2 304.2402 
3β-Methoxyandrost-5-en-16β-ol         C20H32O2 304.2402 
17β-Hydroxy-6β‐methyl‐5αandrostan-3-one propionate   C23H36O3 360.2664 
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Discussion 
In our previous studies, loss of Abcb6 expression did not alter heme levels significantly 
at basal level; however, loss of Abcb6 expression significantly compromised PAH-mediated 
induction of hepatic porphyrin synthesis. These observations are in agreement with recent 
report by Ulrich et al., demonstrating that in the absence of Abcb6, there is increase PPIX 
accumulation after phenylhydrazine treatment. These reports suggest, when stressed, loss of 
Abcb6 compromises cellular heme biosynthesis and function. In this context, it will be interesting 
to see if loss of Abcb6 expression in vivo (in the Abcb6 gene-deleted animals) compromises 
P450 activity and its effect on drug metabolism and disposition. Thus, in this study, we 
investigated the role of Abcb6 in expression and activity of P450s. 
Cyp3a family is mainly responsible for drug metabolism function and is known to be 
regulated by cellular heme pool. In our initial analysis, we found Cyp3a11 expression and 
catalytic activity decreased and correlated with decrease in Abcb6 gene expression but there is 
no statistical decrease in heme pool of Abcb6 null mice, which suggest heme independent 
regulation of Cyp3a in Abcb6 null mice. Further analysis using succinylacetone, an inhibitor of 
heme biosynthesis, in Abcb6 overexpressor hepatoma supports heme independent regulation of 
Cyp3a by Abcb6 gene. In vivo this decrease in Cyp3a activity affects clearing of pentobarbital 
and affects sleep time in Abcb6 null mice. In addition some other known heme regulated 
cytochromes such as Cyp2a5 and Cyp1a along with several others P450 gene expression, 
which are not reported to be regulated by heme, was altered in Abcb6 null mice suggesting 
heme independent regulation of P450 genes in Abcb6-/- mice. Previously, increased Abcb6 
expression has been demonstrated in several drug resistant cell lines and role of Abcb6 in drug 
resistance has been proposed but there is no direct evidence for Abcb6 mediated drug efflux.  
The observation from this study suggests that there could be altered drug metabolism through 
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altered P450 expression because of Abcb6 which is responsible for drug resistance. This 
hypothesis needs to be evaluated further.  
Nuclear hormone receptor CAR and PXR are known to regulate P450 gene expression. 
CAR and PXR are ligand activated transcription factors which upon activation regulates 
downstream genes. CAR ligands such as androstanol and androrstenol which are endogenous 
steroids are known to function as inverse agonists which block transactivation of CAR. Our 
preliminary analysis suggests that there is an increase in androstane derivatives in Abcb6 null 
mice suggesting a possible role for Abcb6 in regulating the concentration of endogenous ligands 
of CAR. Future studies analyzing the steroid composition of Abcb6 null mice should provide 
answers that could help deduce the mechanism of P450 regulation by Abcb6. 
In summary, the present study demonstrates that Abcb6 expression both in vitro and in 
vivo regulates P450 expression possibly through reduced nuclear activation of CAR. Future 
studies will focus on the mechanisms by which Abcb6 regulates P450 expression and the effect 
of decreased P450 expression on drug metabolism and toxicity. Overall, this suggests role of 
Abcb6 in the regulation of xenobiotic metabolism enzymes and drug metabolism. 
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Chapter 7: DEVELOMENT OF IN VITRO ASSAY FOR SCREENING OF 
ABCB6 SUBSTRATES 
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Abstract 
In this study we developed an in vitro system with pure and active protein. Abcb6 
overexpressed in HEK293 cells was solubilized from mitochondrial membranes and purified to 
homogeneity. Purified Abcb6 showed a high binding affinity for MgATP (Kd = 0.18 μM) and an 
ATPase activity with a Km of 0.99 mM. Reconstitution of Abcb6 into liposomes allowed 
biochemical characterization of the ATPase including (i) substrate stimulated ATPase activity (ii) 
transport kinetics of its proposed endogenous substrate coproporphyrinogen III and (iii) 
transport kinetics of substrates identified using a High-throughput screening (HTS) assay. 
Mutagenesis of the conserved lysine to alanine (K629A) in the Walker A motif abolished ATP 
hydrolysis and substrate transport. These results suggest a direct interaction between 
mitochondrial Abcb6 and its transport substrates that is critical for the activity of the transporter. 
Further, the simple immunoaffinity purification of Abcb6 to near homogeneity and efficient 
reconstitution of Abcb6 into liposomes might provide the basis for future studies on the 
structure, function of Abcb6. 
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Introduction 
The ATP-binding cassette superfamily constitutes the largest and most broadly 
expressed class of proteins found in all kingdoms of life (239). They couple the hydrolysis of 
ATP to active transport of an array of biological compounds, including drugs, bile acids, 
peptides, steroids, ions, and phospholipids across membranes (240-243). Two highly conserved 
hydrophilic cytosolic NBDs, and at least two hydrophobic membrane-spanning domains (MSDs) 
characterize the eukaryotic ABC transporters (244,245). The MSDs serve as the substrate-
binding sites and the transmembrane domains (located within the MSD) form the translocation 
pore. The two NBDs are responsible for the binding and hydrolysis of ATP, which provides 
energy for uphill movement of substrates across membranes. The TMDs and NBDs are found 
as homo- or heterodimers and can be arranged in any combination, e.g. as separate 
polypeptides, as single polypeptides or as half-size transporters with fused TMD and NBD. Each 
NBD contains the highly conserved Walker A and B motifs as well as the C-, H- and D-loops 
(246,247). The Walker A motif contains a lysine that coordinates with the gamma-phosphate of 
ATP, whereas the aspartate in Walker B interacts with Mg2+. The ABC signature or Walker C 
motif distinguishes ABC transporter proteins from other ATP-binding proteins. These domains 
are required to execute ABC transport activities. 
The ATP binding cassette transporter subfamily member B6, Abcb6, gene encodes a 
membrane protein of 842 amino acids with a TMD followed by a NBD (248). Hydrophobicity and 
sequence homology analysis suggests that the TMD contains six transmembrane helices with 
the N and C termini located in the cytoplasm. The minimal functional unit has been suggested to 
be a homodimer residing in the outer mitochondrial membrane (28,249). Abcb6 has been 
characterized as a mitochondrial transporter involved in the translocation of COPIII from the 
cytoplasm into the mitochondria (28,29). COPIII a byproduct of heme synthesis in the cytoplasm 
requires active transport into the mitochondria to complete heme synthesis (41,250). Thus 
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Abcb6 has been characterized with a physiological role in heme synthesis. However, several 
other functions and localization for Abcb6 have been suggested, e.g. Abcb6 has been localized 
to the plasma membrane and specifies the new blood group system Langereis (Lan) (128). Loss 
of Abcb6 function has been associated with developmental defects including ocular coloboma 
(117). Further, exogenous expression of Abcb6 has been correlated with increased cell growth 
and proliferation while loss of Abcb6 expression results in delayed progression through the 
mitotic phase of the cell cycle (117,185). These observations along with the fact that Abcb6 
unlike other mitochondria targeted ABC transporters lacks a classical mitochondrial targeting 
sequence has favored reports of the existence of differentially localized Abcb6 with potentially 
unique functional properties. 
Here, we describe the development of a cell free system to understand the mechanistic 
relationship between ATP binding and hydrolysis and the coupling of these events to substrate 
transport mediated by the mitochondrial transporter Abcb6. Overexpression, purification and 
functional reconstitution of Abcb6 into liposomes permitted us to study the biochemical 
properties of Abcb6 for the first time in the absence of contaminating ATPases and carriers/ 
transporters. In addition, immunoaffinity purification of Abcb6 to homogeneity, allowed 
identification of two isoforms of Abcb6. 
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Results 
7.1. Overexpression and purification of Abcb6 
To facilitate purification of Abcb6 for biochemical analysis, the protein was tagged at the 
C-terminus with the FLAG epitope and expressed from a lentiviral vector under the control of a 
strong constitutively active promoter. As shown in Figure 7.1A, immunoblot analysis of total 
cellular fraction, using antibody specific for the FLAG-epitope demonstrates induced expression 
of FLAG-tagged Abcb6 in HEK293 cells transduced with the Abcb6-FLAG lentiviral construct but 
not in vector only transduced cells. Ponceau staining of the western blot before immunoblot 
analysis demonstrates that the induced expression of Abcb6 in the overexpressing cell is not 
due to differences in loading (Figure 7.1B). To confirm that the addition of the C- terminal FLAG- 
tag to Abcb6 does not affect its function we measured heme synthesis in Abcb6-FLAG 
overexpressing cells. We have previously demonstrated that Abcb6 expression and function is 
directly related to cellular heme synthesis (28). As seen in Figure 7.1C cells overexpressing the 
FLAG tagged Abcb6 protein demonstrate increased heme synthesis relative to empty vector 
control cells, suggesting that the addition of the FLAG-tag to the C-terminus of Abcb6 does not 
alter its function. Interestingly, both the endogenous protein, and overexpressed protein resolve 
as three bands of about 180, 90 and 50 kDa, as evidenced by immunoblot analysis using 
antibodies specific for either Abcb6 or the FLAG-tag (Figure 7.1A). 
For Abcb6 purification, in initial studies, total cellular fractions were employed as starting 
material. To solubilize the protein from the membranes, the non-ionic detergent Triton was 
effective in either the presence or absence of n-Octyl-β-D-glucopyranoside. Abcb6-FLAG in the 
detergent solubilized fractions was separated from other cellular constituents by anti-FLAG 
affinity chromatography. As seen in Figure 7.1D, under the conditions of loading and washing of 
FLAG-sepharose beads, the Abcb6-FLAG protein was quantitatively bound, and upon elution 
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with a buffer containing the FLAG peptide, was highly enriched and readily detectable by 
Coomassie blue staining. Bovine serum albumin (BSA) shown on the same gel was used as a 
loading control for the estimation of protein concentration (Figure 7.1D). The entire purification 
procedure produces approximately 40 μg of purified Abcb6 from one 150-cm2 plate of confluent 
cells. Aside from the major Abcb6 monomer band of approximately 90 kDa, two additional 
staining bands, one with an apparent molecular weight approaching that of a homodimer (~180 
kDa) and one with a lower molecular weight of approximately 50 kDa were also observed in the 
elution fractions (Figure 7.1D and E). All these three bands clearly contain Abcb6 as indicated 
by its detection with both Abcb6 specific monoclonal antibody (Figure 7.1E) as well as by 
MALDI-TOF peptide mass fingerprint analysis. 
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Figure 7.1.
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Figure 7.1. (continued) 
Expression and purification of Abcb6 from total cell fraction.  
Total cell fractions were analyzed by SDS-PAGE (4-15%) followed by (A) immunoblotting and 
(B) Ponceau staining. 50 µg of protein were applied per lane. Ponceau staining was used to 
confirm uniform loading of samples. Actin and Porin are cellular and mitochondrial proteins 
serving as controls. (C) Abcb6-FLAG overexpressing cells show increased heme synthesis 
compared to vector control cells. Values represent mean ± SD. ‘*’ significantly different from 
vector control cells; p < 0.01. (D and E) Solubilization and purification of FLAG-tagged Abcb6 
via FLAG-affinity chromatography. (D) 2 and 5 µg of protein eluted from the affinity column was 
analyzed by SDS-PAGAE (4-15%) followed by Coomassie staining. Bovine Serum Albumin 
(BSA; 2 µg) used as a loading control for the estimation of protein concentration is shown on the 
same gel. Affinity purified Abcb6-FLAG protein bands (at 180, 90 and 50 kDa) were identified as 
Abcb6 by (E) immunoblotting (500 ng-purified protein) using Abcb6-specific antibody and 
peptide mass fingerprinting. Results representative of three independent experiments. 
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7.2. Purified mitochondrial Abcb6 binds ATP and displays ATPase activity 
To identify the form of Abcb6 expressed in the mitochondria, differential density gradient 
centrifugation was used to isolate relatively pure mitochondrial fractions from Abcb6-FLAG 
overexpressing cells. Proteins in the mitochondrial membrane were solubilized with Triton in the 
presence or absence of n-Octyl-β-D-glucopyranoside. Detergent solubilized fractions were 
subjected to anti-FLAG affinity chromatography to separate Abcb6-FLAG from other 
mitochondrial membrane proteins. Proteins bound to the affinity column were subsequently 
eluted by treatment with a buffer containing the FLAG peptide. As seen in Figure 7.2A , Abcb6-
FLAG protein was highly enriched in the eluted fraction and readily detectable by Coomassie 
blue staining. In contrast to Abcb6 purified from total cellular fraction, Abcb6 eluted from the 
mitochondrial preparations revealed only two bands; the Abcb6 monomer band of approximately 
90 kDa, and the potential homodimer of approximately 180 kDa (Figure 7.2A). These results are 
consistent with our previous observations demonstrating a ~90 kDa Abcb6 monomer protein 
band and a ~180 kDa potential Abcb6 homodimer band seen in mitochondria isolated from 
Abcb6 overexpressing cells (28,69). Both the 90 and 180 kDa bands contain Abcb6 as indicated 
by its detection with both Abcb6 specific monoclonal antibody (Figure 7.2B) as well as by 
MALDI-TOF peptide mass fingerprint analysis. 
Transport functions mediated by members of the ABC transporter family require ATP 
binding and hydrolysis. To examine the ATP binding property of Abcb6, the detergent-
solubilized, purified mitochondrial Abcb6 protein was incubated with 8-azido-[α-32P]ATP and 
the azido photoprobe interacting with Abcb6 was irreversibly cross-liked by irradiation with 
ultraviolet light. The Abcb6-ATP interacting complex was separated from free probe by Sodium 
dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) and were subjected to 
autoradiography for detection of 8-azido-[α-32P]ATP labeling and to Coomassie blue staining 
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for determination of protein content (Figure 7.2C). A major band of about 90 kDa consistent with 
the molecular mass of mitochondrial Abcb6 was identified by Coomassie blue staining (Figure 
7.2C: lower panel) and found to be photoaffinity labeled by 8-azido-[α-32P]ATP (Figure 7.2C: 
upper panel). Labeling of Abcb6 by 8-azido-[α-32P]ATP required magnesium and was strongly 
inhibited by the addition of EDTA (1 mM) or excess cold ATP (10 mM) (Figure 7.2C). Nucleotide 
specificity of Abcb6 appeared to be in the following order; ATP > CTP > GTP > UTP (inhibition 
from 85% to 10%; Figure 7.2C). The apparent affinity constant for 8-azido-ATP was determined 
to be 1.39 ± 0.37 μM (Figure 7.2D). Photoaffinity labeling of Abcb6 by 8-azido-[α-32P]ATP (5 
μM) was inhibited by MgATP with an IC50 value of 1.03 μM and an estimated Hill coefficient 
approaching a value of 1 (0.87) (Figure 7.2E). Based on the apparent affinity of 8-azido ATP, a 
dissociation constant for ATP of 0.18 μM was estimated. Taken together these data indicate that 
Abcb6 had retained its ability to bind ATP through the purification process and like other ABC 
transporter proteins has relatively broad nucleotide specificity. 
Purified recombinant ABC transporters have been reported to possess intrinsic ATPase 
activity. To determine the intrinsic ATPase activity of immune affinity purified Abcb6 we used a 
spectrophotometric assay to measure the amount of Pi released from ATP. The dependence of 
the rate of hydrolysis on ATP concentration shown in Figure 7.2F exhibited Michaelis-Menten 
behavior and, when expressed as a Lineweaver-Burk plot (Figure 7.2G), showed a linear 
relationship, yielding a Km for ATP of approximately 0.99 ± 0.11 mM and Vmax of 492.3 ± 17.25 
nmol/mg/min. In parallel experiments the ATPase activity of the ATPase-inactive mutant of 
Abcb6 (Abcb6-MT) was also analyzed; it was solubilized and purified identically to the wild type 
protein in similar yields (Figure 7.3) The purified mutant protein showed very little ATPase 
activity suggesting that the observed Abcb6-WT-ATPase activity is Abcb6 specific (Figure 7.2F). 
In addition, we found that the purified Abcb6 protein was able to interact with and its ATPase 
activity was stimulated by its proposed substrate COPIII. 
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Figure 7.2. 
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Figure 7.2. (continued) 
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Figure 7.2. (continued) 
Purified mitochondrial Abcb6 binds ATP and shows intrinsic ATPase activity. 
(A and B) Solubilization and FLAG affinity purification of Abcb6-FLAG from mitochondria. 2 and 
5 µg of protein eluted from the affinity column was analyzed by SDS-PAGAE (4-15%) followed 
by (A) Coomassie staining and (B) immunoblott (500 ng-purified protein) using Abcb6 specific 
and FLAG-specific antibody. (C – G) ATP binding and ATPase activity of detergent-solubilized  
FLAG-tagged Abcb6. (C-top panel) Phosphor image analysis of purified Abcb6 (2 µM) labeled 
with 8-azido-[α-32P]ATP followed by (C-bottom panel) Coomassie blue staining to verify equal 
protein loading. The effect of EDTA (1mM), ATP (10 mM) and various nucleotides (0.3 mM 
each) on Abcb6 labeling with 8-azido-[α-32P]ATP is also shown. (D) Binding assay with 
increasing concentrations of 8-azido-[α-32P]ATP. The photo cross-linking efficiencies were 
estimated from (D-top panel) phosphor imaging analysis and by (D-bottom panel) quantifying 
the spots and plotting the intensities against the concentration of 8-azido-[α-32P]ATP. The 
apparent Kd(azidoATP) value for Abcb6 (1.39 µM) was obtained from the best fit of the binding 
data to a hyperbolic curve. (E) Competition of 8-azido-[α-32P]ATP binding to Abcb6 (2 µM) by 
MgATP. (E-top panel) Photo cross-linking was performed with 5 µM of 8-azido-[α-32P]ATP with 
increasing concentrations of MgATP and (E-bottom panel) the IC50 for MgATP was derived by 
plotting labeling intensities corresponding to Abcb6 as a function of unlabeled MgATP 
concentrations. The sample without competitor was set to 100%. From the curve, an IC50 value 
of 0.82 µM for Abcb6 was estimated. a.u., arbitrary units. (F and G) ATPase activity of wild type 
and mutant Abcb6. The ATPase activity of Abcb6 (5 µM) was measured as a function of the 
ATP concentration at 37°C. Purified Abcb6 is active in ATP hydrolysis. The data were fitted to 
(F) Michaelis-Menten and (G) Lineweaver-Burk plot resulting in a Km of 0.99 mM and a Vmax of 
492.3 nmol/mg/min. The Abcb6-nonfunctional mutant (Abcb6-MT) showed only background 
ATPase activity. Results representative of three independent experiments. TL: total lysate; ML: 
mitochondrial lysate; Flag-ab: Flag specific antibody; Abcb6-ab: Abcb6 specific antibody. 
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7.3. Reconstitution of Abcb6 into lipid membranes 
To analyze Abcb6 in its membrane-embedded state, purified mitochondrial Abcb6 (both 
WT and MT forms) was reconstituted into preformed detergent-destabilized liposomes 
composed of 0.13 μmol PC; 0.25 μmol PS; 0.67 μmol PE and 0.25 μmol ES. Following 
reconstitution detergent was dialyzed from the proteoliposomes as described in methods. 
Efficiency of Abcb6 reconstitution into liposomes was analyzed by discontinuous Nycodenz 
density gradient centrifugation. As seen in Figure 7.3A reconstitution of Abcb6 into liposomes is 
evident from the co-migration of Abcb6-FLAG containing liposomes to the top of the Nycodenz 
gradient. A majority of reconstituted proteoliposomes float into the 5% fraction of the gradient. In 
contrast, a very small fraction of the purified non-reconstituted protein floats into the 40% 
fraction, which represents the bottom of the gradient (Figure 7.3A). These data suggest that 
both the Abcb6-WT-FLAG and Abcb6-MT-FLAG proteins were successfully reconstituted into 
liposomes with a reconstitution efficiency of ~80%. Integrity of liposome-reconstituted Abcb6 
was analyzed by resolving the proteoliposomes obtained from the 5% fraction of the gradient by 
SDS-PAGE. As seen in Figure 7.3B and C analysis of Abcb6 reconstituted liposomes by 
Coomassie staining (Figure 7.3B) and immunoblot using Abcb6 specific antibody (Figure 7.3C) 
demonstrate that Abcb6 was not degraded during the reconstitution process. 
The orientation of Abcb6 following insertion into liposomes was determined by the 
protease protection assay of the C-terminal FLAG-tag in the presence and absence of 
detergent. The C-terminal FLAG-tag in Abcb6 is accessible to protease-mediated degradation 
on the outside of the intact vesicles with an ‘NBD-out’ orientation but not with an ‘NBD-in’ 
orientation. In contrast, in the presence of detergent, the C-terminal FLAG-tag in Abcb6 is 
accessible to protease degradation irrespective of NBD orientation. Comparison of the protease 
assay data of intact and detergent-permeabilized vesicles revealed that about 70-80% of 
Abcb6-FLAG was inserted into liposomes in an “NBD-out” orientation (Figure 7.3D). 
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Figure 7.3. 
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Figure 7.3. (continued) 
Purified Abcb6 was efficiently reconstituted into liposomes.  
Efficiency of Abcb6 reconstitution in liposomes was analyzed by (A) Western blot analysis of a 
flotation assay of Abcb6-FLAG proteoliposomes (2 µg of each fraction) in a Nycodenz gradient, 
(B) Coomassie blue staining of equal amounts of proteoliposomes (25 µg of protein) obtained 
from the 5% fraction of the gradient and (C) Immunoblotting of equal amounts of 
proteoliposomes obtained from the 5% fraction with Abcb6 specific antibody. Flotation assay 
shows co-migration of majority of Abcb6 proteoliposomes into the 5% fraction of the gradient 
while unincorporated protein is found at the bottom of the gradient (40%). Coomassie staining 
and immunoblotting show comparable efficiency of reconstitution of both Abcb6-wildtype and 
Abcb6-mutant protein. (D) Membrane orientation of reconstituted Abcb6-FLAG (4 µg protein) 
was determined by protease protection assay utilizing the FLAG-tag at the C-terminus and 
orientation of Abcb6 was followed by a FLAG-antibody. SDS was used to permeabilize the 
proteoliposomes (almost 100% cleavage). Data in all panels are derived from three independent 
measurements. WT: Abcb6 wildtype (functional) protein; MT: Abcb6 mutant (non-functional) 
protein; Con-Lip: control liposomes; WT-Lip: Abcb6 wildtype liposomes; MT-Lip: Abcb6 mutant 
liposomes. 
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7.4. Liposome reconstituted Abcb6 interacts with its proposed substrate 
coproporphyrinogen III. 
ABC transporters associate with their transport substrates to facilitate its movement 
across the membrane. Using hemin-agarose affinity chromatography, we have previously 
demonstrated that Abcb6 associates with COPIII, a potential endogenous transport substrate of 
Abcb6 (28). To determine if liposome reconstituted Abcb6 retained its ability to associate with 
COPIII we performed hemin-agarose affinity chromatography as described (28). We found that 
COPIII was able to displace liposome reconstituted Abcb6 from hemin-agarose in a dose 
dependent manner (Figure 7.4A). In contrast, porphobilinogen, a molecule that has been 
previously demonstrated not to interact with Abcb6, does not compete with hemin-agarose for 
Abcb6 (Figure 7.4A). These results suggest that liposome reconstituted Abcb6 retains its ability 
to interact with its transport substrates. 
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Figure 7.4. 
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Figure 7.4. (continued) 
Liposome reconstituted Abcb6 shows substrate stimulated ATPase activity and ATP 
dependent substrate transport.  
(A) Liposome reconstituted Abcb6 interacts with its substrates. (A – top panel) Abcb6 liposomes 
(4 µg protein) were subjected to hemin affinity chromatography in the presence or absence of 
either coproporphyrinogen III or porphobilinogen and bound protein was subjected to 4-15% 
SDS-PAGE followed by western blot using FLAG M2 antibody. (A – bottom panel) Percent 
binding was estimated by plotting the band intensities corresponding to untreated Abcb6, which 
was set to 100%. (B - D) Liposome reconstituted Abcb6 shows both basal and substrate 
stimulated ATPase activity. ATPase activity of Abcb6-WT and Abcb6-MT proteoliposomes (25 -
50 µg protein) was measured as a function of the ATP concentration at 37°C. The data were 
fitted to (B) Michaelis-Menten and (C) ineweaverBurk plot resulting in a Km of 0.97 ± 0.070 mM 
and a Vmax of 614.4 ± 11.53 mol/mg/min. The Abcb6-nonfunctional mutant (Abcb6-MT) 
showed only background ATPase activity. (D) Liposome reconstituted Abcb6 shows substrate 
stimulated ATPase activity. Fold change was calculated relative to basal ATPase activity. 
Values represent mean ± SD. ‘*’ significantly different from basal ATPase activity; P < 0.01. ‘&’ 
significantly different from COPIII ATPase activity; p < 0.01. (E and F) Effect of substrate 
concentration on ATP dependent COPIII uptake by Abcb6 liposomes (25 – 50 µg protein). 
Kinetic parameters were determined by (E) fitting the data to Michaelis-Menten and (F) linear 
regression analysis of the Lineweaver-Burk transformation of the data points. Transport kinetics 
of liposome reconstituted Abcb6 showed a Km of 11.97 µM and Vmax of 29.6 pmol/mg/min. 
Copro III: Coproporphyrinogen III; PBG: Porphobilinogen; PPIX: Protoporphyrin IX; PhA: 
Pheophorbide A. 
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7.5.  ATPase activity of reconstituted Abcb6 is stimulated by coproporphyrinogen III 
(COPIII) 
To determine the ATPase activity of liposome reconstituted Abcb6 the release of 
inorganic phosphate from ATP was assayed as described for the purified protein. As shown in 
Figure 4B lipid reconstituted Abcb6 demonstrated basal ATPase activity that was comparable to 
the ATPase activity of the purified detergent solubilized protein (Figure 7.2F). The basal ATPase 
activity was specific to Abcb6 because no such activity was observed either in the presence of 
control liposomes (data not shown) or in the presence of liposomes carrying an ATPase inactive 
mutant of Abcb6 (Abcb6-MT) (Figure 7.4B). Further, the basal activity was reduced to 98% by 
ortho-vanadate that inhibits ABC transporters and P-type ATPases, indicating that no additional 
ATPases are present in the Abcb6 proteoliposome preparations (data not shown). The 
dependence of the rate of hydrolysis on ATP concentration shown in Figure 7.4B exhibited 
Michaelis-Menten behavior and, when expressed as a Lineweaver-Burk plot (Figure 7.4C), 
showed a linear relationship, yielding a Km for ATP of approximately 0.97 ± 0.07 mM and Vmax 
of 614 ± 11.53 nmol/mg/min. 
Stimulation of ATPase activity by transport substrates is a feature that is common to 
most ABC transporters. Consequently, it was of interest to determine whether known Abcb6 
substrates affected its ATPase activity in a similar manner. As shown in Figure 7.4D ATPase 
activity of liposome reconstituted Abcb6 was strongly stimulated in the presence of COPIII, 
hemin and protoporphyrin IX (COPIII > Hemin > PPIX) but not in the presence of PBG. This 
multifold increase in Abcb6 ATPase activity by COPIII, hemin and PPIX suggests that these 
compounds are potential transport substrates of Abcb6. These results are in agreement with our 
earlier observations demonstrating that porphyrins such as COPIII and hemin are potential 
substrates of Abcb6 (28). 
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7.6.  Coproporphyrinogen III transport kinetics of reconstituted Abcb6 
Abcb6 is proposed to be involved in the transport of COPIII from the cytoplasm into the 
mitochondria. However, a direct role for Abcb6 in COPIII transport has not been demonstrated 
in the absence of other potential interacting components (mitochondrial preparations). Thus, 
kinetic parameters of COPIII transport mediated by Abcb6 were carried out with the Abcb6 
proteoliposomes. According to the Lineweaver-Burk analysis, the apparent Km for COPIII was 
11.97 ± 1.10 μM with a Vmax of 25.79 ± 0.81 pmole/mg/min (Figure 7.4E and F). To confirm 
these observations further COPIII uptake studies were performed in control liposomes and in 
liposomes reconstituted with either a transport competent Abcb6 (Abcb6-WT) or the transport 
incompetent Abcb6 (Abcb6-MT) protein. As seen in Figure 7.4E COPIII uptake in Abcb6-MT 
proteoliposomes were very low and reflected transport rates similar to what was seen in control 
liposomes (Figure 7.4E). 
We recently developed a HTS assay to identify potential substrates and inhibitors of 
Abcb6 (69). Two of the compounds identified in the HTS assay, tomatine and verteporfin were 
transported into mitochondria in an Abcb6 dependent manner but a third compound 
benzethonium was not transported by Abcb6 (69). We used the transport features of these three 
molecules to test and validate the robustness of liposome reconstituted Abcb6 as a potential 
model to identify Abcb6 transport substrates. As with COPIII, both tomatine and verteporfin 
competed with hemin binding to Abcb6 (Figure 7.5A), stimulated Abcb6 ATPase activity (Figure 
7.5B) and were transported into liposomes by Abcb6 (Figure 7.5C and D) with varying transport 
kinetics (verteporfin Vmax 5.13 ± 0.23 pmol/mg/min; tomatine Vmax 2.7 ± 0.19 pmol/mg/min). 
However, unlike verteporfin and tomatine, benzethonium did not stimulate Abcb6 ATPase 
activity (Figure 7.5B) nor was it transported by Abcb6 proteoliposomes (data not shown). These 
results are consistent with the transport properties of Abcb6 observed using mitochondrial 
fractions isolated from Abcb6 overexpressing cells (69). 
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Figure 7.5. 
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Figure 7.5. (Continued) 
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Figure 7.5. (Continued) 
Liposome reconstituted Abcb6 shows ATP dependent transport of molecules identified 
in a HTS assay.  
(A) Liposome reconstituted Abcb6 interacts with both tomatine and verteporfin. (A – Top panel) 
Abcb6 liposomes (4 µg protein) were subjected to hemin affinity chromatography in the 
presence or absence of molecules identified in the HTS assay and bound protein was subjected 
to 4-15% SDS-PAGE followed by western blot using FLAG M2 antibody. (A – Bottom panel) 
percent binding was estimated by plotting the band intensities corresponding to untreated 
Abcb6 which was set to 100%. (B) Liposome reconstituted Abcb6 shows increased ATPase 
activity in the presence of molecules identified in the HTS assay. Values represent mean ± SD. 
‘*’ significantly different from basal ATPase activity; P < 0.01. ‘&’ significantly different from 
Copro III ATPase activity; p < 0.05. ‘#’ significantly different from vertiporfin ATPase activity;  p < 
0.01. (C and D) Liposome reconstituted Abcb6 shows ATP dependent transport of (C) 
verteporfin and (D) tomatine. Kinetic parameters were determined by linear regression analysis 
of the Lineweaver-Burk transformation of the data points. 
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Discussion 
Mitochondrial ABC transporters are difficult to study because of the two-membrane 
architecture of mitochondria, problems associated with analyzing transport process, and the 
high abundance of other ATPases and carriers/transporters. Thus the development of an in vitro 
system with pure and active protein, is a necessary prerequisite toward understanding the 
mechanistic relationships between ATP binding and hydrolysis and coupling of these events to 
translocation of substrates across the lipid membranes. In this study, we describe for the first 
time a successful purification protocol and biochemical characterization of the putative 
mitochondrial porphyrin transporter Abcb6. The purification procedure comprised of lentiviral-
mediated overexpression of Abcb6 carrying a C-terminal FLAG tag followed by a single step 
solubilization of Abcb6 from mitochondrial membranes and immunoaffinity purification using the 
FLAG antibody. Purified Abcb6 was found to be mostly monodisperse by PAGE electrophoresis 
and was efficiently reconstituted into liposomes allowing its biochemical characterization with 
respect to ATP binding, ATP hydrolysis and transport kinetics. 
A prerequisite for the purification of integral membrane proteins is the dissolution of the 
biological membrane in which the protein resides so that the membrane protein exists in 
solution in a monodisperse state while maintaining its structure in a physiological relevant 
condition. The success of a purification strategy is thus largely dependent on the type of 
detergent used, for both initial solubilization and the subsequent steps of column 
chromatography. The choice of detergent (Triton and n-Octyl-β-D-glucopyranoside) used for 
solubilization and purification of Abcb6 appeared acceptable as reasonable amounts of Abcb6 
were extracted from the membrane, with preserved oligomeric state and activity of the proteins. 
After purification by immunoaffinity chromatography, Abcb6 bound MgATP with a relatively high 
affinity (Kd = 0.18 μM), and showed an ATPase activity of 0.493 μmol/mg/min. The observed 
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activity is similar to that reported for ABC transporters such as MRP1 (0.46 μmol/min/mg; (251) 
but is relatively high compared to ABC transporters e.g. MRP3 (0.075 μmol/mg/min; (252) and 
MsbA (0.15 μmol/mg/min; (253). Interestingly Abcb6 ATPase activity, is lower than activities 
seen for other mitochondrial ABC proteins such as Mdl1 [2.3 μmol/mg/min; (254)] and Atm1 [1.9 
μmol/min/mg; (255)]. The relatively high ATPase activity indicates that immunoaffinity purified 
Abcb6 is in an active state. This conclusion is further supported by the observation that 
solubilized and reconstituted Abcb6 have comparable ATPase activities. Further, given that the 
apparent affinity for MgATP is 700 times higher than the Michaelis-Menten constant for ATP 
hydrolysis (Km = 0.99 mM) this implies that ATP binding and ATP hydrolysis are potentially 
distinct steps. 
There is increasing evidence that Abcb6 localizes to multiple cellular compartments 
including the plasma membrane (204,256-258). However, the precise identity, substrate 
specificity (if any), and functional significance of the differentially localized Abcb6 is not well 
defined. In our studies, although the principal form of Abcb6 purified from total cell fractions was 
a ~90 kDa protein, a second band of ~50 kDa was also purified following affinity 
chromatography. Both the purified bands contain Abcb6 as confirmed by western blot and 
MALDI-TOF analysis. The ~90 kDa band represents the mature form of the protein, which has 
been previously described as localizing to the mitochondria (28,249). Interestingly however, the 
50 kDa band was not seen in the Abcb6 purified from mitochondrial fractions suggesting that the 
~50 kDa form of Abcb6 might localize to cellular compartments other than the mitochondria. The 
ability of our experimental protocol to purify sufficient quantities of these two forms of Abcb6 
should in the future enable us to characterize their localization, identity and potential functional 
significance. 
It is well established that the lipid environment in which a membrane protein is 
reconstituted can affect its reconstitution and interaction with its substrates thus modulating its 
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activity (259). For example, it has been shown that MRP3, which is expressed in both the liver 
and the brain, exhibits efficient reconstitution and highest ATPase activity when reconstituted in 
liver lipids but not in brain lipids (252). Similarly, certain lipids significantly influence the 
characteristics of purified Pgp ATPase activity and the apparent coupling between its drug-
binding and catalytic sites (260,261). In contrast, the ATPase activity of human ABCA4 could 
not be stimulated by its substrate, all-trans-retinal, when the protein was reconstituted in 
vesicles composed of single synthetic lipids (262). Thus, overall, there appears to be 
considerable variability among the ABC transporters with respect to their response to their lipid 
environment. 
Results from the present study suggest that for Abcb6 a combination of various 
phospholipids constitutes an optimal environment for substrate binding and stimulation of basal 
ATPase activity. However, whether these values are true representations of the ATPase activity 
of native Abcb6 requires further investigation. The fact that the basal ATPase activity of lipid 
reconstituted Abcb6 was relatively higher than that observed for the purified protein suggests 
that the lipid environment may play a role in influencing the ATPase activity of native Abcb6. In 
this context, and given that Abcb6 is ubiquitously expressed, native Abcb6 in different organ 
systems or in different cellular compartments might exhibit varied ATPase activity and 
potentially different substrate specificities. We speculate that these suppositions could provide 
the basis to explain some of the Abcb6 loss of function phenotypes described in the literature 
(115-117,132,263,264). 
Many ABC transporters have been shown to possess intrinsic ATPase activity that is 
stimulated in the presence of transported substrates. The best-investigated example is the 
mammalian Mdr1, which possesses an ATPase activity stimulated by various drugs that are 
known to be transported (265,266). The ATPase activity of lipid reconstituted Abcb6 was 
stimulated by porphyrins known from previous studies to be potential substrates for this 
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transport protein (28,29). COPIII has the highest affinity for Abcb6 and this compound 
stimulated ATPase activity by approximately five fold above basal activity. The lack of substrate 
stimulated ATPase activity in control liposomes and in liposomes reconstituted with a non-
functional mutant of Abcb6 indicates that the observed ATPase activity is specific to Abcb6. In 
addition to COPIII significant induction in ATPase activity was also observed with verteporfin a 
compound which we recently identified as a potential substrate of Abcb6, by a HTS assay that 
was developed to identify functional modulators of Abcb6 (69). In contrast, tomatine, which was 
also identified as a potential transport substrate of Abcb6, was not as efficient as verteporfin in 
stimulating Abcb6 ATPase activity. The observation that porphobilinogen, which lacks a 
completed ring structure is unable to stimulate ATPase activity, leads to the speculation that 
transport substrates of mitochondrial Abcb6 might require a ring structure. 
The results presented here demonstrate for the first time transport of COPIII by purified 
Abcb6 in an artificial lipid bilayer system. The relatively high hydrophilicity and the inherent 
endogenous fluorescence capacity of COPIII facilitated analysis of its transport kinetics in this 
system. The lack of transport in control liposomes and in liposomes reconstituted with a non-
functional mutant of Abcb6 confirmed that the ATP-dependent uptake of this substrate by Abcb6 
proteoliposomes involved transport into the vesicle lumen. This conclusion is further supported 
by our findings that the Km values for COPIII were comparable with those reported previously in 
mitochondrial transport studies (29). The specific stimulation of Abcb6 ATPase activity by 
COPIII and the efficient transport of this molecule into proteoliposomes suggest that this 
molecule might be the primary substrate for mitochondrial Abcb6, and transporting across the 
mitochondrial membrane could be the physiological function of Abcb6. Collectively these data 
provide strong support for the conclusion that mitochondrial Abcb6 acts as an energy-driven 
pump that appears not to require additional components for its basal and substrate stimulated 
ATPase activity and substrate transport.  
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In summary, we have purified Abcb6 to homogeneity and reconstituted it into 
proteoliposomes. The reconstituted Abcb6 demonstrates both substrate stimulated ATPase 
activity and ATP dependent translocation of candidate transport substrates across the lipid 
membrane. These studies represent the first characterization of the ATPase activity and ATP 
dependent transport kinetics of purified Abcb6 in the absence of other potential interacting 
components. Abcb6 is increasingly being recognized as a relevant physiological and therapeutic 
target (115-117,128,186,263,264). Abcb6 expression is upregulated in many tumor cells with 
acquired chemotherapeutic resistance (132,187,234,235,267-269). However, the mechanism by 
which Abcb6 provides therapy resistance is not known. In this regard, reconstitution of purified 
Abcb6 into proteoliposomes in the absence of contaminating factors might facilitate mechanistic 
studies of ATP dependent Abcb6 mediated transport of therapy drugs. In addition, the simple 
immunoaffinity purification of Abcb6 to near homogeneity might provide the basis for future 
studies on the structure, function of Abcb6, and potentially help characterize the identity, 
localization and functional significance of the smaller isoform of Abcb6. 
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Chapter 8: CONCLUSIONS AND FUTURE DIRECTIONS 
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8.1. Summary and conclusions  
The present dissertation provides a comprehensive analysis of the physiological 
function, regulation of expression and clinical significance of the mitochondrial ABC transporter 
Abcb6. Initial characterization of Abcb6 proposed a role for this protein in heme synthesis. 
Consistent with this observation Abcb6 expression is induced in response to signals that 
promote heme synthesis. Under conditions of induced heme synthesis Abcb6 expression is 
regulated by the nuclear hormone receptors AhR, PXR and CAR which mediate transcriptional 
induction of Abcb6. Studies using loss of function and gain of function mutations in Abcb6 
helped define the clinical role of this transporter in porphyria and toxicities associated with 
oxidative stress. These same studies also provided the first examination of a heretofore-
unknown role for Abcb6 in drug metabolism, and cholesterol and steroid homeostasis. Finally 
the dissertation describes the simple immunoaffinity purification of Abcb6 to near homogeneity 
and its reconstitution into liposomes, which should provide the basis for future studies on the 
structure, function of Abcb6, and potentially help characterize the substrates for this 
mitochondrial protein.  
Chapter 4 comprehensively presents the regulation of Abcb6 by xenosensors (nuclear 
receptors AhR, CAR and PXR) and arsenic. Using specific ligands for nuclear receptor AhR (3-
MC, B[a]P and TCDD), CAR (TCPOBOP) and PXR (PCN) we demonstrated that Abcb6 
expression is up-regulated in mice after ligand exposure. Moreover, in vivo studies in AhR-null, 
CAR-null and PXR-null mice demonstrated that lignad mediated induction of Abcb6 is regulated 
by AhR, CAR and PXR, respectively. We also show that sodium arsenite induces Abcb6 
expression in a dose-dependent and time-dependent manner both in mice and in hepatoma 
cells. Using Nrf2 null mice we were able to show that arsenite-induced Abcb6 expression is not 
mediated by the redox-sensitive transcription factor Nrf2. Further, using promoter activation 
studies in association with EMSA and ChIP assay, we demonstrated direct interactions of AhR 
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protein with the AhR binding sites in the Abcb6 promoter. These studies are the first to describe 
direct transcriptional activation of Abcb6 by xenobiotics and also implicated drug activation 
mechanisms for Abcb6 similar to those found in inducible P450s. 
Chapter 5 demonstrates the role of Abcb6 in PAH mediated porphyria and also provides 
evidence of a protective role for Abcb6 in arsenic toxicity. Using Abcb6 knockdown hepatoma 
cells (Huh7 and HepG2) and primary hepatocytes from Abcb6 knock-out mice, we demonstrate 
that loss of Abcb6 expression does not alter porphyrin levels in the absence of B[a]P; however, 
loss of Abcb6 expression significantly compromised B[a]P-mediated induction of hepatic 
porphyrin levels. These results suggest that under normal physiological conditions, the absence 
of Abcb6 expression and the ensuing decrease in porphyrin biosynthesis is compensated by a 
complementary increase in mechanisms that regulate porphyrin synthesis. But when stressed 
with increased functional demand for heme, the compensatory mechanisms might not be 
sufficient to complement the loss of Abcb6 expression. These observations support recent 
findings by Ulrich et al. (29) demonstrating that in the absence of Abcb6, compensatory 
mechanisms are activated to compensate for the loss of Abcb6. However, when stressed, loss 
of Abcb6 compromises cellular heme biosynthesis and function. 
Direct correlation between arsenic resistance and Abcb6 expression was suggested in 
various human and mouse cell lines (203,204). In Chapter 5 we demonstrated that, in 
Hepatoma cells (HepG2 and Hep3B), knockdown of Abcb6 expression using Abcb6-specific 
siRNA sensitized the cells to arsenite toxicity. In contrast, stable overexpression of Abcb6 
conferred a strong survival advantage by decreasing arsenite-induced oxidative stress.  The 
protection against arsenic toxicity in Abcb6 overexpressors is in part mediated by its ability to 
potentiate catalase activity as treatment of cells with the catalase inhibitor 3-AT blocked Abcb6-
mediated activation of catalase but had only a modest effect on the survival of cells exposed to 
sodium arsenite.  
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Collectively, results from Chapter 5 suggest a role for Abcb6 in PAH mediated porphyria 
and also suggests that Abcb6 expression might be an endogenous protective mechanism 
activated to protect cells against arsenite-induced oxidative stress. 
To investigate the role of Abcb6 in vivo we generated Abcb6 knockout mice on 
C57BL6/N background. Chapter 6 describes generation of Abcb6 knockout mice and its initial 
characterization. The whole body knockout is viable and has sporadic stunted growth with the 
Mendelian inheritance showing 11% decrease in knockout number (observed 11% compared to 
25%) than expected. Hepatic heme levels show a decreasing trend that correlates well with the 
number of Abcb6 alleles in the mouse genome. A global gene expression analysis using 
Affymetrix microarray demonstrates significant changes in gene expression in the liver of Abcb6 
null mice compared to wild type controls. Mapping the gene expression changes in the knockout 
mice using the Ingenuity pathway analysis demonstrate that the highest number of genes 
altered are related to one of the following pathways; a) drug metabolism; b) growth and survival; 
c) cholesterol and lipid homeostasis; and d) development. Consistent with this observation 
Abcb6 knockout mice show decreased metabolism of the classic Cyp substrate pentobarbital, 
sporadic growth defects, decreased serum cholesterol after fasting and increase in androgens. 
These results suggest a heretofore-unknown role for Abcb6 in growth and development and in 
lipid and cholesterol homeostasis. 
Chapter 7 of this dissertation describes establishment of a liposomal vesicular transport 
assay for purified Abcb6 protein. This assay provides an advantage over cell based assay in 
identifying and characterizing Abcb6 transport substrates. In this study, FLAG tagged Abcb6 
was overexpressed in HEK293 cells and purified to homogeneity from solubilized mitochondrial 
membranes by FLAG-immunoaffinity purification. Purified Abcb6 protein was then reconstituted 
into liposomes and the liposome reconstituted Abcb6 was characterized for the ATPase activity 
including (i) substrate stimulated ATPase activity (ii) transport kinetics of its proposed 
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endogenous substrate coproporphyrinogen III and (iii) transport kinetics of substrates identified 
using a High-throughput screening (HTS) assay. Mutagenesis of the conserved lysine to alanine 
(K629A) in the Walker A motif of Abcb6 abolished ATP hydrolysis and substrate transport. In 
conclusion, results from Chapter 7 suggest a direct interaction between mitochondrial Abcb6 
and its transport substrates that is critical for the activity of the transporter. Efficient 
reconstitution of Abcb6 into liposomes might provide the basis for future studies on the 
structure, function of Abcb6. 
Collectively, using a combination of tissue culture, mouse models and cell free systems, 
this dissertation explored the role of Abcb6 protein in arsenic toxicity, porphyria and drug 
metabolism. It also examined regulation of Abcb6 by xenobiotics and environmental toxicants. 
The findings from this dissertation suggest protective role of Abcb6 in arsenic toxicity and 
porphyria. It also provides valuable information on the role of Abcb6 in drug and xenobiotic 
metabolism and the effect of xenobiotics on regulation of Abcb6 expression. Finally the reagents 
developed during the course of these studies could continue to provide powerful tools in the 
future studies evaluating Abcb6’s physiological and pathological significance.  
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8.2. Future directions 
The results presented in this dissertation provide a foundation upon which the role of 
Abcb6 in normal physiology and disease pathology could be explored further. The results 
support the public health relevance of studying Abcb6 and in combination with the recent clinical 
findings suggests that Abcb6 might be a potential therapeutic target during development, 
oxidative stress response and metabolic disorders.  
Potential future studies from results presented in Chapter 4: 
Our future studies will focus on further understanding the regulation of Abcb6. Our 
results demonstrated transcriptional activation of Abcb6 by sodium arsenite so future studies will 
focus on understanding the mechanism of sodium arsenite–mediated activation of Abcb6. In 
addition to Nrf2, arsenic exposure has been shown to activate several transcription factors 
including p53, Sp1, AP-1, and NF-kβ (215-220). Preliminary analysis of the human and mouse 
Abcb6/Abcb6 promoter using a pattern search program (nubiscan) reveals several putative cis-
elements that may be capable of binding AP-1, NF-kβ, and p53. Future studies will address the 
role of these transcription factors in the activation of Abcb6.  
In silico analysis of Abcb6 promoter also identified potential cis-elements in the Abcb6 
promoter region that may be capable of binding nuclear receptor PXR and CAR. Involvement of 
these elements will be investigated for Abcb6’s induction through PXR and CAR. Current 
studies for PXR and CAR mediated activation of Abcb6 do not address the question of species 
differences so further investigation will be done using human primary hepatocytes and human 
hepatoma cells.  
PAH mediated activation of Abcb6 has shown through binding of AhR to AhR response 
element in Abcb6 promoter but it is interesting to note that the AhRE sequence 5-GCGTG-3 is 
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similar to the HIF-1 response element sequence (consensus 5-RCGTG-3), suggesting a 
potential role of HIF and hypoxia in regulating Abcb6 expression. So future experiments will 
investigate role of HIF and hypoxia in regulating Abcb6 expression and significance of Abcb6 
expression in hypoxic induction, if any. Another, interesting aspect of AhR mediated regulation 
of Abcb6 is mutation of the AhRE element at 115 bp (Abcb6-M2) showed an increase in 
promoter activation in response to B[a]P which was significantly higher than the unmutated 
native sequence. This observation suggests the potential existence of repressor motifs in close 
proximity to the AhRE motif at115 bp which needs to be further investigated. From the EMSA 
results (Figure 4.1.6C) it is interesting to note that treatment with B[a]P led to additional DNA-
protein complex formation in the Abcb6 promoter. However, this interaction appeared to be 
independent of AhR interaction with the Abcb6 promoter. At present, it is not clear what these 
interacting proteins are and what if any is the significance of these interactions to Abcb6 
expression and function. Future studies will try to identify these interaction and effect of those 
proteins to Abcb6 expression and function. 
Potential future studies from results presented in Chapter 5: 
The results from our arsenic exposure studies suggest the possibility that Abcb6 
expression is induced in response to short-term low-dose exposure to arsenic and that this 
increased expression could protect against short-term acute arsenic toxicity. However, human 
diseases are associated with chronic arsenic exposure at moderate dose of arsenic. So, future 
studies need to address the effect of long-term moderate level arsenic exposure on Abcb6 
expression and effect of Abcb6 expression to prolonged protection against arsenic toxicity using 
Abcb6-null mice. Another interesting observation from Arsenic protection study is that Abcb6 
overexpressor has decreased oxidative stress at basal level and Abcb6 protection against 
sodium arsenite is mediated partially by its ability to potentiate catalase activity. Thus, future 
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studies will focus on mechanism(s) by which Abcb6 protects against arsenite toxicity and role of 
Abcb6 in maintenance of cellular oxidative stress. 
Abcb6 was speculated as a multidrug resistance gene because of its elevated mRNA 
expression in drug-resistant cell lines (adriamycin, camptothecin, paclitaxel, and 5-fluorouracil–
resistant tumor cell lines) (203,233,234). Based on these observations, it was suggested that 
the multidrug resistance phenotype could be attributed to Abcb6’s ability to function as a 
transporter to reduce intracellular concentrations of the respective drug compounds. It is quite 
possible that a similar transport mechanism mediated by Abcb6 for inorganic arsenic or its 
metabolite could reduce cellular arsenic concentrations. Supporting the hypothesis of Abcb6 as 
a efflux transporter, cells engineered to overexpress Abcb6 demonstrate plasma membrane 
localization of Abcb6 (204). However, in our studies reported here, we were not able to detect 
endogenous Abcb6 expression at the plasma membrane. It is quite possible that the analytical 
techniques used were not sensitive enough to detect endogenous Abcb6 expression at the 
plasma membrane. Thus, future studies will evaluate endogenous expression of Abcb6 at the 
plasma membrane and its potential contribution to drug resistance and arsenic toxicity. 
Potential future studies from results presented in Chapter 6: 
Availability of Abcb6 knockout mice will increase our understanding of physiological 
function of Abcb6. Role of Abcb6 in transport of COPIII from in vitro studies was confirmed 
using Abcb6 knockout mice but its proposed effect on heme biosynthesis was not observed. In 
our preliminary observation there is no significant change in heme levels at basal in Abcb6 
knockout mice suggesting activation of compensatory mechanism in Abcb6 knockout mice. 
Therefore, our future studies will try to understand the compensatory mechanism activated 
using gene array for mitochondrial transporters and carrier proteins.  In addition, there is 
possibility of alternate pathway for heme biosynthesis bypassing need for COPIII transport by 
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Abcb6. Indeed, evidence of an alternative pathway via harderoporphyrinogen to 
protoporphyrinogen-IX and heme has been reported previously. Our future studies will explore 
potential possibility of increased alternate heme biosynthesis pathway in Abcb6-/- mice. 
Our microarray data provided insight into biological and canonical pathways which are 
altered in Abcb6 knockout mice. Interestingly, organismal death pathway was increased the 
most suggesting susceptibility of Abcb6 knockout mice. In this context, it will be interesting to 
see the effect of various toxicants in Abcb6 knockout mice, starting with Arsenic against which 
Abcb6 is shown to protect hepatoma cells in vitro. Another interesting finding from the array is 
alteration in genes related to cholesterol homeostasis. So our future studies will focus on 
understanding role of Abcb6 in cholesterol homeostasis and also focus on disease related to 
cholesterol homeostasis such as heart disease, obesity and liver diseases. It will be interesting 
to examine the differences in steroids if any in Abcb6 knockout mice. Our future studies will 
focus on elucidating Abcb6’s effect on steroids using metabolomics approach, we expect this 
will provide novel role of Abcb6 in gene expression regulation as several of steroid molecules 
function as endogenous ligands and signal for gene expression regulation (e.g. P450s). 
Our preliminary data for drug metabolism enzymes P450s suggests a role for Abcb6 in 
regulation of P450s metabolism. So our future studies will illustrate effect of Abcb6 on P450 
function and will also focus on regulation of P450 isomers. Our current results suggest 
decreased pentobarbital metabolism, we will further examine effect of Abcb6 on metabolism of 
some over the counter drugs and its adverse effect, if any. 
Potential future studies from results presented in Chapter 7: 
We have purified Abcb6 protein to homogeneity and the protein is active in the 
solubilized state. Our future studies will outsource this protein for structural analysis which will 
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provide insight into mechanism by which Abcb6 interacts with its substrates and the dynamics of 
transport. This will provide a unique opportunity for drug discovery to predict Abcb6 interacting 
molecules in silico.   An in vitro liposomal assay developed in Chapter 7 will be used in future for 
confirming substrates of Abcb6 screened from HTS assay or in silico predictions. 
In summary, future studies will explore the role of Abcb6 protein in arsenic resistance, 
porphyria and drug metabolism in vivo using the Abcb6 null mouse that we have developed. We 
will also explore the mechanism of Abcb6 regulation mediated by xenobiotics and environmental 
toxicants. Collectively these studies should help define the physiological and pathological 
significance of Abcb6 and provide and opportunity to explore its therapeutic relevance.  
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